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ABSTRACT
While it is well-known that ciliary neurotrophic factor (CNTF) promotes the
survival of a myriad of neuronal phenotypes, little is understood on the specific
CNTF-induced neuroprotective mechanisms in the central nervous system
(CNS). Elucidation of these mechanisms may provide insight that would assist in
the development of future therapeutic strategies. Therefore, the goal of my
research is to determine the mechanisms underlying the neuroprotective effects
of CNTF within the rat magnocellular neurosecretory system. The central
hypothesis of my research is that CNTF acts as both a neuronal survival and
sprouting factor for hypothalamic magnocellular neurons in vitro and in vivo. In
order to determine the neuroprotective mechanisms that CNTF utilizes, we
performed extensive animal work including, in vivo stereotaxic surgeries and in
vitro organotypic explant cultures, in addition to Western blot and
immunohistochemical analyses. Our analyses demonstrated that following injury
to the magnocellular neurosecretory system, CNTF is up-regulated in the
supraoptic nucleus (SON) that undergoes a collateral sprouting response and
this increase is not due to heightened neurosecretory activity. Moreover, we
demonstrated a reduction in the protein levels of the CNTF specific receptor,
CNTFRa, in the mature SON. Thus, we believe that the inability of the mature rat
to elicit the sprouting response is due to a deficit in CNTF signaling. CNTF has
been demonstrated to promote survival and potentiate process outgrowth of
XVII

magnocellular neurons. Utilizing hypothalamic organotypic cultures, we
demonstrated that the Jak-STAT and MAPK-ERKV2 pathways are necessary for
CNTF to mediate its pro-survival effects on oxytocinergic neurons. Conversely,
we demonstrated that the PI3K-AKT pathway is necessary to promote CNTFinduced process outgrowth. Interestingly, our results show that the p38, JNK, and
mTOR signaling components appear to mediate the post-axotomy apoptotic
cascade that results in the significant loss of oxytocinergic neurons following the
organotypic culture preparation. Altogether, these novel data provide evidence of
the mechanisms that CNTF utilizes to elicit its neuroprotective actions. We
submit that gaining a greater understanding of these mechanisms will lead to the
development of future therapeutic strategies that will target nervous system
injuries or disorders that result in neurodegenerative processes.

xviii

CHAPTER I
INTRODUCTION
Magnocellular Neurosecretory System
General Anatomy
The magnocellular neurosecretory system is characterized anatomically
as being comprised of oxytocinergic and vasopressinergic magnocellular
neurons in the supraoptic (SON) and paraventricular nuclei (PVN) of the
hypothalamus, their non-myelinated axons that form the hypothalamoneurohypophysial tract, and their axon terminals located in the neural lobe
(NL; neurohypophysis, posterior pituitary) (Scharrer, 1954). Axons of the PVN
and SON project ventromedally and dorsomedially, respectively, towards the
dorsal part of the optic chiasm. From there the axons project posteromedially and
travel through the median eminence, a structure located at the floor of the third
ventricle. Within the median eminence, axons originating from the magnocellular
neurons of the SON decussate in the internal zone of the median eminence,
while axons from the PVN parvocellular neurons remain ipsilateral and terminate
in the external zone of the median eminence.(Silverman & Zimmerman, 1983).
For the PVN and SON magnocellular axons continuing to the NL they course
through the infundibulum, a stalk that connects the median eminence with the
NL, and terminate in the NL where axon terminals, upon stimulation, release
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oxytocin and vasopressin into surrounding fenestrated capillaries leading to the
general circulation.
Physiology of Magnocellular Neurons
Most magnocellular neurons contain mRNA for both oxytocin and
vasopressin, but in different amounts (Mezey & Kiss, 1991; Xi, Kusano, & Gainer,
1999). However, typically hypothalamic magnocellular neurons produce either
oxytocin or vasopressin. Oxytocin and vasopressin are produced in the form of
precursor molecules, prohormones, from which they are processed after
translation to biologically active proteins by specific enzymatic cleavages. The
prohormones also encode for the carrier protein neurophysin, which interacts
with the biologically active hormones following post-translational processing
(Brownstein, 1983). Following the production of the oxytocin and vasopressin
prohormones in the neuronal somata, the prohormones are packaged in
immature neurosecretory vesicles and transported down axons to the nerve
varicosities and terminals in the NL. The specific enzymes necessary for
prohormone processing are localized in the neurosecretory vesicles (Kanmera &
Chaiken, 1985); thus, the prohormones are processed into hormones and
associated proteins during the axonal transport of the neurosecretory vesicles.
The biologically active hormones are stored with neurophysin in the
neurosecretory vesicles in the NL until stimulation induces the release of the
hormones into capillary plexus within the NL. Upon physiological stimulation, an
action potential, initiated in the neuronal somata, propagates down the axon
causing calcium to enter the neurosecretory ending, resulting in exocytosis of the

2

neurosecretory granules. Fusion of the granular membrane with the
neurosecretory membrane results in oxytocin or vasopressin entering the
perivascular space of the NL, through which the hormones diffuse into the
fenestrated capillary vessels surrounding the NL (Hatton, 1990). While oxytocin
and vasopressin may both be released following the same stimuli (Miyata &
Hatton, 2002), each peptide is generally released preferentially in response to
specific physiological stimuli.
Oxytocin is released into the general circulation during parturition,
lactation, and osmotic challenge in the rat (for review see; Leng, Caquineau, &
Sabatier, 2005; Poulain & Wakerley, 1982). While oxytocin is important for
parturition, it is essential for the milk ejection reflex that stimulates the release of
milk during lactation (Young et al., 1996). In response to suckling of nursing
pups, neuronal stimuli trigger the production and release of oxytocin into the
general circulation surrounding the NL, after which, oxytocin acts on the
myoepithelial cells of the mammary gland to cause contraction of the smooth
muscle which allows the milk to be delivered to the suckling pups. In the rat, pups
suckle continuously but are only rewarded with milk every 5-15 minutes (Leng, et
al., 2005). This is a result of the oxytocinergic neurons firing in bursts, resulting in
oxytocin being released in pulses which leads to effective milk let down (Leng, et
al., 2005). The result is a large dose of oxytocin released at one time, which is
necessary for mammary gland function because the mammary gland best
responds to high concentrations of oxytocin and is rapidly desensitized in
response to continued exposure (Leng, et al., 2005). Although bolus injection of
3

vasopressin can elicit milk ejections, it is much less potent than oxytocin (Bisset
et at., 1967), and vasopressinergic neurons do not show synchronized burst
firing, and few otherwise respond during suckling (Lincoln & Wakerley, 1974). For
this reason, vasopressin cannot substitute for oxytocin during lactation.
The primary physiological role of vasopressin is to conserve body water
and maintain plasma osmolality (Verney, 1947). Consequently, in response to
osmotic stress such as dehydration or denial of water, vasopressin is produced
and released into the general circulation to help conserve water (for review see;
Baylis, 1989). In addition, vasopressin in high concentrations raises blood
pressure by inducing moderate vasoconstriction (Dunn, Brennan, Nelson, &
Robertson, 1973); however, compared to increases in plasma osmolality, it is a
less sensitive signal of vasopressin secretion. When the osmolality of the plasma
increases, cells involved in sensing changes in body fluid osmolality, called
osmoreceptors, have been shown to excite magnocellular neurons leading to the
secretion of vasopressin from the NL (Bourque, diet, & Richard, 1994).
Centrally, osmoreceptors are located in the subfornical organ (SFO) and
organum vasculosum lamina terminalis (OVLT) (Bourque, et al., 1994), which are
areas that lack the blood-brain-barrier (BBB) and can monitor and respond to
changes in plasma osmolality. Tracer studies have demonstrated that the SON
receives afferent connections from both the SFO and OVLT (W. A. Anderson,
Bruni, & Kaufmann, 1990) and that electrical stimulation within each of these
structures has been shown to modify the excitability of the magnocellular
neurons (Ferguson, Day, & Renaud, 1984; Renaud, Cunningham, Nissen, &
4

Yang, 1993). Once vasopressin is in the body’s general circulation it will travel to
the kidney where it will bind to the vasopressin V2 receptors on the principal cell
of the distal tubule and collecting duct. This results in vesicles containing
aquaporin-2 water channels to be incorporated in the luminal membrane of the
principal cell, which increases the water permeability of the distal tubules and
collecting ducts to conserve body water (Fenton, Brand, Nielsen, & Praetorius,
2007).
Anatomy of the Supraoptic Nucleus
The SON are paired hypothalamic nuclei that are positioned immediately
lateral to the optic chiasm and dorsal to the ventral pial surface of the brain. A
homogeneous population of neurons, magnocellular neurons, comprise the
somatic region of the SON and the magnocellular neurons produce the
neuropeptides oxytocin and vasopressin (Silverman & Zimmerman, 1983). The
magnocellular neurons are densely packed throughout the SON (Sofroniew &
Glasmann, 1981) and are spatially organized so that generally oxytocinergic
magnocellular neurons tend to occupy the more dorsal and rostral parts of the
somatic zone while the more ventral and caudal regions contain mostly
vasopressinergic magnocellular neurons (Swaab, Pool, & Nijveldt, 1975;
Vandesande & Dierickx, 1975); however, there is a lot of mixing in the central
regions of the SON (Hou-Yu, Lamme, Zimmerman, & Silverman, 1986).
Immunohistochemical analysis demonstrated that the somata of
magnocellular neurons are round or oval in shape and have a diameter of
20-35 pm (Sofroniew & Glasmann, 1981), hence the term magnocellular.
5

Magnocellular neurons are classified as multipolar neurons (Sofroniew &
Glasmann, 1981) and have two or three dendrites and a single non-myelinated
axon arising from the primary dendrite (Glenn Hatton, personal communication)
that projects dorsomedial to course over the dorsal extent of the optic chiasm
(Silverman & Zimmerman, 1983). In the rat, the dendrites of the magnocellular
neurons in the SON project ventrally from the somatic zone into the dendritic
zone, a region that also contains numerous astrocytic processes. Similar to the
magnocellular neuron axons, neurosecretory granules packaged with oxytocin or
vasopressin are found in magnocellular neuron dendrites, and in response to
physiological stimuli oxytocin and vasopressin may be released by exocytosis
from these dendrites into the extracellular space of the SON (Ludwig, 1998). The
dendritic release of oxytocin and vasopressin promotes the magnocellular
neurons to stay active during increased neurosecretory activity because
V-i vasopressin receptors are located on vasopressinergic magnocellular neurons
(Berlove & Piekut, 1990; Hurbin, Orcel, Alonso, Moos, & Rabie, 2002) and
oxytocin receptors are located on oxytocinergic magnocellular neurons in the
SON (Freund-Mercier, Stoeckel, & Klein, 1994), which is of major importance for
the fine-tuning of neurosecretory activity in the NL (Gouzenes, Desarmenien,
Hussy, Richard, & Moos, 1998).
The predominant glia cells in the SON are astrocytes, with ramified
microglia (Mander & Morris, 1994) and oligodendrocytes, which myelinate
afferent axons, seldom seen in the unstimulated SON (Miyata & Hatton, 2002).
Although, an increase in activated microglia in the SON is observed following
6

chronic osmotic stimulation (Ayoub & Salm, 2003). Within the SON, the majority
of the astrocytic cell bodies are located in the ventral glial limitans of the SON
(SON-VGL), which is ventral to the dendritic zone and dorsal to the underlying
pia mater. These astrocytes have a morphology reminiscent of radial glia in the
developing CNS and are immunoreactive for the intermediate filaments glial
fibrillary acidic protein (GFAP) and vimentin, with the latter prominently present in
developing glia (Bonfanti, Poulain, & Theodosis, 1993). Under normal conditions
the astroglial processes project dorsally throughout the parenchyma of the SON
and occupy the spaces in between the densely packed magnocellular neuron
somata, forming physical barriers by interposing between adjacent SON
dendrites and somata (W. E. Armstrong, Scholer, & McNeill, 1982; Bonfanti, et
al., 1993). Within the parenchyma of the SON there is a second phenotype of
astrocytes. These astrocytes have a stellate morphology and while they are
immunoreactive for GFAP they do not exhibit vimentin-immunoreactivity
(Bonfanti, et al., 1993; Miyata & Hatton, 2002). Altogether, the astrocyte
processes of the SON contribute to an extensive ensheathment of the
magnocellular neurons that are necessary for the maintenance of the SON.
Anatomy of the Paraventricular Nucleus
While the SON is a homogenous mixture of magnocellular neurons, the
PVN is a heterogeneous mixture of two neuronal cell types, the large
magnocellular neurons and the smaller parvocellular neurons (Gurdjian, 1927;
Krieg, 1932). Eight distinct subdivisions, three of which are magnocellular, are
found in standard Nissl preparations (Swanson & Kuypers, 1980). The
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magnocellular divisions can be divided into anterior, medial, and posterior
subdivisions. The posterior is the largest magnocellular subdivision and
corresponds to the magnocellular division of the PVN referred to by most authors
(Swanson & Sawchenko, 1983). The posterior subdivision forms a compact cell
mass at the lateral margin of the PVN and can be further divided into medial and
lateral halves (Hatton, Hutton, Hoblitzell, & Armstrong, 1976). The parvocellular
division of the PVN consists of five distinct subdivisions; anterior, dorsal, lateral,
medial, and periventricular. Cell counts estimate that the magnocellular division
of the PVN contains approximately 1300-2000 neurons (Bandaranayake, 1971;
Bodian & Maren, 1951; Olivecrona, 1957), while the parvocellular division
contains around 7000 neurons (Sawchenko & Swanson, 1981b). The bulk of the
parvocellular neurons are immunoreactive for biologically active substances
other than oxytocin or vasopressin, including but not limited to; somatostatin
(Sawchenko & Swanson, 1982), dopamine (Swanson et al., 1981), and
cortiocotropin releasing factor (CRF) (Sawchenko, Swanson, & Joseph, 1982).
The majority of oxytocinergic and vasopressinergic neurons in the PVN are
magnocellular, with only 20-30% classified as parvocellular (Sawchenko &
Swanson, 1982).
The magnocellular neurons of the PVN are similar to those in the SON.
They are multipolar neurons with dendritic processes that remain within the
confines of the nucleus, although the more caudal groups have some dendrites
projecting away from the nucleus (W. E. Armstrong, Warach, Hatton, & McNeill,
1980). Collectively, all of the axons of the PVN neurons leave the nucleus and
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contribute to the hypothalamo-neurohypophysial tract by projecting
ventrolaterally, coursing above or below the fornix, and the arching
posteroventromedially toward the median eminence (Krieg, 1932). Within the
median eminence, all of the PVN axons remain ipsilateral and the parvocellular
axons terminate in the external zone of the median eminence and the
infundibular stalk, while the magnocellular axons terminate in the NL.
Interestingly, direct soma-soma interactions are observed quite frequently
between magnocellular neurons in the ipsilateral PVN and SON (Tweedle &
Hatton, 1976, 1977). Furthermore, certain magnocellular subdivisions of the PVN
have an afferent input to the contralateral PVN (Silverman, Hoffman, &
Zimmerman, 1981). These observations indicate that the internuclear
connections may facilitate neurosecretion during states of increased
neurosecretory activity.
Similar to the SON, the predominant glia cell in the PVN are astrocytes.
However, unlike the SON that contains two distinct phenotypes of astrocytes, the
astrocytes in the PVN are primarily stellate. In the unstimulated rat, the stellate
astrocytes of the PVN express GFAP but do not express vimentin (Yuan, Scott,
So, & Wu, 2007). However, in response to hypophysectomy, which will only
lesion the PVN magnocellular and not the parvocellular axons, the stellate
astrocytes increase their expression of the immature intermediate filaments,
vimentin and nestin, in the magnocellular divisions of the PVN (Yuan, et al.,
2007). These observations indicate that astrocytes in magnocellular subdivisions
of the PVN can be activated by injury.
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Anatomy of the Neural Lobe
The NL is primarily occupied by thousands of neurosecretory axons and
their terminals from the SON, PVN, and the accessory magnocellular cell groups,
which include the anterior and posterior fornical nuclei, the nucleus circularis, and
the nucleus of the medial forebrain bundle (Silverman & Zimmerman, 1983). In
addition, the NL contains an extensive network of fenestrated capillaries and
several intrinsic populations of glia cells including, pituicytes and microglia
(Vazquez-Lopez, 1942). Pituicytes, which are astrocytic in nature, are
immunoreactive for GFAP and are the only cell bodies of neural origin in the NL
(Lederis, 1965; Salm, Hatton, & Nilaver, 1982). Of the three nucleated cell types
found in the NL, the majority are pituicytes, which account for 53% of all the
nucleated cells followed by endothelia at 34%, and microglia at 13% (Pow, Perry,
Morris, & Gordon, 1989). Of the microglia cells, approximately 75% are located
within the perivascular spaces and the other 25% are found in the parenchyma of
the NL (Mander & Morris, 1994).
The vasculature of the NL is characterized by the lack of a BBB. The
vascular compartment of the NL consists of fenestrated endothelia surrounded
by a perivascular basal lamina followed by a perivascular space, which in turn is
surrounded by a parenchymal basal lamina. The perivascular space not only
surrounds vessels but extends in multiple directions to penetrate widely between
rows of parenchymal cells. The parenchymal basement membrane is
characterized by discontinuities which allow for the penetration of neurosecretory
axons into the perivascular space. The perivascular space also includes
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macrophages, fibroblasts and collagen fibrils, and the occasional mast cell
(Seyama, Pearl, &Takei, 1980).
Activity-Dependent Plasticity of the Magnocellular Neurosecretory System
A unique feature of the magnocellular neurosecretory system is that in
response to increased neurosecretory activity, such as lactation or dehydration,
magnocellular neurons and glia will undergo reversible morphological changes
that facilitate neurosecretion (Hatton, 2004). For example, osmotic stimulation
increased the amount of soma-somatic contact in the SON (Tweedle & Hatton,
1977) and PVN (Theodosis & Poulain, 1989), and increased the formation of
phenotype-specific double synapses (single boutons contacting more than one
post-synaptic element) between magnocellular neurons, which are not frequently
seen in the unstimulated rat SON (Hatton & Tweedle, 1982; Theodosis, Poulain,
& Vincent, 1981). These actions, along with an increase in intercellular
communication between magnocellular neurons following osmotic stimulation
(Hatton, Yang, & Cobbett, 1987), help to synchronize the activity of the
magnocellular neurons during states of heightened neurosecretory activity.
As previously mentioned, osmotic stimulation increased the amount of
activated microglia present within the SON (Ayoub & Salm, 2003). Moreover, the
predominant glia cells in the SON, astrocytes, undergo several reversible
morphological changes. In response to osmotic stimulation, the astrocytic
processes, which normally project vertically (dorsally) in between magnocellular
neuron somata and dendrites, withdraw and reorient themselves in a horizontal
manner (Bobak & Salm, 1996). The reorientation of the astrocyte processes
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leads to a thinning of the SON-VGL (Bobak & Salm, 1996) and a 30% increase in
the mediolateral width of the SON-VGL (Salm & Hawrylak, 2004). These
changes were not due to changes in total astrocyte numbers, increases in the
volume of the SON-VGL or dendritic zone, or changes in the length or thickness
of the astrocyte processes (Bobak & Salm, 1996; Salm & Hawrylak, 2004).
Altogether, these morphological changes are thought to facilitate the activity of
the magnocellular neurons during states of heightened neurosecretory activity.
Similar to the SON and PVN, the NL undergoes morphological changes
that facilitate neurosecretion. During periods of low secretory activity, pituicytes
completely surround and engulf neurosecretory axons and their terminals in the
NL (Tweedle & Hatton, 1980, 1982). Also, under these conditions, pituicytes tend
to occupy a relatively large portion of the parenchymal basement membrane,
interposing themselves between it and the neurosecretory terminals (Tweedle &
Hatton, 1987; Wittkowski & Brinkmann, 1974). In response to osmotic
stimulation, pituicytes retract from the parenchymal basement membrane
resulting in an increase in neuronal-basement membrane contact area thereby
facilitating neuropeptide release (Tweedle & Hatton, 1980, 1982, 1987). This
response is presumably due to release of the axons by the pituicytes (Hatton,
1988).
To allow for the complex anatomical changes that occur in the SON during
states of increased neurosecretory activity, the cells of the SON express proteins
that are normally present only in the developing brain and help the SON retain
the plastic nature that is similar to the embryonic brain. Cell adhesion molecules
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(CAMs) are cell surface glycoproteins that allow for cell to cell interactions and
are present in various isoforms throughout the body. Neural cell adhesion
molecule (NCAM) is found at the earliest stages of neural tube formation and in
most developing neuronal structures; however, NCAM is less abundant in the
adult brain (Grumet & Edelman, 1988). The ability of NCAM to promote cell-tocell adhesion is attenuated by the addition of an unusually high amount of
a-2,8-linked polysialic acid (PSA) on the extracellular domain of the molecule
(Finne, Finne, Deagostini-Bazin, & Goridis, 1983). Therefore, it has been
suggested that the PSA molecule may serve as an overall regulator of contactdependent cell-to-cell interactions (Sadoul, Hirn, Deagostini-Bazin, Rougon, &
Goridis, 1983). Interestingly, PSA-NCAM-immunoreactivity has been observed in
the adult rat SON, PVN, and NL (Theodosis, Rougon, & Poulain, 1991). Within
the adult rat magnocellular neurosecretory system, PSA-NCAM-immunoreactivity
was localized to dendrites, axons, and terminals and in associated astrocytes,
but not in neuronal somata (Theodosis, et al., 1991). Removal of PSA from NCAM abolishes lactation-induced structural plasticity in the SON (Theodosis,
Bonhomme, Vitiello, Rougon, & Poulain, 1999). These observations suggest that
the retention of the PSA-NCAM allows for the anatomical changes that occur in
the SON following activation.
The Magnocellular Neurosecretory System as a Model System
for Investigating Axonal Reorganization
Unlike most systems of the central nervous system (CNS), the
magnocellular neurosecretory system has the unique ability to structurally
reorganize and functionally recover following axotomy of magnocellular neuron
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axons (Moll, 1957; Raisman, 1973; Silverman & Zimmerman, 1982; Watt et al.,
1999; Watt & Paden, 1991). This phenomenon has been demonstrated across
numerous species and by different axotomy approaches including;
hypophysectomy (Kiernan, 1971), infundibular stalk compression (Dohanics,
Hoffman, Smith, & Verbalis, 1992) and transection (Dellmann & Carithers, 1992)
and unilateral lesion of the hypothalamo-neurohypophysial tract (Watt & Paden,
1991). These surgical interventions result in degeneration of oxytocinergic and
vasopressinergic magnocellular neurons; however, vasopressinergic
magnocellular neurons have been demonstrated to be more vulnerable to injury
(Dohanics, Hoffman, & Verbalis, 1996). It has been well-documented that in the
absence of any external intervention strategies, the neurons surviving these
injuries will undergo axonal reorganization to form an ectopic NL or reinnervate
the denervated NL (Dellmann & Carithers, 1992; Dohanics, et al., 1992; Kiernan
1971; Watt, et al., 1999; Watt & Paden, 1991). Thus, the well established
regenerative capacity of the magnocellular neurosecretory system has
established it as a model system for studying plasticity of the injured CNS.
The previous reports led us to investigate the ability of magnocellular
neurosecretory axons to undergo collateral sprouting following partial
denervation of the NL (Watt, et al., 1999; Watt & Paden, 1991). We utilized
unilateral lesion of the hypothalamo-neurohypophysial tract in which the
neurosecretory axons in the animal’s right hemisphere PVN and SON are
severed while the contralateral nuclei are spared (Watt & Paden, 1991). The
lesion results in the loss of 42% of the neurosecretory axons in the NL followed
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by a return to control levels by four weeks post-lesion (Watt & Paden, 1991). The
axonal recovery results from a collateral sprouting response arising from the noninjured, contralateral magnocellular neurons with a concomitant increase in the
magnocellular neuron somatic and nuclear area, oxytocin and vasopressin
mRNA expression (Watt & Paden, 1991), and alpha-l and beta-ll tubulin mRNA
expression (Paden et al., 1995a). Daily measures of urine osmolality revealed a
chronic hyperosmolality with a concomitant decrease in daily water intake and
urine excretion volume, which persists throughout the post-surgical period.
Together these results indicate that the sprouting event is not a compensatory
response as it occurs in the absence of a functional deficit. Hence, the
mechanism underlying the axonal sprouting remains the focus of our
investigations.
Collateral sprouting has been shown to occur in a variety of neuronal
populations; however, the factor or factors responsible for mediating the
sprouting response are still largely ill defined. There is evidence suggesting that
ciliary neurotrophic factor (CNTF) may play an important role. CNTF has been
implicated in hypothalamic magnocellular neuron sprouting in vitro (Vutskits,
Bartanusz, Schulz, & Kiss, 1998) and has been demonstrated to promote motor
neuron sprouting (Gurney, Yamamoto, & Kwon, 1992; Guthrie, Woods, Nguyen,
& Gall, 1997; Kwon & Gurney, 1994; Oyesiku & Wigston, 1996; Siegel, Patton, &
English, 2000; Simon, Jablonka, Ruiz, Tabares, & Sendtner, 2010; Ulenkate,
Kaal, Gispen, & Jennekens, 1994; Wright, Cho, & Son, 2007; J. J. Xu, Chen, Lu,
& He, 2009) and process outgrowth of retinal ganglion cells (Leibinger et al.,
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2009; A. Muller, Hauk, & Fischer, 2007; A. Muller, Hauk, Leibinger, Marienfeld, &
Fischer, 2009). Previously, we demonstrated a significant increase in CNTFimmunoreactivity within the non-injured, contralateral, sprouting SON between
3 and 10 days post unilateral lesion (Watt, Bone, Pressler, Cranston, & Paden,
2006) in conjunction with an increase in the mRNA for the CNTF-specific
receptor, CNTF receptor alpha (CNTFRa), at 7 days post unilateral lesion (Watt,
Lo, Cranston, & Paden, 2009). Taken together, these studies suggest that CNTF
may be involved in modulating axonal sprouting in the injured magnocellular
neurosecretory system.
Ciliary Neurotrophic Factor
Properties of Ciliary Neurotrophic Factor
CNTF was originally described for its effects on the survival of cultured
parasympathetic neurons of the chick ciliary ganglia (Adler, Landa, Manthorpe, &
Varon, 1979; Barbin, Manthorpe, & Varon, 1984; Manthorpe, Skaper, Adler,
Landa, & Varon, 1980). Purification and sequencing of CNTF revealed that it is a
200 amino acid peptide of approximately 23 kDa (Manthorpe, Skaper, Williams,
& Varon, 1986; Stockli et al., 1989) and is included in the structurally related
family of the interleukin-6 (IL-6) cytokines which include leukemia inhibitory factor
(LIF), interleukin-11 (IL-11), oncostatin M (OSM), cardiotrophin 1 (CT-1), and
cardiotrophin-like cytokine (CLC) (Barbin, et al., 1984). Moreover, the IL-6
cytokine family share the receptor subunit glycoprotein 130 (gp130) (Hirano,
Matsuda, & Nakajima, 1994). This feature is not unique to the IL-6 cytokine
family but rather a general feature of the cytokine receptor system (Hirano,
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Nakajima, & Hibi, 1997). CNTF is now well established as a survival, sprouting,
and differentiation factor for various neuronal and glial populations in vivo and in
vitro.
CNTF protein and mRNA are expressed in astrocytes of the CNS and
Schwann cells of the peripheral nervous system (Dobrea, Unnerstall, & Rao,
1992; Friedman et al., 1992; Sendtner, Stockli, & Thoenen, 1992; Stockli et al.,
1991; Stockli, et al., 1989; Watt, et al., 2006). While CNTF expression is strongly
enhanced in reactive astrocytes adjacent to lesions (Choi et al., 2004; M. Y. Lee,
Deller, Kirsch, Frotscher, & Hofmann, 1997; T. N. Lin, Wang, Chi, & Kuo, 1998),
it was thought that CNTF was not endogenously expressed in the non-injured
CNS. However, our lab demonstrated that within the magnocellular
neurosecretory system CNTF is endogenously expressed in astrocytes of the
SON (Watt, et al., 2006), and consistent with what others have reported, injury
increases CNTF expression in the NL and SON (Lo, SunRhodes, & Watt, 2008;
Watt, et al., 2006). Therefore, while the neuroprotective functions of CNTF have
been extensively demonstrated throughout the nervous system, the high levels of
endogenous CNTF in the highly plastic SON provide an excellent model system
for studying the physiological role of CNTF in the CNS.
There are conditions other than injury that have been demonstrated to
regulate CNTF synthesis; however, these mechanisms remain ill defined. Studies
have demonstrated that CNTF protein and mRNA were decreased in primary
astrocyte cultures following the addition of forskolin and isoproterenol, which
stimulate the production of intracellular cyclic AMP (Nagao, Matsuoka, &
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Kurihara, 1995; Rudge, Morrissey, Lindsay, & Pasnikowski, 1994). Similarly,
CNTF was down-regulated in cultured astrocytes following addition of adrenergic
agonists that increase intracellular cyclic AMP such as; adrenaline,
noradrenaline, dopamine, and adenosine (Carroll, Sendtner, Meyer, & Thoenen,
1993; Rudge, et al., 1994). One study demonstrated that phorbol 12-myristate
13-acetate (PMA), an activator of PKC, resulted in an initial decrease in CNTF
mRNA expression, which was followed by a persistent increase in CNTF mRNA
levels (Nagao, Matsuoka, & Kurihara, 1996). In regard to CNTF up-regulation,
Cagnon & Braissant (2009) demonstrated that hyperammonemia increased
CNTF protein levels in cultured astrocytes. Altogether, these studies demonstrate
that CNTF synthesis may be modulated by factors other than injury.
CNTF lacks the secretory signal sequence which is necessary for protein
secretion from the cell via the classic protein secretion pathway through the
endoplasmic reticulum (ER) and Golgi apparatus (Vergara & Ramirez, 2004).
The secretory signal sequence allows the protein to be packaged in a secretory
vesicle at the ER and transported to the cell surface where fusion of the vesicle
with the cell’s membrane results in the protein released into the extracellular
environment. Yet, there are proteins that lack the secretory signal sequence that
can be secreted via non-classical pathways such as interleukin 1-beta (IL-112.)
and basic fibroblast growth factor (bFGF) (Mignatti, Morimoto, & Rifkin, 1992;
Rubartelli & Sitia, 1991). Thus far it has not been conclusively demonstrated if, or
how, rat CNTF is secreted, however, chick CNTF has been demonstrated to be
secreted through a non-classical secretory pathway (Reiness et al., 2001) and
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reports have demonstrated that CNTF may be secreted in the absence of injury
from cultured rat astrocytes (Kamiguchi et al., 1995) and cultured bovine corneal
endothelium (Koh, 2002). Moreover, there are reports of detectable levels of
serum CNTF in healthy individuals and patients with amyotrophic lateral sclerosis
(ALS) indicating that CNTF may be released in both the presence and absence
of a pathological condition.
CNTF Receptor Complex
To have an effect on the target cell’s transcriptional activities, CNTF binds
to a three part receptor complex consisting of the ligand-specific binding subunit
CNTFRa that is attached to the membrane via a glycosylphosphatidylinositol
(GPI) linkage, and the intracellular signal transducing subunits gp130 and
leukemia inhibitory factor receptor beta (LIFRI3>) (Davis, Aldrich, Stahl, et al.,
1993; Ip et al., 1993; Ip et al., 1992; Schuster et al., 2003). Our lab previously
demonstrated that CNTFRa is localized to the magnocellular neurons and
astrocytes of the SON (Watt, et al., 2009), however, the localization of the gp130
and LIFRG. receptor components in the magnocellular neurosecretory system has
not been reported. Knockout studies performed in mice have confirmed the
neuroprotective role of CNTF and have demonstrated the importance of the
CNTF receptor components. While knockouts of CNTF resulted in fairly healthy
offspring with relatively minor motor deficiencies, individual knockouts of gp130,
LIFRI2., or CNTFRa led to either embryonic or perinatal death (Heinrich,
Behrmann, Muller-Newen, Schaper, & Graeve, 1998). Specifically, CNTFRa
gene disruption is devastating, with deletions in motor nuclei causing perinatal
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death from the inability to suckle (DeChiara etal., 1995). In contrast to the
relatively minor effects seen because of a loss of CNTF, deletion of CLF-1, the
co-factor for CLC signaling, resulted in a phenotype similar to that seen in
CNTFRa knockouts (Alexander et al., 1999), suggesting that CLC may be the
more critical ligand for CNTFRa during development.
In order to modulate intracellular signaling, CNTF first binds to CNTFRa,
then recruits gp130 and finally complexes with LIFRI3> (Stahl & Yancopoulos,
1994). It has been demonstrated that CNTFRa, but not gp130 or LIFRI3-, is
located within lipid rafts on the plasma membrane; however, CNTF binding to
CNTFRa induces a rapid translocation of gp130 and LIFRI3> into the lipid rafts
(Port, Gibson, & Nathanson, 2007). Interestingly, LIF stimulation does not induce
receptor translocation of gp130 or LIFRI3>, suggesting that CNTF induces different
patterns of signaling and/or receptor trafficking due to the membrane localization
of CNTFRa (Port, et al., 2007). The differential signaling patterns of cell surface
receptors in lipid rafts are possible because lipid rafts are microdomains of the
plasma membrane that are enriched in cholesterol, sphingomyelin, and
glycosphingolipids, and lipid rafts contain distinct subsets of proteins and lipids
and can thus create distinct environments for cell signaling (Simons & Ikonen,
1997; Simons & Toomre, 2000). Localization of CNTFRa within the CNS has
been largely considered to be neuronal (M. Y. Lee, Hofmann, & Kirsch, 1997;
MacLennan et al., 1996). However, within the SON, CNTFRa is localized to
magnocellular neurons and astrocytes (Watt, et al., 2009). To date, few reports
have demonstrated gp130 and LIFRI3. localization within the CNS; however,
20

differential localization of the three receptor components would not be surprising
since other members of the IL-6 cytokine family utilize the gp130 and LIFRR
receptor components in various combinations.
Following CNTF binding to CNTFRa and the subsequent recruitment of
the gp130 and LIFRR signal transducing subunits, CNTF has been demonstrated
to activate multiple intracellular signal transduction pathways (Figure 1) including:
The Jak-STAT (janus kinase-signal transducer and activator of transcription)
pathway (Bonni, Frank, Schindler, & Greenberg, 1993; Dolcetetal., 2001;
Lutticken et al., 1994; A. Muller, et al., 2009; K. Park, Luo, Hisheh, Harvey, & Cui,
2004; Peterson, Wang, Tzekova, & Wiegand, 2000; Rhee, Goureau, Chen, &
Yang, 2004; Sango, Yanagisawa, Komuta, Si, & Kawano, 2008; Symes et al.,
1994), the PI3K-AKT (phosphoinositide 3-kinase-AKT) pathway (Dolcet, et al.,
2001; A. Muller, et al., 2009; K. Park, et al., 2004; Sango, et al., 2008), the
MAPK-ERK (mitogen-activated extracellular signal-regulated kinases, ERK1
/2
isoforms or p44/42) pathway (Kassen et al., 2009; A. Muller, et al., 2009; K. Park,
et al., 2004; Sango, et al., 2008; Trimarchi, Pachuau, Shepherd, Dey, & MartinCaraballo, 2009), the p38-MAPK (p38 a, R>, y, and 5 isoforms) pathway (Loy et
al., 2011), the JNK-MAPK (c-Jun N-terminal kinase, JNK-1, -2, -3, isoforms, also
named Stress-Activated Protein Kinase or SAPK) pathway (Cagnon & Braissant,
2009), as well as the transcription factor NF-k B (nuclear factor kappa-light-chainenhancer of activated B cells) (Gallagher et al., 2007; Nishimune et al., 2000).
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CNTF-Mediated Signal Transduction
The Jak-STATPathway
The Jak-STAT intracellular signal transduction pathway (Figure 1) is
considered the canonical signaling pathway utilized by CNTF (Bonni, et al., 1993;
Bonni et al., 1997; Darnell, Kerr, & Stark, 1994). After ligand binding and receptor
dimerization the of LIFRI3, and gp130 receptor components, their constitutively
bound Janus kinase (Jak) molecules, which includes the ubiquitously expressed
Jak1, Jak2, and Tyk2, are tyrosine phosphorylated (Stahl & Yancopoulos, 1994).
The resultant phosphotyrosines on LIFRI3> and gp130 serve as specific Src
homology 2 (SH2) domain-docking sites for other cytoplasmic substrates that
include members of the STAT family (Segal & Greenberg, 1996; Stahl et al.,
1994; Stahl & Yancopoulos, 1994). Subsequently, STAT molecules, preferentially
STAT3, are recruited to the S-components of the receptor complex (gp130 and
LIFRS), are tyrosine phosphorylated by Jaks, dimerize and translocate to the
nucleus, and bind DNA in a sequence specific fashion, thus activating gene
transcription (Bonni, et al., 1993; Boulton et al., 1995; Lutticken, et al., 1994;
Stahl et al., 1995). Other transcription factors have been demonstrated to
associate with STAT molecules, including; c-Jun, CREB (cAMP response
element binding), and NF-k B (Brown, Ades, & Nordan, 1995; Kojima, Nakajima,
& Flirano, 1996). Several genes have been linked to Jak-STAT activation,
including; vasoactive intestinal peptide (VIP) (Symes, Gearan, Eby, & Fink,
1997), BcI-Xl (Fujio, Kunisada, Hirota, Yamauchi-Takihara, & Kishimoto, 1997),
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gp130 (O'Brien & Manolagas, 1997), and suppressors of cytokine signaling
(SOCS) (Bjorbaek et al., 1999).
When signaling through Jak, CNTF preferentially phosphorylates STAT3
at tyrosine 705 (Tyr705) (Bonni, et al., 1997; Darnell, et al., 1994; Wegenka,
Buschmann, Lutticken, Heinrich, & Horn, 1993). However, STAT molecules can
become activated by members of the MAPK pathway. Unlike Jak molecules,
which are tyrosine kinases, members of the MAPK pathway are serine/threonine
(Ser/Thr) kinases. Thus, MAPK-dependent activation of STAT3 occurs at serine
727 (Ser727) as opposed to the more commonly Jak-dependent phosphorylated
Tyr705 (Decker & Kovarik, 2000). Interestingly, Chung et al. (1997) demonstrated
that serine phosphorylation of STAT3 via MAPK pathways negatively modulates
the tyrosine phosphorylation of STAT3, suggesting a possible feedback
mechanism to regulate STAT3 activity. However, others have reported that
serine phosphorylation of STAT3 is required for maximal activation of STAT3
(Yokogami, Wakisaka, Avruch, & Reeves, 2000). A more commonly appreciated
negative feedback mechanism for STAT activity is the SOCS proteins. There are
seven known SOCS proteins, and they have been implicated in the regulation of
many cytokines that signal through the Jak-STAT pathway (Croker, Kiu, &
Nicholson, 2008). There are four major ways by which SOCS can inhibit cytokine
signaling; blocking STAT recruitment to the receptor, targeting the receptor for
degradation by the proteosome, binding to Jaks and inhibiting their kinase
activity, or targeting Jaks for degradation by the proteosome (Palmer & Restifo,
2009). Moreover, others have demonstrated that SOCS3 mRNA is activated by
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CNTF within the hypothalamus (Bjorbaek, et al., 1999), indicating that CNTF can
negatively regulate its signaling response.
The MAPK Pathways
Along with the Jak-STAT pathway, CNTF can activate the MAPK
pathways via other SH2 domain-containing proteins, such as the phosphatases
SHP2 and She, which are bound to the activated receptors (Giordano et al.,
1997; Stahl, et al., 1995). Four conventional families of MAPKs have been
described: MAPK-ERK/4, MAPK-ERK5, p38-MAPK, and JNK-MAPK (Cargnello
& Roux, 2011).
Each group of conventional MAPKs is comprised of a set of three
conserved, consecutively acting kinases; a MAPK, a MAPK kinase (MAPKK),
and a MAPKK kinase (MAPKKK). The MAPKKKs are activated through
phosphorylation and/or as a result of their interaction with a small GTP-binding
protein of the Ras/Rho family in response to extracellular stimuli (Cargnello &
Roux, 2011). MAPKKK activation leads to phosphorylation and activation of a
MAPKK, on serine and threonine residues, which then stimulates MAPK activity
through phosphorylation of serine, threonine, and tyrosine residues (Cargnello &
Roux, 2011). Phosphorylation of these residues is essential for enzymatic
activities (Robbins et al., 1993). The wide range of functions regulated by the
MAPKs is mediated through phosphorylation of several substrates, including
member of a family of protein kinases termed MAPK-activated protein kinases
(MAPKAPKs) (Gaestel, 2008). Within this family are the p90 ribosomal S6
kinases (RSKs) (Carriere, Ray, Blenis, & Roux, 2008), mitogen- and stress24

activated kinases (MSKs) (Arthur, 2008), and MAPK-activated protein kinases
2/3 (MK2/3) and 5 (MK5) (Perander, Keyse, & Seternes, 2008; Ronkina,
Kotlyarov, & Gaestel, 2008).
MAPK-ERKVz pathway. The MAPK-ERK/4 pathway (Figure 1) is primarily
activated by cell surface receptors, especially receptors that undergo Tyr
phosphorylation (Cargnello & Roux, 2011), which include the CNTF receptor
components. These phosphorylated residues serve as specific binding sites for
proteins that contain SH2 domains, such as Grb2 (growth factor receptor-bound
protein 2) (Cargnello & Roux, 2011). A guanine nucleotide exchange factor
(GEF) called SOS (son of sevenless) is recruited from the cytosol to the plasma
membrane as a result of its interaction with Grb2. SOS stimulates the exchange
of GDP bound to Ras (rat sarcoma), which is a small GTPase, to GTP, which is
required for Ras activation (Campbell, Khosravi-Far, Rossman, Clark, & Der,
1998). This nucleotide exchange allows Ras to interact directly with its target
effectors, one of which is Raf, the initiating kinase of the ERK14 pathway
(Campbell, et al., 1998). Activated Raf binds to and phosphorylates the dual
specificity kinases MEKY (MAPKK1/2), which in turn phosphorylates ERK1 at
T hr^/T yr204 and ERK2 at Thr185TTyr187 (Ferrell & Bhatt, 1997; Roux & Blenis,
2004). Significant ERK activation requires phosphorylation at both sites, with Tyr
phosphorylation preceding that of Thr (Ferrell & Bhatt, 1997). While in quiescent
cells ERK1/4 is localized to the cytoplasm; however, upon extracellular
stimulation, a significant proportion of ERKY2 accumulates in the nucleus
(R. H. Chen, Sarnecki, & Blenis, 1992; Lenormand et al., 1993). In addition to
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activation of the cytosolic RSKs, transcription factors such as CREB are
activated by ERK1/2. Interestingly, ERK1
/4 activated RSKs have been
demonstrated to inhibit the pro-apoptotic molecule BAD, while ERK1/2-induced
CREB activity directs transcription of the anti-apoptotic proteins Bcl-2 and Bcl-XL
(Nagata, 1999). These proteins provide evidence of one of the functions of the
MAPK-ERKV2 pathway; induction of cellular survival.
MAPK-ERK5 pathway. The ERK5 pathway is a separate MAPK pathway
from the MAPK-ERK/4 pathway (Figure 1). ERK5 has 51% homology to ERK2
(Cargnello & Roux, 2011) and there are three spliced forms of ERK5: ERK5a,
ERK5b, and ERK5c (C. Yan, Luo, Lee, Abe, & Berk, 2001). ERK5 is ubiquitously
expressed in all tissues, with particularly high levels in the brain, thymus, and
spleen (L. Yan et al., 2003). Genetic deletion of ERK5 demonstrated that it is
essential for early embryonic development (Regan et al., 2002; L. Yan, et al.,
2003) and ERK5 is also required for normal development of the vascular system
as well as cell survival (Sohn, Sarvis, Cado, & Winoto, 2002).
MEK5 was identified as the MAPKK that phosphorylates ERK5, while
other MEKs do not appear to influence ERK5 activity (English, Vanderbilt, Xu,
Marcus, & Cobb, 1995; G. Zhou, Bao, & Dixon, 1995). MEK5 is phosphorylated
by both MEKK2 and MEKK3 in a stimulus- and cell type-dependent manner
(Wang et al., 2006); however, the signaling cascade at this level is not entirely
specific to ERK5 since MEKK2 and MEKK3 can also activate the JNK and p38
pathways. Similar to ERK/4, ERK5 localizes to the cytoplasm in resting cells and
upon activation ERK5 is found in the nucleus (Wang, et al., 2006). There are a
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number of molecules that have been identified as ERK5 substrates, including;
c-Myc and connexin 43 (Hayashi & Lee, 2004; Wang, et al., 2006). ERK5 activity
is increased by growth factors and oxidative stress and was found to regulate cell
survival and proliferation (Wang, et al., 2006).
p38-MAPK pathway. Generally more responsive to stimuli such as
environmental stressors, the p38 family (Figure 1) contains the p38 a, (3., y, and 5
isoforms (Han, Lee, Bibbs, & Ulevitch, 1994; J. C. Lee et al., 1994; Rouse et al.,
1994). p38a and p38l3> are more ubiquitously expressed, while p38y and p385
have more restricted expression patterns and may have specialized functions
(Y. Jiang et al., 1996). Since p38a is generally more highly expressed than p38l3>,
most of the published reports on p38-MAPKs refer to p38a.
In mammalian cells, the four p38 isoforms are strongly activated by
various environmental stresses and inflammatory cytokines (Cuadrado &
Nebreda, 2010). MKK3 (MAPKK3) and MKK6 (MAPKK6) are thought to be the
major kinases responsible for p38 activation (Derijard et al., 1995; Han et al.,
1996; Stein, Brady, Yang, Young, & Barbosa, 1996), but MKK4 (MAPKK4) has
also been shown to possess some activity toward p38 (Meier, Rouse, Cuenda,
Nebreda, & Cohen, 1996). Most stimuli that activate p38-MAPKs also stimulate
JNK isoforms, and many MAPKKKs, including MEKK2/3, in the p38 pathway are
shared by the ERK5 and JNK pathways (Cargnello & Roux, 2011). Upon
activation, p38 has been demonstrated within the nucleus (Ben-Levy, Hooper,
Wilson, Paterson, & Marshall, 1998). Moreover, p38 signaling has been
demonstrated to utilize, among others, the NF-k B transcription factor (Karin,
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2006), and many transcriptional products are produced by the p38 pathway,
including the pro-apoptotic molecule, Bax (Cuadrado & Nebreda, 2010). While
some studies have reported pro-survival functions for the p38 pathway, many
more have associated p38 activity with the induction of apoptosis (Cuenda &
Rousseau, 2007).
JNK-MAPK pathway. Similar to the p38-MAPK pathway, the JNK-MAPK
pathway (Figure 1) is largely responsive to cellular stresses, cytokines, and some
growth factors. There are three JNK isoforms, JNK1-3 (also known as SAPKy
(p46), SAPKa (p54), and SAPKI3., respectively) (Derijard et al., 1994; Kyriakis et
al., 1994). JNK1 and JNK2 are ubiquitously expressed, while JNK3 seems to be
localized primarily to neuronal tissues, testis, and cardiac myocytes (Bode &
Dong, 2007). Furthermore, it has been demonstrated that JNK2 and JNK3 are
expressed within the SON and localized to magnocellular neurons in vivo and in
vitro (Meeker & Fernandes, 2000), while JNK1 localization within the SON has
not been reported.
The MAPKKs involved in the JNK-MAPK pathway are MKK4 and MKK7,
which appear to work in conjunction in the phosphorylation of the JNKs (Lawler,
Fleming, Goedert, & Cohen, 1998). MKK4 and MKK7 are activated by several
MAPKKKs, many of which are involved in ERK5 and p38 signaling, including
MEKK1-4, MLK1-3, and Tpl-2 (Kyriakis & Avruch, 2001; Wagner & Nebreda,
2009). Thus, due to the overlap of signaling components between the MAPK
pathways, multiple pathways may be activated by similar stimuli. Conversely, the
activation of a specific pathway would be dependent on a combination of the
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following; the stimuli, the cellular phenotype activated, and the research
paradigm. Similar to the other MAPK pathways, activated JNKs have been
shown to translocate into the nucleus following stimulation (Mizukami, Yoshioka,
Morimoto, & Yoshida, 1997). The transcription factor cJun is a well-described
substrate for JNKs. cJun is a component of the activator protein-1 (AP-1)
transcription factor complex (Tibbies & Woodgett, 1999), which also include
members of the cFos and cJun families. Interestingly, one of the primary targets
of AP-1 is the cJun gene itself (Tibbies & Woodgett, 1999), indicating a positive
feedback loop regulating cJun activity. Additional transcription factors have been
shown to be phosphorylated by JNK, including; STAT3, c-Myc, and JunB
(Bogoyevitch, Ngoei, Zhao, Yeap, & Ng, 2010; Raman, Chen, & Cobb, 2007).
Analogous to the p38-MAPK pathway, the JNK-MAPK pathway has been
primarily implicated in the induction of neuronal apoptosis (Dhanasekaran &
Reddy, 2008).
The PI3K-AKT Pathway
CNTF may also activate the PI3K-AKT pathway (Figure 1) in some cell
types, possibly via a Jak-dependent signaling mechanism (Dolcet, et al., 2001;
Gold, Duronio, Saxena, Schrader, & Aebersold, 1994; Oh et al., 1998). Activation
results in the recruitment of PI3K to the plasma membrane where the catalytic
subunit of PI3K phosphorylates the membrane phospholipid phosphatidylinositol
(4, 5)-diphosphate (PIP2), generating phosphatidylinositol (3, 4, 5)-triphosphate
(PIP3). The accumulation of PIP3 promotes the translocation of AKT to the
plasma membrane, where AKT binds to PIP3 via its PH domain, allowing
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phosphorylation of Thr308 on AKT by phosphoinositide-dependent kinase
1 (PDK1) (Alessi et al., 1996; K. E. Anderson, Coadwell, Stephens, & Hawkins,
1998). Maximal AKT activity requires the additional phosphorylation of Ser473,
and reports have demonstrated that mammalian target of rapamycin (mTOR), in
a rapamycin-insensitive complex with Sin1 and rictor (mTORC2), functions as the
‘PDK2’ and provides the kinase activity at Ser473 (Hresko & Mueckler, 2005;
Sarbassov, Guertin, Ali, & Sabatini, 2005).
AKT can directly regulate apoptotic machinery by phosphorylating BAD,
which inhibits the pro-apoptotic: functions of BAD (Datta et al., 1997). In addition,
there are many transcriptional targets of AKT, including the transcription factors
CREB (Du & Montminy, 1998), NF-k B (Kane, Shapiro, Stokoe, & Weiss, 1999;
Romashkova & Makarov, 1999), and mTOR, in a rapamycin-sensitive complex
with raptor, DEPTOR, and GI3>L (mTORCI) (Asnaghi et al., 2004; Nave, Ouwens,
Withers, Alessi, & Shepherd, 1999). There are multiple downstream targets of
mTORCI; however, the best characterized are p70 S6 kinase (S6K1) and
eukaryotic initiation factor 4E (elF4E) (H. Zhou & Huang, 2010). After p70S6K1
and elF4E are phosphorylated, mTOR has been reported to be involved in
mechanisms inducing process outgrowth, including axonal regeneration and
dendritic arborization (Jaworski & Sheng, 2006; K. K. Park, Liu, Hu, Kanter, &
He, 2010).
In general, the PI3K-AKT pathway has been implicated in promoting cell
survival, differentiation, and several aspects of neurite outgrowth, including
elongation, branching, and neurite caliber (Read & Gorman, 2009). Interestingly,
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while the Jak-STAT pathway was important to mediate neuronal survival, the
PI3K-AKT pathway was necessary to promote CNTF-induced process outgrowth
of primary neuronal cultures (Ozog, Modha, Church, Reilly, & Naus, 2008).
These reports indicate that CNTF-mediated activation of intracellular signal
transduction pathways is phenotype specific and individual pathways may
mediate different responses dependent on the cellular phenotypes.
The NF-k-B Transcription Factor
CNTF has been demonstrated to signal through NF-k B in various
experimental conditions (Gallagher, et al., 2007; Nishimune, et al., 2000).
Interestingly, NF-k B was implicated in mediating CNTF-induced process
outgrowth in developing sensory neurons (Gallagher, et al., 2007). However, as
indicated above, multiple signaling pathways are capable of utilizing NF-k B; thus,
the CNTF-induced immediate signaling responses that activate NF-k B are not
clear.
NF-k B is a ubiquitously expressed transcription factor system that consists
of homodimers or heterodimers of five structurally related proteins: p65, RelB,
c-Rel, p50, and p52, of which the p50/p65 heterodimer is the most abundant and
widely expressed (Hayden & Ghosh, 2004). NF-k B is held in an inactive form in
the cytosol by interaction with a member of the Ik B family of inhibitory proteins,

which include; Ik Bo, Ik BB, kBy Ik Bs, p100, p105, of which kBa is the
predominantly expressed inhibitor. In the NF-k B signaling pathway, NF-k B is
activated by phosphorylation on serine residues 32 and 36 by an Ik B kinase
complex (Hayden & Ghosh, 2004). This leads to ubiquitination and proteosome31

mediated degradation of Ik Bo and translocation of the liberated NF-k B to the
nucleus where it binds to responsive genes (Hayden & Ghosh, 2004).
Biological Actions of CNTF
While it has already been mentioned that CNTF acts as a survival factor
for cultured parasympathetic neurons, CNTF has also been demonstrated to
promote the survival of retinal ganglion cells (Lehwalder, Jeffrey, & Unsicker,
1989), cortical (Magal, Burnham, & Varon, 1991), hippocampal (Ip et al., 1991),
motor (Albrecht, Dahl, Stoltzfus, Levenson, & Levison, 2002; Arakawa, Sendtner,
& Thoenen, 1990), Purkinje (Larkfors, Lindsay, & Alderson, 1994), and sensory
neurons (Barbin, et al., 1984) in vitro. Within the magnocellular neurosecretory
system, organotypic cultures of the SON and PVN cultured with CNTF rich media
have increased survival of hypothalamic magnocellular neurons over control
cultures (House, Li, Yue, & Gainer, 2009; Rusnak, House, Arima, & Gainer,
2002; Rusnak, House, & Gainer, 2003; Shahar, House, & Gainer, 2004; Vutskits,
et al., 1998; Vutskits, Gascon, & Kiss, 2003). In vivo, CNTF has been shown to
prevent neuronal death in the facial motor nucleus following axotomy by
application of 5 pg CNTF to the stump of the lesioned facial nerve (Sendtner,
Kreutzberg, & Thoenen, 1990). CNTF has also been shown to protect retinal
ganglion cells from apoptosis following optic nerve transection (van Adel, Arnold,
Phipps, Doering, & Ball, 2005), and rescue axotomized anterior thalamic neurons
from retrograde cell death following infusion of 500 pg/mL of rat recombinant
CNTF (rrCNTF) (Clatterbuck, Price, & Koliatsos, 1993). Furthermore, over
expression of CNTF using a retroviral vector rescued 30% of ciliary ganglia
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neurons that would normally undergo cell death during development (Finn, Kim,
& Nishi, 1998).
Along with being a survival factor, CNTF has also been reported as being
a sprouting factor for injured neurons. Following transection of fibers innervating
the gastrocnemius muscle, CNTF null mice did not demonstrate motorneuron
sprouting; however, when exogenous CNTF was administered to mice lacking
CNTF the typical sprouting response was observed (Siegel, et al., 2000). When
organotypic cultures of rat PVN are cultured in the presence of the NL, there is
an observed process outgrowth from the severed magnocellular neurons of the
PVN towards the NL (Vutskits, et al., 1998), which contains a cellular source of
CNTF (Lo, et al., 2008; Watt, et al., 2006) as well as CNTF mRNA (Vutskits, et
al., 1998), suggesting that CNTF may play a role in the sprouting of
neurosecretory axons following partial denervation of the NL (Watt, et al., 1999;
Watt& Paden, 1991).
Given the dramatic and widespread neuroprotective effects of CNTF,
several phase ll-lll clinical trials were undertaken with recombinant human CNTF
(rhCNTF) in patients with ALS (R. G. Miller, Bryan, et al., 1996; R. G. Miller,
Petajan, et al., 1996). Ultimately, these studies reported that systemically
administered CNTF had no beneficial effect, as well as unacceptable side-effects
including cachexia, fever, and a marked immune response, all of which have
limited CNTF’s clinical application. The limited efficacy and undesired sideeffects were attributed to ineffective CNTF administration, because doses greater
than 5pg/kg rhCNTF caused unacceptable toxicity (R. G. Miller, Bryan, et al.,
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1996). Consequently, several phase l-ll clinical studies have been subsequently
performed using encapsulated cells genetically engineered to secrete CNTF for
the treatment of ALS, Huntington’s disease, and retinal degeneration (Bloch et
al., 2004; Sieving et al., 2006; Zurn et al., 2000). Collectively, these studies have
demonstrated the safety and feasibility of using the CNTF gene therapy
procedure, but subsequent phase ll-lll clinical trials have not yet been reported.
Moreover, because of the weight loss side effects from the early clinical trials
(R. G. Miller, Bryan, et al., 1996; R. G. Miller, Petajan, et al., 1996), CNTF is now
being actively pursued as an anorexic therapy (Foster-Schubert & Cummings,
2006).
Research Goal
While it is known that CNTF promotes the survival of a myriad of neuronal
phenotypes, little is understood on the specific CNTF-induced neuroprotective
mechanisms in the CNS. Elucidation of these mechanisms may provide insight
into the development of future therapeutic strategies due to the deleterious sideeffects of systemic CNTF administration. Because of the well-established
plasticity and high endogenous expression of CNTF and CNTFRa, we believe
that the magnocellular neurosecretory system, and specifically the SON,
provides an excellent model system for investigating the neuroprotective role of
CNTF. Therefore, the goal of my research is to determine the mechanisms
underlying the neuroprotective effects of CNTF within the rat magnocellular
neurosecretory system.
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Hypothesis
The central hypothesis of my research is that CNTF acts as both a
neuronal survival and sprouting factor for hypothalamic magnocellular neurons in
vitro and in vivo. The following Specific Aims testing this hypothesis were
pursued.
Specific Aims
Specific Aim 1: Determine the Effect that Injury, Neuronal Activity,
and Age Have on the Protein Levels of CNTF and the CNTF Receptor
Components in the SON and NL
Previous studies have demonstrated that following unilateral lesion of the
hypothalamo-neurohypophysial tract there is a collateral sprouting response that
reinnervates the partially denervated NL (Watt, et al., 1999; Watt & Paden,
1991). Moreover, the observed sprouting response does not occur as a result of
a functional deficit. Conversely, the magnocellular neurons undergo an increase
in neurosecretory activity (Watt, et al., 1999). Therefore, the factor or factors
responsible for the sprouting remained to be determined. Following reports
demonstrating that CNTF promotes magnocellular neuron survival and possibly
potentiates process outgrowth (Rusnak, et al., 2002; Vutskits, et al., 1998), we
demonstrated an increase in CNTF-immunoreactivity and CNTFRa mRNA levels
in the sprouting SON (Watt, et al., 2006; Watt, et al., 2009). However, it remained
be determined if the observed changes in CNTF and CNTFRa were due to the
sprouting or the increase in neurosecretory activity. Thus, I designed
experiments to determine the protein levels of CNTF and the CNTF receptor
components following chronic physiological activation in the male and female rat.
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Furthermore, these studies will extend our previous studies to demonstrate the
protein levels of CNTF and the CNTF receptor components in the SON and NL
following unilateral lesion of the hypothalamo-neurohypophysial tract. In addition,
the localization of gp130 and LIFRI3, within the SON and NL had not been
reported, and these data would provide valuable insight into possible
mechanisms of action by CNTF in the magnocellular neurosecretory system.
While the collateral sprouting response occurs in 35 day old rats following
unilateral hypothalamic lesion, there is an absence of a sprouting response
following unilateral hypothalamic lesion in 125 day old rats (J.A. Watt,
unpublished observation). We have hypothesized that this is due to a deficit in
the CNTF signaling process within the magnocellular neurosecretory system.
Thus, I compared the protein levels of the CNTF signaling components, including
STAT3, in the SON and NL of 35 day old rats to 125 day old rats. In addition, I
determined the protein levels of CNTF and the CNTF receptor components in the
SON and NL following unilateral lesion of the hypothalamo-neurohypophysial
tract in 125 day old rats. The results of these studies may lead to future
experiments demonstrating the role of CNTF in the collateral sprouting response
in the magnocellular neurosecretory system.
Specific Aim 2: Determine the Functional Role of the
Jak-STAT Pathway in CNTF Signal Transduction
in Hypothalamic Organotypic Cultures
The Jak-STAT pathway is considered the canonical pathway for CNTF
signal transduction (Bonni, et al., 1993; Bonni, et al., 1997; Darnell, et al., 1994).
In this regard, our lab has demonstrated that exogenous rrCNTF injection in to
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the SON in vivo activates STAT3 in astrocytes (Askvig et al., 2012b). Thus, I will
extend this observation and determine the temporal activation of the Jak-STAT
pathway following exogenous rrCNTF injection into the SON in vivo.
Others have demonstrated the neuroprotective effects that CNTF has on
hypothalamic magnocellular neurons in organotypic cultures (House, et al., 2009;
Rusnak, et al., 2002; Rusnak, et al., 2003; Shahar, et al., 2004; Vutskits, et al.,
1998; Vutskits, et al., 2003). However, the mechanisms of these neuroprotective
effects have not been reported. Therefore, I designed experiments to determine
the functional role(s) of the contribution of the Jak-STAT pathway in CNTFinduced neuroprotection in hypothalamic organotypic cultures. Organotypic
cultures exhibit several advantages over other in vitro culture systems primarily
because of the preservation of the in vivo cytoarchitecture and the use of fully
differentiated neurons (House, Thomas, Kusano, & Gainer, 1998; Vutskits, et al.,
1998). Furthermore, the ability to directly manipulate the culture media with
growth factors and pharmacological agents and assess magnocellular neuron
survival in hypothalamic organotypic cultures facilitates analysis of pathwaymediated cellular events more rapidly than can be achieved using our in vivo
injury model system.
Specific Aim 3: Determine the Functional Role of the MARK and
PI3K-AKT Pathways in CNTF Signal Transduction
in Hypothalamic Organotypic Cultures
While the Jak-STAT pathway is considered the canonical CNTF signal
transduction pathway, CNTF has been demonstrated to activate multiple
intracellular signaling pathways (Bonni, et al., 1993; Cagnon & Braissant, 2009;
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Dolcet, et al., 2001; Gallagher, et al., 2007; Kassen, et al., 2009; Loy, et al.,
2011; Lutticken, et al., 1994; A. Muller, et al., 2009; K. Park, et al., 2004;
Peterson, et al., 2000; Rhee, et al., 2004; Sango, et al., 2008; Symes, et al.,
1994; Trimarchi, et al., 2009). This occurs because there are multiple points of
convergence between the signaling components of the different pathways.
Moreover, it appears that the activation of a specific pathway is dependent on a
combination of various factors, such as; the stimulus, the cellular phenotype
activated, and the research paradigm. Therefore, I sought to determine if
exogenous rrCNTF injection in to the SON in vivo results in the activation of other
major signaling pathways. Additionally, I assessed the functional role(s) of these
pathways in mediating the CNTF-induced neuroprotective mechanisms that are
observed in hypothalamic organotypic cultures. The results and a discussion of
the implications of our findings are presented herein.
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CHAPTER II
MATERIALS AND METHODS
To test the previously stated hypothesis-driven questions regarding CNTF
acting as both a neuronal survival factor and sprouting factor for hypothalamic
magnocellular neurons in vitro and in vivo, various experimental techniques were
employed. Extensive animal work was performed including stereotaxic surgeries
and organotypic explant culture preparation. In addition to the animal
preparations, Western blot and immunohistochemical analyses were performed.
Animals
Male and female Sprague-Dawley rats used in the in vivo studies were
purchased from Charles River Laboratories (Wilmington, MA) while pregnant
female Sprague Dawley rats (E15) were purchased from Harlan (Minneapolis,
MN). All rats were housed in the University of North Dakota Center for
Biomedical Research Facility, an AAALAC accredited facility, under a 12L:12D
light cycle with ad lib access to lab chow and tap water throughout the
investigations, unless otherwise noted. Experimental protocols utilized in these
studies followed the guidelines in the NIH guide for the care and use of
laboratory animals and were approved by the UND Institutional Animal Care and
Use Committee (protocol #0704-2c). All efforts were made to minimize the
number of animals used in this study and their suffering.

39

Rats in the in vivo analyses were assigned randomly to the following
experimental groups: 35 day old male control (75-1 OOg), 35 day old male lesion
(75-1 OOg), male salt-loaded control (200-250g), male salt-loaded (200-250g),
male acute CNTF-injected (250-400g), 125 day old male control (450-600g),
125 day old male lesion (450-600g), female virgin control (250-300g), female
lactating (250-300g), and female salt-loaded (250-300g). Rats in the salt-loaded
groups were given 2% salt water for 10 days in place of tap water and female
lactating rats were taken from their cage following 21 days of nursing their pups
and sacrificed within five minutes of their pups suckling.
Stereotaxic Surgery
Unilateral Lesion of the Hypothalamo-Neurohypophysial Tract
Male rats were either 35-40 (75-1 OOg) or 125 days of age (450-600g) at
the time a unilateral hypothalamic knife cut of the hypothalamo-neurohypophysial
tract was performed. The animals were secured in a stereotaxic apparatus
(Stoelting, Wood Dale, IL) and kept under constant isoflurane anesthesia (2.5%;
Abbot Laboratories; Abbott Park, IL) using a tabletop anesthesia machine (Matrx
Quantiflex Low Flow V.M.C.; Matrx, Orchard Park, NY) equipped with an
isoflurane Vaporizer (Matrx VIP 3000; Matrx). The knife tract extended from the
dorsal to the ventral surface of the brain, medial to the ipsilateral SON, but
passing through the lateral aspect of the ipsilateral PVN. Stereotaxic lesion
coordinates were 0.6 mm (for 35 day old lesion) or 0.8 mm (for 125 day lesion)
lateral to the midsagittal suture, and the lesion extended from -4.0 mm to
+4.0 mm anterior-posterior from bregma. This results in complete transection of
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the ipsilateral hypothalamo-neurohypophysial tract (Watt & Paden, 1991). The
animals were sacrificed 10 days post surgery along with age-matched noninjured control animals. A 90% success rate was confirmed using a cresyl violet
(Sigma, St. Louis, MO) counterstain to demarcate the lesion tract and only the
animals with a complete transection were included in these studies.
Acute rrCNTF Injections
For acute injection of exogenous rrCNTF into the rat SON, male SpragueDawley rats (250-400g) were secured in a stereotaxic apparatus and kept under
constant isoflurane anesthesia (2.5%) using a tabletop anesthesia apparatus
equipped with an isoflurane vaporizer. Lyophilized carrier-free rrCNTF (#03835,
lot #080M1730, Sigma; St. Louis, MO) solubilized in artificial cerebral spinal fluid
(aCSF, 290 mOsmo/l) to a final concentration of 100 ng/pl was drawn into a
10 pi syringe (26 gauge; Hamilton, Reno, NV). The syringe was placed in a
stereotaxic injector (Quintessential Stereotaxic Injector; Stoelting) mounted onto
a stereotaxic apparatus (Stoelting) and 1 pi rrCNTF, or vehicle (aCSF), was
pressure injected immediately dorsal to the right SON (coordinates: AP -0.9 mm,
ML -2.3 mm, DV -9.5 mm) at a rate of 0.2 pl/minute over a 5 minute period.
Following injection, the syringe was left in place for 5 minutes to allow for
diffusion away from the injection site. Precise targeting of the cannula tip was
confirmed by immunohistochemical confirmation of the syringe tract with goat
anti-rat CNTF. We observed an 80-90% success rate in cannula targeting and
only those animals with a confirmed syringe tract were used in these studies. The
following groups were prepared for quantitative Western blot analysis following
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CNTF injection (n=6 per time point); 1 hr post-vehicle injected SON; non-infused
contralateral control SON from 1 hr post-CNTF injection; 1 hr post-CNTF injected
SON; and 3 hrs post-CNTF injected SON. The pharmacological inhibitor of Jak2,
AG490 (#658401, Calbiochem, Gibbstown, NJ), was dissolved in
dimethylsulfoxide (DMSO) and administered (10 mg/kg, intraperitoneally) 1 hour
prior to rrCNTF injection. These rats were sacrificed at 1 hour post-CNTF
injection (AG490 + 1 hr CNTF-injected SON). Moreover, a qualitative Western
blot analysis (n=1 per time point) was performed at; 15, 30, 45 minutes, 6, 12, 24,
and 48 hours post CNTF-injection.
Gel Electrophoresis and Western Blot Analysis
Following acute injection of rrCNTF, animals were anesthetized with
isoflurane anesthesia and decapitated. SON samples were carefully collected
under a dissecting microscope and pooled from 3 rats (18 total rats, n=6 per time
point) in a solution of radioimmuno-precipitation assay (RIPA) buffer containing
20 mM Tris (pH 7.5; Sigma), 150 mM NaCI (Sigma), 1% nonidet P-40 (Roche
Diagnostics; Indianapolis, IN), 0.5% sodium deoxycholate (Sigma), 1 mM EDTA
(Sigma), 0.1% SDS (Pierce; Rockford, IL), 1% protease inhibitor (Protease
Inhibitor Cocktail; Sigma), and 1% phosphatase inhibitor (Phosphatase Inhibitor
Cocktail 2; Sigma). Following other experimental paradigms (i.e. unilateral lesion,
salt-loading, lactation), SON and NL samples were pooled in RIPA from 6 rats
(30 total rats, n=5 per group). The tissue samples were then homogenized in
RIPA buffer and centrifuged at 10,000 rpm for 20 minutes at 4°C. Supernatant
from each sample was stored at -80°C until needed. Each lane was loaded with
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either 10 pg (for tubulin experiment), 15 pg (for signal transduction analysis), or
50 pg (for other experiments) of protein and separated by a 12% SDS-PAGE gel
(Precise Protein Gels; Pierce) at 90 V for approximately 1.25 hours and then
electrophoretically transferred to a PVDF membrane (0.2 pm; BioRad, Hercules,
CA) at 70 V for 2 hours. Membranes were washed in PBS containing 0.5%
Tween 20 (PBS-Tween; Sigma) for a minimum of 4x15 minute intervals between
incubations. Membranes were then incubated in blocking solution (5% BSA or
dehydrated milk in PBS-Tween; Sigma) for 1 hour at room temperature. Next, the
membranes were incubated in a primary antibody (Table 1) overnight at 4°C.
Following PBS-Tween washes for 2 hours, the membranes were incubated in the
appropriate species-specific horseradish peroxidase secondary antibody
(1:150,000; Santa Cruz). Subsequently, the bands were visualized, following
PBS washes for 2 hours, using the West Femto chemiluminescent detection kit
(Pierce) with high performance chemiluminescence film (Amersham Hyperfilm
ECL; VWR; West Grove, PA) developed using an AGFA CP1000 film processor.
Afterward bound antibodies were stripped with a stripping buffer (pH 2.2;
15g glycine; Sigma, 1g SDS; Bio-Rad, 10ml Tween 20 in 1L ultrapure water) for
10 minutes and the blots were sequentially re-probed with subsequent antibodies
including the loading control, anti-G-actin.
All of the primary antibodies utilized in the Western blot analysis have
been previously characterized either within our lab or by other labs. The mouse
anti-G>-actin antibody recognizes an epitope located on the N-terminal end of the
rat (3-isoform of actin (Gimona et: al., 1994). 13,-actin was used as a tissue loading
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control for our Western blot analyses and the anti-l3.-actin antibody consistently
recognized a band at approximately 42 kDa in all tissue samples analyzed in the
present study. Moreover, to assess specificity of the anti-CNTF and -CNTFRa
antibodies to the antigen of interest, the Western blot was incubated with the
antibody plus a 10 molar excess of the appropriate purified rat recombinant
protein overnight at 4°C (pre-adsorption control).
Densitometric analysis of immunoblot signals was performed using MCID
image analysis software (version 7.0, Imaging Research Inc.). Band intensities
were expressed as relative optical density (ROD) units. To obtain accurate
density measurements band areas were multiplied by the ROD value and the
background was subtracted. The ROD of all bands was normalized to the
respective ROD of l3>-actin bands to obtain ratios. Flowever, in order to determine
the amount of total protein that is phosphorylated in the signal transduction
analyses, the ROD of the phosphorylated protein was normalized to the ROD of
the total protein, as opposed to the ROD of l2>-actin, to obtain a ratio used for
statistical analysis. Analysis was repeated on 3 separate samples per group
resulting in mean ratio values for each group that were used for statistical
analysis as described below.
Immunohistochemistry
Peroxidase Immunohistochemistry
Following experimental periods rats utilized in immunohistochemical
analyses were perfused intracardially with 100 mL of saline under deep
isoflurane anesthesia followed by perfusion of 450 mL of periodate-lysine44

paraformaldehyde fixative (PLP; 3.2% paraformaldehyde, 2.2% lysine,
0.33% sodium-(meta) periodate; Sigma) prepared immediately before use
(McLean & Nakane, 1974). The brains and NLs were removed intact and then
the brains were blocked with a razor blade to contain the magnocellular
neurosecretory system nuclei, post-fixed in PLP overnight and then
cryoprotected in 20% sucrose (Sigma) in phosphate buffered saline (PBS) for
three to five days. Next, the tissue was embedded in OCT (Ted Pella; Redding,
CA) and frozen in isopentane (Sigma) chilled to -80°C for three to five minutes.
Once the tissue was frozen, serial cryosections were collected coronally
throughout the brain (16 pm) or NL (10 pm) using a cryostat (Microm HM550;
Fisher Scientific; Pittsburgh, PA) and thaw mounted on gelatin coated slides.
For all immunohistochemical staining runs sections were first rehydrated
in PBS followed by a treatment with 0.3% hydrogen peroxide in PBS for
30 minutes to remove endogenous peroxidase activity. All incubations were
followed by a minimum of 3x10 minute washes with PBS containing 0.1% triton
(PBS-T; Sigma). Next, non-specific staining was alleviated by treatment with
4% normal serum from the secondary antibody species in PBS-T (blocking
buffer) for 1 hour at room temperature followed by an overnight incubation at 4°C
in the primary antibody prepared in blocking buffer (Table 1). The tissue sections
were then incubated in a biotinylated immunoglobulin G (IgG; 1:500 in blocking
buffer; Vector; Burlingame, CA), specific for the species of the primary antibody,
for 1 hour, followed by an incubation in avidin-biotin complex (ABC; ABC Elite kit;
Vector) in PBS for 1 hour. Binding of ABC reagent was visualized with a
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14.5 minute reaction in 0.05% diaminobenzidine (DAB; 200 mg glucose,
40 mg ammonium chloride, 50 mg DAB per 100 mL PBS; Sigma) with the
enzyme glucose oxidase (300 pL per 100 mL DAB; Sigma) used to generate the
hydrogen peroxide needed for the reaction (Itoh et al., 1979). Following PBS
washes, sections labeled with anti-oxytocin and -vasopressin were incubated in
the nuclear counterstain hematoxylin (Vector) for 30 seconds before proceeding
through the alcohol dehydration steps. All sections were dehydrated in increasing
concentrations of alcohol followed by xylene washes and coverslipped with
Permount (Fisher).
Fluorescence Immunohistochemistry
For dual-label fluorescence immunohistochemistry, all steps were the
same as listed above unless otherwise noted. Tissue immunoreactivity was
detected by incubation in a cocktail containing either goat anti-CNTFRa, rabbit
anti-LIFRI3>, or rabbit anti-gp130 with either mouse anti-GFAP, mouse anti-s100G>,
guinea pig anti-vasopressin, or guinea pig anti-oxytocin (Table 1) in blocking
buffer overnight at 4°C followed by species-specific secondary IgG and
fluorescently conjugated Texas Red or FITC (1:1000; Jackson ImmunoResearch,
West Grove, PA). Fluorescent sections were coverslipped with Vectashield
mounting medium containing DAPI (Vector). All sections were viewed and
images were captured using either an Olympus BX-51 light microscope with
attached DP-71 color camera and dedicated software or an Olympus fluoview
confocal microscope. Images were prepared for reproduction using Adobe
Photoshop CS3.
46

As a control for the dual label fluorescence immunohistochemistry,
incubations with either goat anti-CNTFRa, rabbit anti-LIFRG., or rabbit anti-gp130
antibodies on separate sections of tissue were followed by an incubation with the
species-specific fluorescent-conjugated secondary antibodies for anti-GFAP,
-oxytocin, -s100l2>, and -vasopressin. Similarly, after separate sections of tissue
were incubated with the anti-GFAP, -oxytocin, -s100R>, or-vasopressin antibodies
the tissue was exposed to the fluorescent-conjugated secondary antibodies for
the opposing primary antibodies. These controls demonstrated an absence of
immunoreactivity in the rat SON (see Results), indicating that the fluorescentconjugated secondary antibodies were specific for their appropriate primary
antibody and there was no observable cross-reactivity between the secondary
antibodies.
Stationary Hypothalamic Organotypic Cultures
Organotypic cultures were prepared using a modification of techniques
described previously (House, et al., 2009; House, Rusnak, Liu, Youle, & Gainer,
2006; House, et al., 1998; Rusnak, et al., 2002; Rusnak, et al., 2003; Vutskits, et
al., 1998). Briefly, 6-day-old Sprague Dawley rat pups were decapitated and their
brains were removed and placed in chilled Geys Balanced Salt Solution (Gibco,
Grand Island, NY) enriched with glucose (5 mg/ml; Sigma). The brains were
trimmed to remove exterior cortical material and 350 pm coronal sections were
obtained using a Mcllwain Tissue Chopper (Stoelting). The sections containing
the magnocellular neurosecretory system nuclei were placed in chilled Geys
Balanced Salt Solution and then trimmed dorsal to the third ventricle and lateral
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to the SON under a dissecting microscope. Sections from each animal were then
placed on a single Millicell-CM filter insert (pore size 0.4pm, 30mm diameter;
Millipore, Bedford, MA) and each filter insert was then placed in a 35x10 mm
Petri dish containing 1.1-1.2 ml of culture media for the experimental period.
Media and Incubations
The standard culture media was made fresh at the beginning of every
experiment and consisted of Eagle’s Basal Medium with Earle’s salts (50%;
Gibco), heat inactivated horse serum (25%, #26050-088 lot #1034545; Gibco),
Hank’s balanced salt solution (25%; Gibco), glucose (0.5%; Sigma),
penicillin/streptomycin (25 units/ml; Gibco), and glutamine (1.0 mM; Gibco). The
osmolality and pH of the culture media were measured from the stock media
solution every 48 hours using a Wescor vapor pressure osmomoter (Wescor
5500; Logan, UT) and a mini pH meter (IQ Scientific Instruments, Loveland, CO),
respectively. Incubation of the cultures was stationary in 5% C 02-enriched air at
35°C for the entire experimental period.
In the current studies, hypothalamic slices were cultured in the presence
or absence of rrCNTF (#C3835, lot #080M1730 and #091M1403, Sigma) for 7 or
14 days. All groups had their culture media replaced every 48 hours and always
received fresh additions of rrCNTF. Inhibition experiments were performed by
administering the small molecule pharmacological inhibitor (Table 2) in the
absence of rrCNTF for 1 hour prior to treatment of the cultures followed by
replacement with media containing the inhibitor plus rrCNTF for the duration of
the experimental period. Additional control cultures received only the inhibitor for
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the entire experimental period. Briefly, inhibition of the Jak-STAT pathway was
achieved by utilizing AG490 and cucurbitacin I (Figure 2), various components of
the MAPK pathway were inhibited with U0126, PD98059, PD184352, SP600125,
and SB203580 (Figure 3), the PI3K-AKT pathway was inhibited with LY294002
and wortmannin (Figure 4), mTOR signaling was inhibited utilizing rapamycin and
torin-1 (Figure 4), and the NF-k B transcription factor was inhibited by bay 117082 and sc-514 (Figure 5). In order to be thorough, multiple inhibitors were used
to inhibit the pathways at various points. The concentrations used for each
inhibitor was determined from literature searches of inhibitor concentrations used
in primary cell cultures, or when available, in organotypic cultures.
As a control for the rrCNTF protein, we had a construct generated for the
reverse sequence of the rat CNTF sequence (NEO Group, Inc., Cambridge, MA).
The construct contained a His-tag and was generated in E.Coli BL21 (DE3) strain
using the protein sequence: 1MNHKVHHHHH HMKKNNAIYH SGRAPIGPQH
SSAFRLDHIS RVTWQSLEQL 51VKLGWLKKEF LGGDGVNIPM GDAENRPIKY
ELLIMLEEIQ YAFAAVQLLL 101THIAQHFDGE TPTFHVQQDE LLRALLVHFT
RYAQLNEQLR EAETLESWQD 151TSAVPMGDAS DLNINKNLGQ HKVYSETLAT
LDSRLKRALW ISRSCLDRRH 201PTLPSHETFA M. The reverse sequence CNTF
construct was estimated to be 80% pure by a Coomassie blue-stained SDSPAGE gel (NEO Group, Inc.). Subsequently, a group of hypothalamic
organotypic explant cultures received 25 ng/ml reverse CNTF for 14 days.
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Organotypic Culture Immunohistochemistry
Following experimental periods, the explants were prepared for
immunohistochemistry with fixation in 4% paraformaldehyde (Sigma) in
0.1 M phosphate buffer for 1.5 hours. For immunohistochemical analysis,
sections were washed with PBS in 3x10 minute intervals before and after all
incubations. For single-label peroxidase immunocytochemistry, endogenous
peroxidase activity and non-specific staining were prevented by treatment with
0.3% H20 2 (Sigma) followed by incubation in blocking buffer (10% normal horse
serum containing 0.3% Triton X-100) for 1.5 hours. The explants were then
incubated for 36 hours at 4°C in highly specific monoclonal mouse antibodies
against oxytocin-neurophysin or vasopressin-neurophysin (Table 1). These
antibodies were characterized by Ben-Barak et al. (1985) and have been
consistently utilized to label oxytocinergic and vasopressinergic neurons and
their processes within organotypic cultures (House, et al., 2009; House, et al.,
2006; House, et al., 1998; Rusnak, et al., 2002; Rusnak, et al., 2003; Shahar, et
al., 2004; Vutskits, et al., 1998; Vutskits, et al., 2003). Next the cultures were
incubated in horse anti-mouse biotinylated secondary antibody (1:500; Vector),
followed by avidin-biotin complex (ABC; 10 pl/ml in PBS; Vector ABC Elite kit) for
1 hour at room temperature. Bound antibodies were visualized using 0.05%
diaminobenzidine (DAB, Sigma) in PBS developed through the glucose-oxidase
method (Itoh, et al., 1979). The hypothalamic slices were then removed from
their filters and placed directly on gelatin coated slides. All slides were then
dehydrated in increasing concentrations of alcohol followed by xylene rinses and
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coverslipped with Permount (Fisher, Pittsburgh, PA). All images were captured
using an Olympus BX-51 light microscope with attached DP-71 color camera and
dedicated software. Montage images were prepared for reproduction using the
‘photomerge’ option in Adobe Photoshop CS3.
Data Analysis
In Vivo Oxytocin and Vasopressin Magnocellular Neuron Counts
To ensure that the same magnocellular neuron was not counted twice,
adjacent sections were stained for oxytocinergic and vasopressinergic
magnocellular neurons and a minimum of five sections (80 pm) were skipped
before the next section was processed. Following immunocytochemical labeling
of oxytocinergic and vasopressinergic magnocellular neurons, the sections were
randomly coded by a third-party blind to experimental conditions. Immunopositive
neurons containing a counterstained nucleolus were counted using a drawing
tube attached to an Olympus BX51 microscope. In order to account for the
rostral-caudal size difference of the SON, we determined the numbers of cells
per unit area of SON by obtaining the total area of each SON using Image J.
Data are expressed as the percentage of the age-matched controls.
Organotypic Culture Magnocellular Neuronal Counts
The slides containing the immunoreactive explant culture slices were
coded by a third party blind to the experimental conditions. In order to obtain the
total number of neurons in the PVN, SON, and accessory nuclei (ACC),
immunoreactive cells were counted using a drawing tube attached to an Olympus
BX51 microscope. The values used in statistical analysis represent the total
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number of immunoreactive neurons for each nuclei of one neonatal hypothalami
(i.e. one filter insert) and it was the mean of two individual’s independent
neuronal counts that were used as the group mean for statistical analysis as
described below.
Organotypic Culture Process Outgrowth Analysis
In order to quantify the neuronal process outgrowth in the SON of
organotypic cultures, we utilized a previously described organotypic culture
process stereological analysis technique modified for our culture system
(Bilsland, Rigby, Young, & Harper, 1999). First, slides were coded by a third
party blind to the experimental conditions and the SON was viewed at 10x
magnification on an Olympus BX51 microscope. In order to ensure consistency
across groups, the SON was placed in the lower center frame of the picture
(1360x1024 image size). A grain counting function in MCID image analysis
software (Cambridge, England) was used in order to quantify the area occupied
by the neuronal processes. Grain counting is an automatic target detection and
measurement feature that quantifies the area in pixels occupied by a target
according to the defined target criteria (Bilsland, et al., 1999). The target criteria
are set combining the optical density and spatial characteristics of the target. In
order to establish this criterion, the image was opened in MCID and ‘Grain Count’
was selected, which was under ‘Settings’ - ‘Study’ tab. In the ‘Scan Area’ box,
the density for the target was adjusted to fill the neuronal processes and cell
bodies. Once the density was set, any pixel falling within this range in the image
was automatically counted. A full image scan of the micrograph was performed
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which gave the proportional area of the entire micrograph that was occupied by
the neuronal processes and cell bodies (total proportional area). Next, the
density was determined as described above, however, just for the neuronal cell
bodies, which gave the proportional area of the picture that was occupied by the
neuronal cell bodies (somata proportional area). The somata proportional area
was subtracted from the total proportional area to determine the proportional
area that was occupied by the neuronal processes (process proportional area),
which was the value that was utilized in the statistical analysis. As each
organotypic culture differs in terms of intensity of immunoreactivity and
background, the density was set for each image before quantification was
undertaken. Since each SON varies in the amount of magnocellular neurons, we
corrected for the number of neurons in the SON by standardizing the process
proportional area to the total number of neurons in the SON. Thus, the values
utilized for statistical analyses, as described below, represent the ratio of process
proportional area to total number of neurons in the SON.
Statistical Analysis
Distribution normality of each group of data was tested using the
Kolmogorov-Smirnov test (GraphPad InStat) and all groups were normally
distributed. Student’s t test, one-way ANOVA with post hoc Tukey’s tests, or
2-way ANOVA with Bonferroni post hoc test to compare replicate means by row
(GraphPad InStat, version 3.06 for Windows, San Diego California) were used,
where appropriate, to compare groups with p<0.05 considered statistically
significant. Results are expressed as the group means ± SD.
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CHAPTER III
RESULTS
Specific Aim I: Determine the Effect that Injury, Heightened Neurosecretory
Activity, and Age Have on the Protein Levels of CNTF and the
CNTF Receptor Components in the SON and NL
We demonstrated previously that unilateral lesion of the hypothalamoneurohypophysial tract results in an increase in CNTF mRNA expression in the
axotomized SON (Watt, et al., 2006). This occurs concomitant with an increase in
CNTF-immunoreactivity (Watt, et al., 2006) and CNTFRa mRNA expression
(Watt, et al., 2009) in the contralateral, sprouting SON. However, the protein
levels of CNTF and the CNTF receptor components following unilateral lesion of
the hypothalamo-neurohypophysial tract remained to be determined. Therefore,
in the current study we quantified the protein levels of CNTF and components of
the tripartite receptor complex, CNTFRa, gp130, and LIFRIi, in the contralateral
intact and axotomized SON and NL and sought to determine if the previously
observed responses in the contralateral SON are due to increased
neurosecretory activity. Moreover, previous studies have demonstrated the
complete absence of sprouting in the mature, 125 day old rat following unilateral
hypothalamic lesion (J.A. Watt, unpublished observations). Therefore, we will
determine the protein levels of CNTF and the CNTF receptor components in the
SON and NL of the 125 day old rat in the absence and presence of unilateral
hypothalamic lesion.
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Protein Levels of CNTF and the Receptor Components Following Unilateral
Lesion of Flypothalamo-Neurohypophysial Tract in the 35 Day Old Rat
Confirmation of the lesion tract was performed using a cresyl violet
counterstain, which clearly demarcates the lesion tract as well as the surviving
magnocellular neurons (Figure 6A). Only those animals with a complete rostralcaudal transection of the hypothalamo-neurohypophysial tract were included in
the following analyses. At 10 days post-lesion (10 dpi), it is apparent that there
was a dramatic reduction in the number of magnocellular neurons in the SON
following unilateral lesion in the 35 day old rat (Figure 6A). Moreover, Figure 6B
illustrates the reduction in oxytocinergic axonal profiles arising from the right
SON within the median eminence. These observations were quantified by
performing oxytocinergic and vasopressinergic magnocellular neuron counts that
was corrected for the size of the SON. Our analysis demonstrated that at 10 dpi
there was an 85% and 90% loss of oxytocinergic and vasopressinergic
magnocellular neurons, respectively, in the axotomized SON of the 35 day old rat
(one-way ANOVA, F=119.0, p<0.0001\ Figure 7). Furthermore, there was no
significant difference in the number of oxytocinergic or vasopressinergic
magnocellular neurons in the SON contralateral to the injury (one-way ANOVA,
F=119.0, p=0.6533, p=0.5327\ Figure 7), which is the SON from which the
sprouting response arises (Watt, et al., 1999; Watt & Paden, 1991). These data
indicate that the axotomy only results in neuronal loss ipsilateral to the lesion
tract.
As a control to ensure specificity of the antibody to the antigen of interest,
a pre-adsorption control for the anti-CNTF and -CNTFRa antibodies utilized in
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the Western blot analyses was performed. When staining for anti-CNTF, Western
blot analysis revealed multiple bands for CNTF in the SON (Figure 8A). In
addition to the expected band for CNTF at 23 kDa, there were two prominent
bands observed between 36 and 55 kDa that have been previously reported in
the literature (Henderson, Seniuk, & Roder, 1994; Narhi et al., 1997). Reports
have demonstrated that CNTF exists primarily as monomers; however, as a
means of physiological storage of CNTF, dimer formation occurs as the protein
concentration increases (McDonald, Panayotatos, & Hendrickson, 1995; Narhi, et
al., 1997). Together, these reports suggest that the observed higher molecular
weight bands for CNTF are dimeric CNTF. Following the pre-adsorption of the
anti-CNTF antibody with a 10 molar excess of exogenous rrCNTF, there was a
dramatic reduction in band intensity (Figure 8B), indicating that the anti-CNTF
antibody is specific for rat CNTF. When staining for anti-CNTFRa, Western blot
analysis revealed two bands at approximately 40 and 60 kDa corresponding to
the non-glycosylated and glycosylated forms of CNTFRa, respectively
(Figure 8C). Following the pre-adsorption of the anti-CNTFRa antibody with
10 molar excess of exogenous rrCNTFRa, there was a complete loss of the
bands (Figure 8D). Furthermore, when 50 ng of rrCNTF or rrCNTFRa were run
on a Western blot, the anti-CNTF and anti-CNTFRa antibodies detected
prominent bands at 23 (Figure 9A) and 40 kDa (Figure 9B), respectively.
Therefore, all Western blot analyses for CNTF and CNTFRa were performed on
the bands at their reported molecular weights, 23 and 40 kDa, respectively, as
opposed to the higher molecular weight bands that were also observed.
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Our lab has previously demonstrated an increase in CNTFimmunoreactivity in the SON and NL (Lo, et al., 2008; Watt, et al., 2006), and
CNTFRa mRNA levels in the SON following unilateral lesion (Watt, et al., 2009).
We sought to confirm and extend these observations by determining the protein
levels of CNTF and the CNTF receptor components in the SON and NL following
unilateral hypothalamic lesion. By 10 dpi Western blot analysis demonstrated that
CNTF protein levels were significantly elevated by 79% in the SON contralateral
to the injury (one-way ANOVA, F=91.94, p=0.0003; Figure 9A) and by 169% in
the axotomized SON compared to age-matched control SON (one-way ANOVA,
F=91.94, p<0.0001; Figure 9A). Protein levels of CNTFRa undergo similar
changes in the SON following unilateral lesion. As shown in Figure 9B, in the
non-injured control SON, low endogenous CNTFRa protein levels were
detectable by Western blot analysis with a small and faint band. However, at
10 dpi we observed a 140% increase in CNTFRa protein levels in the SON
contralateral to the injury and a 233% increase in the axotomized SON compared
to age-matched control SON (one-way ANOVA, F=81.24, p<0.0001\ Figure 9B).
While CNTFRa provides the specificity for CNTF signaling, it is the gp130 and
LIFRI3. components that directly mediate intracellular signaling in response to
CNTF (Davis, Aldrich, Stahl, et al., 1993). Therefore, we next examined whether
the changes in CNTFRa were accompanied by changes in gp130 and LIFRG
protein levels. As shown in Figure 9C, Western blot analysis demonstrated a
prominent band at approximately 190 kDa corresponding to LIFRI3> in the noninjured control SON. LIFRI3. protein levels in the SON contralateral to the injury
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and the axotomized SON were significantly elevated by 34% (one-way ANOVA,
F=65.28, p=0.0013; Figure 9C) and 98% (one-way ANOVA, F=65.28, p<0.0001\
Figure 9C), respectively, from the age-matched control levels at 10 dpi. As
shown in Figure 9D, Western blot analysis demonstrated a faint band at
approximately 130 kDa corresponding to gp130 in the non-injured control SON.
By 10 dpi protein levels of gp130 increased by 176% in the SON contralateral to
the injury (one-way ANOVA, F=22.67, p=0.0004; Figure 9D) and 258% in the
axotomized SON (one-way ANOVA, F=22.67, p=0.0002\ Figure 9D) compared to
age-matched control SON.
In addition to CNTF being endogenously expressed in the SON, our lab
previously demonstrated that CNTF is endogenously expressed in perivascular
cells of the NL (Lo, et al., 2008). Furthermore, similar to the response observed
in the SON, unilateral hypothalamic lesion results in the increase in the number
of CNTF-immunoreactive cells in the NL (Lo, et al., 2008). However, the protein
levels of CNTF the CNTF receptor components in the NL following unilateral
lesion of the hypothalamo-neurohypophysial tract remained to be determined.
Therefore, we quantified the change in the protein levels of CNTF and the CNTF
receptor components in the NL following unilateral lesion.
At 10 dpi Western blot analysis demonstrated that CNTF protein levels
were significantly elevated by 72% in the axotomized NL compared to agematched control NL (Student’s (test, p=0.0024; Figure 10A). Similarly, protein
levels of CNTFRa were significantly increased in the axotomized NL above agematched control NL by 160% at 10 dpi (Student’s t test, p<0.0001\ Figure 10B).
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Moreover, Western blot analysis demonstrated a significant increase in LIFRG
and gp130 protein levels by 69% (Student’s t test, p=0.0003\ Figure 10C) and
108% (Student’s t test, p=0.0183\ Figure 10D), respectively, at 10 dpi in the
axotomized NL compared to age-matched control NL.
Altogether, these data demonstrate that the injury associated with
unilateral hypothalamic lesion increased the protein levels of CNTF and its
receptor components in the axotomized SON in spite of an almost complete loss
of magnocellular neurons. In addition, protein levels of CNTF and the CNTF
receptor components were elevated in the terminal field following unilateral
hypothalamic lesion. Furthermore, protein levels of CNTF and its receptor
components are significantly elevated in the sprouting, metabolically active SON,
in the absence of neuronal loss, suggesting that either the sprouting response
per se or the increase in neurosecretory activity resulted in the increase in
protein levels of CNTF and its receptor components.
Tubulin Protein Levels Following Unilateral Lesion of HypothalamoNeurohypophysial Tract in 35 Day Old Rat
The regulation of axonal growth following axotomy is believed to be under
the influence of the levels of a- and l2>-tubulin subunits since their products form
microtubules which are the major structural components that enable neurite
extension (Paden, et al., 1995a). Others have demonstrated that axonal injury
that results in robust axonal growth is accompanied by elevations in several
tubulin mRNAs (Hoffman & Cleveland, 1988; K. J. Jones & Oblinger, 1994; Wong
& Oblinger, 1990). Of interest to our lab, it was demonstrated that unilateral
hypothalamic lesion results in an increase in al- and Gll-tubulin mRNAs in the
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sprouting SON at 10 dpi (Paden, et al., 1995a). Thus, we sought to determine if
the mRNA increases translate to changes in the protein levels of a- and
(3>ll-tubulin in the magnocellular neurosecretory system following unilateral
hypothalamic lesion.
Since a reliable antibody for the al-tubulin subtype was not commercially
available, we utilized a general a-tubulin antibody that recognizes all a-tubulin
subtypes and a specific G.Il-tubulin antibody. Moreover, due to the high protein
levels of a- and SI l-tubulin in the magnocellular neurosecretory system, 10 pg of
total protein was run for the tubulin experiments. Unlike the increases observed
in the al- and Sll-tubulin mRNAs at 10 dpi, our results demonstrated that there
was no significant difference in the a-tubulin (one-way ANOVA, F=1.307,
p=0.1812; Figure 11A) or Sll-tubulin (one-way ANOVA, F=0.6302, p=0.3327\
Figure 11B) protein levels in the sprouting SON. Similarly, we did not observe a
significant difference in the a-tubulin (one-way ANOVA, F=1.307, p-0.2297\
Figure 11 A) or SI l-tubulin (one-way ANOVA, F=0.6302, p=0.3352\ Figure 11B)
protein levels in the axotomized SON. We extended the observations to
determine the tubulin protein levels in the NL following unilateral hypothalamic
lesion. Similar to the SON, our results demonstrated that there was no significant
difference in the a-tubulin (Student’s ftest, p=0.2068; Figure 11C) or Sll-tubulin
(Student’s ^ test, p=0.2242; Figure 11D) protein levels in the NL at 10 dpi. These
data demonstrate that the previously demonstrated increases in tubulin message
levels did not translate in to increases in the tubulin protein levels.
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Protein Levels of CNTF and the Receptor Components Following Fleightened
Neurosecretory Activity
Male Rat
In order to determine if the increase in neurosecretory activity resulted in
the increase in the protein levels of CNTF and its receptor components following
unilateral hypothalamic lesion, we utilized a chronic hypernatremia paradigm in
which non-injured magnocellular neurons are physiologically activated for
10 days by substituting tap water with a 2% salt-water solution. Previous reports
have demonstrated that physiological activation of the MNS via salt loading
results in heightened neurosecretory output and synthetic activity which is
reflected in increased size of magnocellular somata and nuclei in the SON
(Hatton & Walters, 1973; S. H. Lin, Miyata, Kawarabayashi, Nakashima, &
Kiyohara, 1996; Theodosis & Poulain, 1984; Watt, etal., 1999). Consistent with
those reports, we demonstrated a significant hypertrophy of 25% and 32% in
oxytocinergic and vasopressinergic magnocellular neuron nuclei area,
respectively, in the salt-loaded SON (Askvig, Leiphon, & Watt, 2012a). These
data demonstrate that 10 days of chronic salt loading successfully induces
physiological activation of the magnocellular neurons of the SON. Quantitative
Western blot analysis was then performed to determine CNTF, CNTFRa, LIFRI3.,
and gp130 protein levels in the SON and NL following physiological activation.
In contrast to our observations in the axotomized and contralateral
sprouting SON, our Western blot analysis revealed a significant decrease of 60%
in CNTF protein levels in the salt-loaded SON compared to the age-matched
control SON from animals maintained on tap water (Student’s ftest, p<0.001\
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Figure 12A). Western blot analysis demonstrated no significant difference
between CNTFRa (Student’s t test, p-0.5784\ Figure 12B), LIFRI3> (Student’s
^ test, p=0.5279; Figure 12C), orgp130 (Student’s t test, p=0.6128\ Figure 12D)
protein levels in the salt-loaded SON and the age-matched control SON. When
extending these observations to the effect that chronic salt-loading has on CNTF
and the CNTF receptor component protein levels in the NL, we found that there
was no change in the protein levels of CNTF (Student’s / test, p=0.5763; Figure
13A), CNTFRa (Student’s t test, p=0.2182\ Figure 13B), LIFRI3, (Student’s t test,
p=0.9670; Figure 13C), orgp130 (Student’s ftest, p=0.7721\ Figure 13D)
compared to control NL from animals maintained on tap water.
Thus, these data demonstrate that an increase in neurosecretory activity
in the absence of injury does not result in increased CNTF or CNTF receptor
component protein levels in the SON as was observed in the sprouting SON
contralateral to unilateral hypothalamic lesion. In addition, we extended these
observations and determined that following chronic salt-loading there was no
change in the protein levels of CNTF or the CNTF receptor components in the
NL. However, we did observe the first evidence of an activity-dependent change,
in the absence of injury, in CNTF protein levels in the CNS.
Female Rat
While the unilateral hypothalamic lesion paradigm has been exclusively
performed in male rats, the magnocellular neurosecretory system of female rats
can be activated to sustain chronic periods of increased neurosecretory activity
by lactation and chronic salt loading. Thus, we sought to determine if the
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observed response in male rats following increased neurosecretory activity
occurs within the female magnocellular neurosecretory system. Female rats were
physiologically activated either via 10 days of chronic salt-loading or 21 days of
sustained lactation. In addition to the hypertrophy of magnocellular neuron nuclei
following chronic salt loading, we demonstrated that 21 days of sustained
lactation induced a significant hypertrophy of 17% and 8% in oxytocinergic and
vasopressinergic magnocellular neuron nuclei area, respectively (Askvig, 2008).
These data indicate that similar to 10 days of chronic salt loading, 21 days of
sustained lactation are stimuli capable of inducing physiological activation of the
magnocellular neurons of the SON.
Quantitative Western blot analysis was performed to determine the protein
levels of CNTF and the CNTF receptor components in the SON and NL following
physiological activation. Unlike the male SON, there was no significant difference
observed between CNTF protein levels in the female physiologically activated
SON and the female control SON (one-way ANOVA, F=1.028, p=0.3870; Figure
14A). However, the CNTFRa bands present in the female physiologically
activated groups were more intense than the female control CNTFRa band.
Quantitative analysis of the CNTFRa band normalized to the ROD of the G-actin
loading control revealed a significant increase of 73% in CNTFRa protein levels
in the female lactating SON (one-way ANOVA, F=16.98, p=0.0020\ Figure 14B)
and by 116% in the female salt-loaded SON (one-way ANOVA, F=16.98,
p=0.0010; Figure 14B) compared to age-matched control SON. Conversely,
neither of the signal transducing receptor subunits, LIFR(3> (one-way ANOVA,
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F=0.6958, p=0.5177; Figure 14C) orgp130 (one-way ANOVA, F=1.111,
p=0.3607; Figure 14D), demonstrated a change in protein levels following
sustained neurosecretory activity in the female SON.
We extended these observations to determine the effect that chronic salt
loading has on CNTF and the CNTF receptor component protein levels in the
female NL. Western blot analysis demonstrated that there was no change in the
protein levels of CNTF (one-way ANOVA, F=0.3583, p=0.7061\ Figure 15A),
CNTFRa (one-way ANOVA, F=0.004481, p=0.9955; Figure 15B), orgp130 (one
way ANOVA, F=0.8948, p=0.4343\ Figure 15D) in the female activated NL
compared to control NL from animals maintained on tap water. Surprisingly, we
observed a significant decrease in LIFR(3> protein levels following 21 days of
sustained lactation compared to control NL (one-way ANOVA, F=38.72,
p=0.0002; Figure 15C) and female salt loaded NL (one-way ANOVA, F=38.72,
p<0.0001\ Figure 15C). Altogether, these data indicate a gender-specific
response of CNTF and the CNTF receptor protein levels following an increase in
neurosecretory activity in the SON.
Protein Levels of CNTF and CNTF Receptor Components in the Maturing
Magnocellular Neurosecretory System
While the collateral sprouting response occurs in 35 day old rats following
unilateral hypothalamic lesion, there is an absence of a sprouting response
following unilateral hypothalamic lesion in 125 day old rats (J.A. Watt,
unpublished observation). We have hypothesized that this is due to a deficit in
the CNTF signaling process within the magnocellular neurosecretory system.
Thus, I compared the protein levels of the CNTF signaling components, including
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total STAT3 (tSTAT3), in the non-injured control SON and NL of 35 day old rats
versus 125 day old rats.
Western blot analysis demonstrated that within the control SON (one-way
ANOVA, F=3.331, p=0.0707\ Figure 16A) and NL (one-way ANOVA, F=2.063,
p=0.1698; Figure 16B) there was not a significant difference in the CNTF protein
levels between 35, 60, or 125 day old rats. However, CNTFRa protein levels in
the maturing SON were significantly decreased by 38% in the 125 day old rat
compared to the 35 day old rat (one-way ANOVA, F=9.290, p=0.0029; Figure
17A) and by 31% compared to the 60 day old rat (one-way ANOVA, F=9.290,
p=0.0087; Figure 17A). The observed decrease in CNTFRa protein levels only
occurred within the SON. Western blot analysis demonstrated that there was no
significant difference in the CNTFRa protein levels in the maturing NL (one-way
ANOVA, F=1.342, p=0.2978; Figure 17B). We did not observe a statistical
difference in the protein levels of LIFRI3. in the maturing SON (one-way ANOVA,
F=2.034, p=0.1049; Figure 18A) or NL (one-way ANOVA, F=1.469, p=0.2687\
Figure 18B), of gp130 in the maturing SON (one-way ANOVA, F=1.398,
p=0.2846; Figure 19A) or NL (one-way ANOVA, F=2.192, p=0.1543\ Figure 19B),
ortSTAT3 in the maturing SON (one-way ANOVA, F=0.3135, p=0.7367\ Figure
20A) or NL (one-way ANOVA, F=0.5549, p=0.5882\ Figure 20B). Altogether,
these data indicate that as the rat matures, there is a reduction in the protein
levels of CNTFRa in the SON.
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Protein Levels of CNTF and the Receptor Components Following Unilateral
Lesion of Hypothalamo-Neurohypophysial Tract in 125 Day Old Rat
In addition to determining the effect that age has on the protein levels for
CNTF signal transduction, we also wanted to determine if unilateral hypothalamic
lesion in the 125 day old rat elicits a similar response in the protein levels of
CNTF and the CNTF receptor components as seen in the 35 day old rat following
unilateral lesion. Thus, unilateral hypothalamic lesions were performed on male
rats at the age of 125 days and were sacrificed 10 dpi for Western blot and
neuronal cell count analyses.
Unlike the 35 day contralateral SON, Western blot analysis demonstrated
that CNTF protein levels were not significantly different in the SON contralateral
to the injury of the 125 day rat at 10 dpi compared to age-matched control SON
(one-way ANOVA, F=4.222, p=0.2315; Figure 21A). However, the lesion did
result in a significant increase of 81% in CNTF protein levels in the axotomized
SON compared to age-matched control SON (one-way ANOVA, F=4.222,
p=0.0139; Figure 21A). Protein levels of CNTFRa undergo similar changes in the
SON following unilateral lesion in the 125 day old rat. As shown in Figure 21B,
we did not observe a significant difference in CNTFRa protein levels in the SON
contralateral to the injury (one-way ANOVA, F=14.76, p=0.0572; Figure 21B);
however, we did observe a 311% increase in the axotomized SON compared to
age-matched control SON (one-way ANOVA, F=14.76, p=0.0013; Figure 21B).
Western blot analysis demonstrated that LIFRG, protein levels in the 125 day rat
SON contralateral to the injury were not significantly different from age-matched
control SON (one-way ANOVA, F=10.66, p=0.0696\ Figure 21C) and were
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significantly elevated by 33% in the axotomized SON (one-way ANOVA,
F=10.66, p=0.0408\ Figure 21C) compared to age-matched control levels.
Similarly, there was no significant difference in the protein levels of gp130 in the
SON contralateral to the injury (one-way ANOVA, F=97.55, p=0.3568\ Figure
21D) but we did observe a significant increase of 251% in the axotomized SON
of the 125 day old rat (one-way ANOVA, F=97.55, p<0.0001\ Figure 21D)
compared to age-matched control SON.
Next, we quantified the change in the protein levels of CNTF and the
CNTF receptor components in the NL following unilateral hypothalamic lesion in
the 125 day old rat. Unlike the response that occurs in the 35 day old rat
following unilateral hypothalamic lesion, there was no significant difference in
CNTF protein levels the axotomized 125 day rat NL (Student’s t test, p-0.6760\
Figure 22A) compared to age-matched control NL. Similarly, protein levels of
CNTFRa (Student’s t test, p=0.2415; Figure 22B), LIFRI3. (Student’s t test,
p=0.4521\ Figure 22C), and gp130 (Student’s Mest, p=0.9890; Figure 22D) were
not significantly different in the axotomized NL compared to age-matched control
NL at 10 dpi in the 125 day old rat.
While unilateral hypothalamic lesion did not elicit a similar response in
CNTF and its receptor components in the 125 day old rat, the effect of the injury
on neuronal numbers was similar to the 35 day old rat. At 10 dpi there was a loss
of 88% and 93% of the oxytocinergic and vasopressinergic magnocellular
neurons, respectively, in the axotomized SON of the 125 day old rat (one-way
ANOVA, F=184.7, p<0.0001; Figure 23). Moreover, there was no significant
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difference in the number of oxytocinergic (one-way ANOVA, F=184.7, p=0.6941;
Figure 23) or vasopressinergic (one-way ANOVA, F=184.7, p=0.985T, Figure 23)
magnocellular neurons in the SON contralateral to the injury.
Altogether, these data indicate that the injury in the 125 day old rat results
in similar responses to CNTF and CNTF receptor component protein levels and
number of neurons surviving in the axotomized SON. However, while the 35 day
old rat elicits a dramatic increase in CNTF and the CNTF receptor components in
the sprouting SON and NL, which unlike the 125 day old rat also happens to
undergo a collateral sprouting response following the injury (Watt, et al., 1999;
Watt & Paden, 1991), there was no statistically significant increase within the
125 day old rat contralateral SON or NL.
Tubulin Protein Levels Following Unilateral Lesion of HypothalamoNeurohypophysial Tract in 125 Day Old Rat
Similar to the results observed in the a- and (2.Il-tubulin protein levels in the
35 day old rat at 10 dpi, our results demonstrated that there was no significant
difference in the a-tubulin (one-way ANOVA, F=0.2695, p=0.6605\ Figure 24A) or
G>ll-tubulin (one-way ANOVA, F=3.604, p=0.4600\ Figure 24B) protein levels in
the 125 day old contralateral SON. Similarly, we did not observe a significant
difference in the a-tubulin (one-way ANOVA, F=0.2695, p=0.5128\ Figure 24A) or
(3>ll-tubulin (one-way ANOVA, F=3.604, p=0.1467\ Figure 24B) protein levels in
the axotomized SON of the 125 day old rat. We extended the observations to
determine the tubulin protein levels in the 125 day NL following unilateral
hypothalamic lesion. Similar to the SON, our results demonstrated that there was
no significant difference in the a-tubulin (Student’s t test, p=0.7459; Figure 24C)
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or (ill-tubulin (Student’s f test, p=0.4106; Figure 24D) protein levels in the NL at
10 dpi. These data demonstrate that there was no change in the tubulin protein
levels in the magnocellular neurosecretory system of the 125 day old rat
following unilateral hypothalamic lesion.
Localization of CNTF Receptor Components in the Magnocellular
Neurosecretory System
Our lab has previously demonstrated that CNTFRa is localized to
magnocellular neurons and astrocytes within the SON (Watt, et al., 2009).
However, there are no reports of gp130 and LIFRIi localization within the SON.
Therefore, we utilized 35 day, 10 dpi contralateral SON tissue sections and
performed immunohistochemical analysis of gp130 and LIFRR localization to
identify cell phenotypes that express these receptors within the SON. We
observed robust immunoreactivity for gp130 on neuronal somata distributed
throughout the SON (Figure 25A-F), suggesting that virtually all magnocellular
neurons in the SON express the protein. Dual-label immunohistochemistry
confirmed the presence of gp130-immunoreactivity associated with both
vasopressinergic (Figure 25A-C) and oxytocinergic (not shown) magnocellular
neurons. We also observed gp130-immunoreactivity localized to GFAPimmunoreactive astrocytes in the VGL of the SON (Figure 25D-F).
In contrast to gp130-immunoreactivity, we did not observe any LIFRRimmunoreactive profiles that were consistent with neuronal somata (Figure 25GI). However, we did observe a strong band of LIFRft-immunoreactivity in the VGL
of the SON (Figure 25G-L). Dual-label immunohistochemistry demonstrated that
the astrocytes of the SON (Figure 25J-L) contain the LIFRft protein and that
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vasopressinergic (Figure 25G-I) and oxytocinergic (not shown) magnocellular
neurons do not contain the LIFRI3. protein.
As a control for the dual label fluorescence immunohistochemistry,
incubations with rabbit anti-LIFRG or rabbit anti-gp130 antibodies on separate
sections of tissue were followed by incubation with the species-specific
fluorescent-conjugated secondary antibodies for anti-GFAP and -vasopressin.
Similarly, after separate sections of tissue were incubated with the anti-GFAP or
-vasopressin antibodies the tissue was exposed to the fluorescent-conjugated
secondary antibodies for the opposing primary antibodies. These controls
demonstrated an absence of immunoreactivity in the rat SON (Figure 25M-N),
indicating that the fluorescent-conjugated secondary antibodies were specific for
their appropriate primary antibody and there was no observable cross-reactivity
between the secondary antibodies.
While our lab has demonstrated previously that CNTF is localized to
perivascular cells in the NL (Lo, et al., 2008), there are no reports demonstrating
the localization of the CNTF receptor components within the NL. Thus, we
utilized 35 day 10 dpi lesioned NL tissue sections and performed
immunohistochemical analysis of the receptors to identify cell phenotypes that
express these receptors within the NL. Figure 26 demonstrates that each of the
CNTF receptor components have similar immunoreactive profiles. Dual-label
immunohistochemistry demonstrated that CNTFRa- (Figure 26A-C), LIFRI2.(Figure 26I-K), and gp130- (Figure 26Q-S) immunoreactive profiles are localized
to oxytocinergic and vasopressinergic (not shown) axons. However, it is apparent
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that there are immunoreactive profiles that do not co-localize with the axonal
profiles. We further determined that CNTFRa- (Figure 26E-G), LIFRR- (Figure
26M-0), and gp130- (Figure 26U-W) immunoreactive profiles also are localized
to s100l3>-immunoreactive pituicytes, which are the astrocyte population of the
NL. In addition, pre-adsorption controls for anti-CNTFRa with Texas red (Figure
26D) and FITC (Figure 26H) demonstrated a strong decrease in
immunoreactivity, indicating that the anti-CNTFRa antibody is specific for
CNTFRa. Moreover, negative controls for LIFRft (Figure 26L and P), and gp130
(Figure 26T and X) demonstrated a lack of immunoreactivity, indicating that the
secondary antibody was specific for species of the primary antibody. Together,
these data indicate that all of the CNTF receptor components are localized to
astrocyte populations in the SON and NL, and axons within the NL.
Specific Aim 2: Determine the Functional Role of the Jak-STAT
Pathway in CNTF Signal Transduction in
Hypothalamic Organotypic Cultures
Others have demonstrated the neuroprotective effects that CNTF has on
hypothalamic magnocellular neurons in organotypic cultures (House, et al., 2009;
Rusnak, et al., 2002; Rusnak, et al., 2003; Shahar, et al., 2004; Vutskits, et al.,
1998; Vutskits, et al., 2003). However, the mechanisms of these neuroprotective
effects have not been reported. The Jak-STAT pathway is considered the
canonical pathway for CNTF signal transduction (Bonni, et al., 1993; Bonni, et
al., 1997; Darnell, et al., 1994). To this point, our lab has demonstrated that
exogenous rrCNTF injection in to the SON in vivo activates STAT3 in astrocytes
(Askvig et al., 2012b). Thus, I extended this observation and determine the
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temporal activation of the Jak-STAT pathway following exogenous rrCNTF
injection in to the SON in vivo. Furthermore, I utilized hypothalamic organotypic
cultures to determine the functional role(s) of the contribution of the Jak-STAT
pathway in CNTF-induced neuroprotection. Organotypic cultures exhibit several
advantages over other in vitro culture systems primarily because of the
preservation of the in vivo cytoarchitecture and the use of fully differentiated
neurons (House, et al., 1998; Vutskits, et al., 1998). In addition, the ability to
directly manipulate the culture media with growth factors and pharmacological
agents and assess magnocellular neuron survival in hypothalamic organotypic
cultures facilitates analysis of pathway-mediated cellular events more rapidly
than can be achieved using our in vivo injury model system.
Assessment of the Jak-STAT Pathway Activation Following
Exogenous rrCNTF Injection in the SON in Vivo
Quantitative Western blot analysis demonstrated that pressure injection of
exogenous rrCNTF (100 ng/pl) into the SON in vivo induced a statistically
significant increase in pSTAT3 (Tyr705) levels at 1 hr post injection (one-way
ANOVA, F=44.77, p<0.0001\ Figure 21A) compared to the control SON (vehicleinjected and contralateral, non-injected SON). At 3 hrs post injection, pSTAT3
(Tyr705) levels remained significantly elevated over control values (one-way
ANOVA, F=44.77, p<0.0001] Figure 27A); but had decreased significantly from
the peak level observed at 1 hour post injection (one-way ANOVA, F=44.77,
p=0.0285\ Figure 27A). In contrast, pSTAT3 (Ser727), which is primarily activated
by the MAPK pathway in a mechanism different from pSTAT3 (Tyr705), was not
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activated following pressure injection of rrCNTF compared to control levels (one
way ANOVA, F=0.3898, p=0.7616\ Figure 27B).
While CNTF preferentially signals through STAT3, there have been
reports of CNTF-induced STAT1 activation (Bonni, etal., 1997; Darnell, etal.,
1994; Wegenka, et al., 1993). Thus, we also screened for rrCNTF-induced
activation of other members of the Jak-STAT pathway, including STAT1, Jak2,
and Tyk2. Quantitative Western blot analysis demonstrated that following
pressure injection of rrCNTF into the SON there was no significant difference in
pSTAH activation attheTyr701 (one-way ANOVA, F=0.2985, p=0.8261\ Figure
28A) or the Ser727 (one-way ANOVA, F=0.03798, p=0.9898; Figure 28B)
residues compared to the control SON. Similarly, at 1 hour and 3 hours post
rrCNTF-injection we did not observe a change in pJak2 (one-way ANOVA,
F=12.38, p=0.0668; Figure 28C) or pTyk2 (one-way ANOVA, F=0.1789,
p=0.9095; Figure 28D) levels compared to control SON. In addition to Jak2 and
Tyk2, Jak1 is also a member of the Jak-STAT signaling pathway. However, after
trying several sources of commercial antibodies for tJakl and pJakl, we were
unable to detect bands for either tJakl or pJakl in our samples.
Intraperitoneal (IP) administration of 10 mg/kg AG490, which is a protein
tyrosine kinase inhibitor of Jak2 (Ozog et al., 2004; K. Park, et al., 2004), was
administered 1 hour prior to pressure injection of rrCNTF in order to confirm the
activation of the Jak-STAT pathway in the SON. Western blot analysis
demonstrated that administration of 10 mg/kg AG490 1 hour before rrCNTF
injection significantly suppressed the phosphorylation of STAT3 (Tyr705) (one-way
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ANOVA, F=44.77, p<0.0001\ Figure 27A) and Jak2 (one-way ANOVA, F=12.38,
p<0.0001\ Figure 28C) compared to the levels at 1 hr post-CNTF injection
without affecting protein levels of tSTAT3 or tJak2. These data demonstrate that
even though we did not observe Jak2 activation at 1 or 3 hours post rrCNTF
pressure injection, STAT3 activation in the SON may be through Jak2.
Since we did not observe activation of a Jak component, but did observe
activation of a STAT component at 1 and 3 hours post rrCNTF injection, we
performed a survey of the Jak-STAT signaling components at various time
points. Flowever, these data are a qualitative observation because they only have
an n=1. Similar to what was observed at 1 and 3 hours post rrCNTF injection, we
did not see activation of pSTAT3 (Ser727) at 15, 30, 45 minutes, 6, 12, 24, or
48 hours post rrCNTF injection (Figure 29). The bands present in the pSTAT3
(Tyr705) survey extend the quantitative observations observed at 1 and 3 hours
post rrCNTF injection. In Figure 29, it appears that pSTAT3 (Tyr705) activation is
apparent by 30 minutes post rrCNTF injection, where it reaches a peak at 1 hour
post rrCNTF injection (Figure 27A) and begins to decline at 3 hours post rrCNTF
injection (Figure 27A). Visible bands of pSTAT3 (Tyr705) are still apparent at
6 and 12 hours post rrCNTF injection (Figure 29); however, by 24 and 48 hours
post rrCNTF injection we no longer see pSTAT3 (Tyr705) bands in the SON
(Figure 29). Consistent with the levels of pSTATI (Ser727) and (Tyr701), pJak2,
and pTyk2 at 1 and 3 hours post. rrCNTF injection, we did not see an apparent
increase in activation of these band sizes at any of the time points surveyed
(Figure 29). Altogether, we did not observe a visual change in band size of
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pSTAT3 (Ser727), pSTATI (Ser727) and (Tyr701), pJak2, or pTyk2 in our survey of
additional time points, but we were able to extend our observations of the
temporal pSTAT3 (Tyr705) activation following rrCNTF injection into the SON.
Characterization of Hypothalamic Organotypic Cultures
We next determined the neuroprotective influence of exogenous rrCNTF
on magnocellular neuron survival. To do so we used stationary hypothalamic
organotypic cultures that contained intact PVN and SON nuclei and the
associated accessory nuclei (ACC), which are defined as the vasopressinergic or
oxytocinergic neurons that were not confined within the PVN or SON.
Organotypic cultures exhibit several advantages over other in vitro culture
systems primarily because of the preservation of the in vivo cytoarchitecture and
the use of fully differentiated neurons (Plouse, et al., 1998; Vutskits, et al., 1998).
In vivo, magnocellular neurons are multipolar neurons (Sofroniew & Glasmann,
1981) that have two or three dendrites and a single non-myelinated axon arising
from the primary dendrite (Glenn Platton, personal communication). As seen in
Figure 30A, the cytoarchitecture of the magnocellular neuron is maintained in
vitro. The oxytocinergic magnocellular neuron contains two dendrites (thick
arrows, Figure 30A) with one axon (thin arrows, Figure 30A) branching from one
of the dendrites. Moreover, the axon contains punctate staining that is consistent
with neurosecretory vesicles. In addition to maintenance of individual
magnocellular neurons, Figure 30B demonstrates the preservation of the specific
magnocellular nuclei after being in culture for 14 days. The organization of the
oxytocinergic magnocellular neurons into their respective magnocellular
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neurosecretory system nuclei (PVN and SON) is typical of what is observed in
adult rat magnocellular neurosecretory system nuclei. Furthermore, analysis of
control organotypic culture media demonstrated that the osmolality and pH did
not change during the entire experimental period, with levels maintained around
310 mmol/kg and 8.1, respectively (Figure 30C), which was consistent with
previous reports (House, et al., 2009; Rusnak, et al., 2003). These observations
were critical since all media was made and used throughout the same 14 day
experimental period.
Determination of Exogenous rrCNTF Concentration Necessary for
Neuroprotection
We first determined the number of oxytocinergic and vasopressinergic
neurons that were in the nuclei at the time of sacrifice (P6; Table 3). It is
apparent how severe the injury is when comparing the number of neurons in the
P6 group to the groups receiving control media for 14 days (Table 3), and that
this injury results in the loss of greater than 90% of the neurons. Moreover, even
though exogenous rrCNTF administration promotes survival of oxytocinergic
neurons, it still does not result in the recovery to the P6 number of neurons
(Table 3). We also established the optimum concentration of exogenous rrCNTF
that significantly increased neuronal survival (Table 3). Unlike previous reports
(House, et al., 2009; Rusnak, et al., 2002; Rusnak, et al., 2003; Vutskits, et al.,
1998), our results demonstrated that addition of 10 ng/ml rrCNTF to control
media for 14 days did not increase the survival of oxytocinergic neurons over
control values in either the SON (one-way ANOVA, F=24.84, p=0.2302\ Figure
31A), PVN (one-way ANOVA, F=23.16, p=0.1837; Figure 31C), or ACC (one-way
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ANOVA, F=12.76, p=0.0768\ Figure 31E). However, in our hands, addition of
25 ng/ml rrCNTF for 14 days significantly increased the number of oxytocinergic
neurons in the SON by 683% (one-way ANOVA, F=24.84, p<0.0001\ Figure
31A), in the PVN by 73% (one-way ANOVA, F=23.16, p=0.0064\ Figure 31C),
and in the ACC by 1835% (one-way ANOVA, F=12.76, p<0.0001; Figure 31E)
over control values. Treatment with 50 ng/ml rrCNTF for 14 days did not promote
oxytocinergic magnocellular neuron survival above that observed in the 25 ng/ml
rrCNTF treatment group in the SON (one-way ANOVA, F=24.84, p=0.6565;
Figure 31A), PVN (one-way ANOVA, F=23.16, p=0.0858; Figure 31C), or ACC
(one-way ANOVA, F=12.76, p=0 9862\ Figure 31E).
In contrast to published reports (Flouse, et al., 2009; Rusnak, et al., 2002;
Rusnak, et al., 2003; Vutskits, et al., 1998), our analysis of vasopressinergic
neuronal survival demonstrated that administration of 10 or 25 ng/ml rrCNTF for
14 days did not promote the survival of vasopressinergic neurons in the SON
(one-way ANOVA, F=2.953, p=0.0793, p=0.0588; Figure 31B), the PVN (one
way ANOVA, F=5.491, p=0.6141, p=0.0207; Figure 31D), or the ACC (one-way
ANOVA, F= 1.816, p=0.4011, p=0.5496; Figure 31F) nuclei of hypothalamic
organotypic explant cultures. However, administration of 50 ng/ml rrCNTF for
14 days resulted in a small, but statistically significant, increase in
vasopressinergic magnocellular neurons in the SON (one-way ANOVA, F=2.953,
p=0.0026; Figure 31B). While there was no change in the amount of
vasopressinergic neurons in the ACC nuclei following administration of 50 ng/ml
rrCNTF (one-way ANOVA, F=1.816, p=0.1739] Figure 31F), there was a
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significant reduction in the amount of vasopressinergic neurons seen in the PVN
following exogenous rrCNTF (25 and 50 ng/ml) treatment (one-way ANOVA,
F=5.491, p=0.0207, p=0.0004; Figure 31D). Therefore, due to the more robust
survival of oxytocinergic neurons following 25 ng/ml rrCNTF administration, all
future experiments utilized a concentration of 25 ng/ml rrCNTF and focused
primarily on oxytocinergic neuron survival.
Determine if Soluble CNTFRa plus CNTF Enhanced Neuroprotection
CNTFRa imparts its functionality either as a membrane bound receptor,
which lacks a transmembrane sequence and is attached via a GPI-linkage or as
a soluble receptor that results from the cleavage of the GPI-linked membranebound receptor in a phosphatidylinositol-specific phospholipase C (PI-PLC)dependent mechanism (Davis, Aldrich, Ip, et al., 1993; Davis et al., 1991). The
enzymatic cleavage of membrane-bound CNTFRa releasing the soluble
CNTFRa into the extracellular space is thought to occur in response to cellular
injury, as demonstrated by its release from skeletal muscle following peripheral
nerve injury (Davis, Aldrich, Ip, et al., 1993). While most examples of soluble
receptors are thought to interfere with the binding of their ligands to membranebound receptors, soluble CNTFRa increases the biological activity of CNTF 30fold (Ip, et al., 1993; Saggio, Gloaguen, Poiana, & Laufer, 1995). Interestingly, a
complex of the soluble CNTFRa bound to CNTF (hereafter referred to as
‘complex’) further enhanced the survival and nerve regeneration of cortical
neurons compared to CNTF administration (Ozog, et al., 2008). Thus, we wanted
to determine if the complex had an enhanced effect on the neuroprotective
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functions of CNTF-induced neuronal survival in hypothalamic organotypic
cultures.
Unlike the results previously reported in a primary neuronal culture
paradigm, (Ozog, et al., 2008), complex administration did not enhance the
survival (Figure 32) or process outgrowth (compare Figures 33C and 33D) of
oxytocinergic magnocellular neurons in hypothalamic organotypic cultures
compared to exogenous rrCNTF administration. Quantitative neuronal cell counts
demonstrated no significant difference between the number of oxytocinergic
neurons between CNTF and complex in the SON (one-way ANOVA, F=29.87,
p=0.7716\ Figure 32A), PVN (one-way ANOVA, F=12.11 ,p=0.1416\ Figure 32C),
or ACC (one-way ANOVA, F=16.02, p=0.7115; Figure 32E). Similarly, we did not
observe a significant difference in the number of surviving oxytocinergic neurons
between control and soluble CNTFRa in the SON (one-way ANOVA, F=29.87,
p=0.2473\ Figure 32A), PVN (one-way ANOVA, F=12.11 ,p=0.1916\ Figure 32C),
or ACC (one-way ANOVA, F=16.02, p=0.0542; Figure 32E).
The results of vasopressinergic neuron survival following complex
administration were similar to what was observed with rrCNTF administration.
We did not observe a significant increase between the number of
vasopressinergic neurons between CNTF and complex in the SON (one-way
ANOVA, F=1.075, p=0.9034\ Figure 32B), or ACC (one-way ANOVA, F=1.146,
p=0.3299; Figure 32F); although, we did observe a significant increase in the
number of surviving vasopressinergic neurons in the PVN following complex
administration compared to exogenous rrCNTF administration (one-way ANOVA,
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F=6.898, p=0.0009\ Figure 32D). Flowever, there was a significant decrease in
the number of surviving vasopressinergic neurons in the PVN following
exogenous rrCNTF administration (one-way ANOVA, F=6.898, p=0.0004;
Figure 32D) and complex administration recovered the amount of
vasopressinergic neurons in the PVN to control levels (one-way ANOVA,
F=6.898, p=0.4936; Figure 32D). Comparable to oxytocinergic neuronal counts,
we did not observe a significant difference in the number of surviving
vasopressinergic neurons between control and soluble CNTFRa in the SON
(one-way ANOVA, F=1.075, p=0.2430\ Figure 32B), PVN (one-way ANOVA,
F=6.898, p=0.3058; Figure 32D), or ACC (one-way ANOVA, F=1.146, p=0.3874\
Figure 32F).
Figure 33A is a micrograph montage of oxytocinergic magnocellular
neurons from a representative explant culture slice fixed and
immunohistochemically stained at the time of sacrifice (post-natal day 6). The
organization of the oxytocinergic magnocellular neurons into their respective
magnocellular neurosecretory system nuclei (PVN and SON) is typical of what is
observed in adult rat magnocellular neurosecretory system nuclei. In addition,
Figure 33A also demonstrates the hypothalamo-neurohypophysial tract (arrows),
which contains the magnocellular neuron axons that project to the NL. Figure
33B illustrates oxytocinergic magnocellular neurons from a representative
explant slice that received only control media for 14 days. These hypothalamic
organotypic explant cultures still exhibit easily distinguishable oxytocinergic
magnocellular neuron cell bodies and processes located within the PVN, SON,
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and ACC nuclei; however, due to the inherent neuronal death associated with the
axotomy, there are significantly fewer oxytocinergic magnocellular neurons
present when compared to Figure 33A. Figure 33C illustrates a representative
explant slice that received 25 ng/ml rrCNTF for 14 days. When compared to
Figure 33B, the substantial increase in the survival of oxytocinergic
magnocellular neurons in the magnocellular neurosecretory system following
exogenous rrCNTF administration is apparent, as well as a prominent increase in
oxytocinergic magnocellular neuron process density throughout the
magnocellular neurosecretory system nuclei, particularly processes extending
between the nuclei (arrows, Figure 33C), indicating that exogenous rrCNTF may
be promoting process outgrowth from oxytocinergic magnocellular neurons.
Figure 33D received complex (25 ng/ml rrCNTF plus 250 ng/ml rrCNTFRa) for
14 days. Quantitative neuronal cell counts demonstrated that the amount of
surviving oxytocinergic neurons was no different between CNTF and complex
treated groups (Figure 32A, C, E), and when comparing their representative
micrograph montages, it is apparent that the exogenous rrCNTF (Figure 33C)
and complex (Figure 33D) organotypic groups are visually indistinguishable.
Moreover, similar to the culture receiving only exogenous rrCNTF, the culture
receiving complex for 14 days also displayed a prominent increase in
oxytocinergic magnocellular neuron process density throughout the
magnocellular neurosecretory system nuclei, particularly processes extending
between the nuclei (arrows, Figure 33D).
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Figure 34 depicts representative micrograph montages of
vasopressinergic neurons in the magnocellular neurosecretory system. While
there are an observable number of vasopressinergic neurons in the control PVN,
the majority of the neurons that are present appear to be parvocellular neurons
(Figure 34A), as opposed to the larger, more prominent, magnocellular neurons
that are visually apparent in the PVN of organotypic cultures
immunohistochemically stained for oxytocinergic neurons (Figure 33B).
Moreover, it is apparent that there was not a significant increase in the amount of
vasopressinergic neurons following exogenous rrCNTF treatment (Figure 34B).
Determine the Effect of Exposure Duration of Exogenous rrCNTF
In order to further characterize the hypothalamic organotypic cultures in
our hands, we sought to determine the number of neurons that survive
exogenous rrCNTF administration for a shorter experimental period and whether
an acute dose of rrCNTF is adequate to promote neuronal survival.
Temporal response of exogenous rrCNTF. For the first experiment, we
compared the number of surviving neurons in the organotypic cultures in the
absence and presence of exogenous rrCNTF for experimental periods of 7 and
the previously studied 14 days in vitro (DIV). Within the SON, our analysis
demonstrated that the number of surviving oxytocinergic magnocellular neurons
were not significantly different between control at 7 and 14 DIV (2-way ANOVA,
F=0.0005084, p=0.5065; Figure 35A), or between exogenous rrCNTF treatment
for 7 or 14 DIV (2-way ANOVA, F=0.0005084, p=0.8098; Figure 35A). However,
there was a significant increase in the number of surviving oxytocinergic
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magnocellular neurons between control and rrCNTF treatment after 7 DIV (2-way
ANOVA, F= 195.2, p<0.0001; Figure 35A) and 14 DIV (2-way ANOVA, F=195.2,
p<0.0001\ Figure 35A). For vasopressinergic magnocellular neurons in the SON,
there was no significant difference between control at 7 and 14 DIV (2-way
ANOVA, F=17.64, p=0.5858\ Figure 35B). Conversely, there was a significant
reduction in the number of surviving vasopressinergic magnocellular neurons at
14 DIV with exogenous rrCNTF treatment compared to 7 DIV with exogenous
rrCNTF treatment (2-way ANOVA, F=17.64, p<0.0001\ Figure 35B). When
comparing the treatment categories, we observed a significant increase of 479%
in the number of surviving vasopressinergic magnocellular neurons after
exogenous rrCNTF treatment for 7 DIV (2-way ANOVA, F=37.21, p<0.0001\
Figure 35B); although, there was still a very low number of surviving
vasopressinergic neurons present in the SON (mean=32). Furthermore, as
previously demonstrated in Figure 31B and 32B, we did not see a significant
difference in the number of vasopressinergic magnocellular neurons in the SON
following 14 days of exogenous rrCNTF treatment (2-way ANOVA, F=37.21,
p=0.0969; Figure 35B).
Within the PVN, from which we did not distinguish magnocellular or
parvocellular neurons from each other, we did not see the same effects on
oxytocinergic neuron survival that we saw within the SON. Our analysis
demonstrated a significant decrease in the number of oxytocinergic neurons in
the PVN between control (2-way ANOVA, F=32.28, p<0.0001\ Figure 35C) and
exogenous rrCNTF treatment (2-way ANOVA, F=32.28, p=0.0002; Figure 35C)
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from 7 to 14 DIV. However, we observed a significant increase in the number of
surviving oxytocinergic neurons in the PVN following exogenous rrCNTF
treatment for 7 (2-way ANOVA, F=39.48, p<0.0001\ Figure 35C) and 14 DIV
(2-way ANOVA, F=39.48, p<0.0001\ Figure 35C). For vasopressinergic neurons
in the PVN, there was no significant difference between control at 7 and 14 DIV
(2-way ANOVA, F=16.78, p=0.1507] Figure 35D). Similar to the SON, there was
a significant reduction in the number of surviving vasopressinergic neurons in the
PVN at 14 DIV with exogenous rrCNTF treatment compared to 7 DIV with
exogenous rrCNTF treatment (2-way ANOVA, F=16.78, p<0.0001\ Figure 35D).
When comparing the treatment categories, we observed no significant difference
in the number of surviving vasopressinergic neurons after exogenous rrCNTF
treatment for 7 DIV (2-way ANOVA, F=1.068, p=0.5844; Figure 35D).
Furthermore, as previously demonstrated in Figure 31D and 32D, we observed a
significant decrease in the number of vasopressinergic magnocellular neurons in
the PVN following 14 days of exogenous rrCNTF treatment (2-way ANOVA,
F=1.068, p=0.0041\ Figure 35D).
For the ACC nuclei, which are characterized as being neurons not located
within the confines of the SON and PVN, we observed responses similar to the
PVN. Our analysis demonstrated a significant decrease in the number of
oxytocinergic neurons in the ACC between control (2-way ANOVA, F=55.86,
p=0.0123\ Figure 35E) and exogenous rrCNTF treatment (2-way ANOVA,
F=55.86, p<0.0001\ Figure 35E) from 7 to 14 DIV. Moreover, we observed a
significant increase in the number of surviving oxytocinergic neurons in the ACC
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following exogenous rrCNTF treatment for 7 (2-way ANOVA, F=89.45, p<0.000T,
Figure 35E) and 14 DIV (2-way ANOVA, F=89.45, p<0.0001\ Figure 35E). For
vasopressinergic neurons in the ACC, there was no significant difference
between control at 7 and 14 DIV (2-way ANOVA, F=19.68, p=0.0871\ Figure
35F). Similar to the SON and PVN, there was a significant reduction in the
number of surviving vasopressinergic neurons in the ACC at 14 DIV with
exogenous rrCNTF treatment compared to 7 DIV with exogenous rrCNTF
treatment (2-way ANOVA, F=19.68, p=0.0015; Figure 35F). When comparing the
treatment categories, we observed no significant difference in the number of
surviving vasopressinergic neurons after exogenous rrCNTF treatment for 7 DIV
(2-way ANOVA, F=10.26, p=0.0156; Figure 35D). Furthermore, as previously
demonstrated in Figure 31D and 32D, we observed no significant difference in
the number of vasopressinergic magnocellular neurons in the ACC following
14 days of exogenous rrCNTF treatment (2-way ANOVA, F=10.26, p=0.2938;
Figure 35D). In summary, there were less oxytocinergic neurons present after
14 days of exogenous rrCNTF treatment in the PVN and ACC nuclei compared
to 7 days; however, there were still enough neurons present in these nuclei after
14 DIV to allow for reproducible analyses. Thus, for our pharmacological
inhibition experiments, we maintained consistency with other reports (House, et
al., 2009; Rusnak, et al., 2002; Rusnak, et al., 2003; Vutskits, et al., 1998) and
utilized the experimental period of 14 DIV.
Acute response of rrCNTF. It was recently demonstrated that pretreatment
with CNTF promoted neuronal survival when an insult occurred two days later,
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suggesting that CNTF reprograms the cell to be neuroprotective (Bechstein et al.,
2012). We hypothesized that an acute dose of exogenous rrCNTF would
promote the survival of oxytocinergic neurons for the entire 14 day experimental
period. Thus, we exposed the organotypic cultures for either 24, 48, or 72 hours
and after which the cultures received control media for the duration of the
14 days. Our results demonstrated that 24, 48, or 72 hours of acute exposure to
exogenous rrCNTF did not result in a significant increase in the number of
oxytocinergic neurons in the SON (one-way ANOVA, F=11.91, p=0.1697,
p=0.1133, p=0.6593; Figure 36A), PVN (one-way ANOVA, F=22.56, p=0.9057,
p=0.3402, p=0.2616; Figure 36B), or ACC nuclei (one-way ANOVA, F=56.94,
p=0.8357, p=0.1772, p=0.1416; Figure 36C) compared to control. These data
indicate that an acute exposure period of less than 72 hours to exogenous
rrCNTF is not adequate to promote the survival of oxytocinergic neurons over a
14 day experimental period in hypothalamic organotypic explant cultures.
Determine the Functional Role(s) of the Contribution of the Jak-STAT Pathway in
CNTF-Induced Neuroprotection
Intracellular signaling pathways known to be activated by CNTF include
MAPK-ERK, Jak-STAT and PI3K-AKT pathways (Bonni, et al., 1993; Dolcet, et
al., 2001; K. Park, et al., 2004; Sango, et al., 2008). However, the Jak-STAT
intracellular signal transduction pathway is considered the canonical intracellular
signaling pathway utilized by CNTF. We demonstrated that pressure injection of
exogenous rrCNTF into the SON resulted in a robust increase in STAT3
activation, indicating that CNTF utilizes the Jak-STAT pathway in the SON. We
previously demonstrated that activation of the Jak-STAT pathway was specific to
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astrocytes in the SON (Askvig et ai., 2012a). Therefore, we sought to determine
the cellular phenotype(s) that undergo activation of the Jak-STAT pathway in
vitro. In addition, we determined the contribution of the Jak-STAT pathway to
rrCNTF-induced oxytocinergic neuron survival in the magnocellular
neurosecretory system.
STAT3 Activation In Vitro
We previously demonstrated that astrocytes, and not the magnocellular
neurons, are the only cellular phenotype within the SON that exhibit activation of
the Jak-STAT pathway following exogenous rrCNTF injection (Askvig et al.,
2012a). While hypothalamic organotypic cultures contain all of the cells that are
present in vivo, it is still an in vitro environment maintained in culture media.
Thus, we wanted to determine which cells in the SON undergo activation of the
Jak-STAT pathway in vitro.
Our results have shown that there is no difference in the amount of
oxytocinergic magnocellular neurons in the SON between 7 and 14 DIV (see
Figure 35). Therefore, we maintained four cultures in control media for 7 days to
allow the for the natural cell death process to occur. Next, we placed two filter
inserts into 25 ng/ml rrCNTF and the other two filter inserts were placed into
fresh control media. After 1 hour, the cultures were fixed with paraformaldehyde
and fluorescently stained for anti-pSTAT3 and -GFAP or -oxytocin. Figures 37B
and 37E demonstrated that even following 7 days of control media there were
pSTAT3-immunoreactive profiles present. These data suggest an injurydependent activation of pSTAT3. However, it is interesting to note, that even in
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the control treated cultures, pSTAT3 activation in the SON occurs exclusively in
GFAP-immunoreactive astrocytes (arrows, Figure 37A-C) and not oxytocinergic
magnocellular neurons of the SON (asterisks, Figure 37D-F). Similarly, after a
1 hour exogenous rrCNTF treatment, pSTAT3 activation only occurred in GFAPimmunoreactive astrocytes (arrows, Figure 37G-I) and not in oxytocinergic
magnocellular neurons of the SON (asterisks, Figure 37J-L). Thus, even though
we did not observe a CNTF-specific activation of pSTAT3, pSTAT3 activation
was only observed in astrocytes in vitro.
Pharmacological Inhibition of the Jak-STAT Pathway
First, in order to confirm that the neuroprotective effects of exogenous
rrCNTF were due to the specific protein sequence and tertiary structure of the
rrCNTF protein, we had a reverse sequence rat CNTF construct generated.
Incubation of hypothalamic organotypic explant cultures in 25 ng/ml reverse
rrCNTF for 14 days resulted in oxytocinergic neuron numbers in the SON (one
way ANOVA, F=42.72, p=0.2175\ Figure 38A), PVN (one-way ANOVA, F=11.8,
p=0.8791; Figure 38B), and ACC (one-way ANOVA, F=20.87, p=0.0871;
Figure 38C) that were not significantly different than what was observed following
14 days of control media treatment. These data are the first reports utilizing a
reverse sequence construct of rrCNTF in order to validate the pro-survival effects
that exogenous rrCNTF has on injured magnocellular neurons and our results
demonstrate that it is the specific protein sequence and tertiary structure of
rrCNTF that resulted in the survival of injured oxytocinergic neurons in the SON,
PVN, and ACC.
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We utilized two pharmacological inhibitors of the Jak-STAT pathway that
act on two separate and distinct signaling components: AG490, a protein tyrosine
kinase inhibitor of Jak2 (Ozog, et al., 2004; K. Park, et al., 2004), and
cucurbitacin I (JSI-124), a selective protein tyrosine kinase inhibitor of STAT3
(Blaskovich et al., 2003). When the hypothalamic organotypic cultures were
treated with 25 ng/ml rrCNTF plus 50 pM AG490 there was a small, but
statistically significant reduction of oxytocinergic magnocellular neurons by 39%
in the SON (one-way ANOVA, F=42.72, p=0.0002\ Figure 38A) compared to the
25 ng/ml rrCNTF treated group. Within the PVN (one-way ANOVA, F=11.8,
p>0.05; Figure 38B) and ACC (one-way ANOVA, F=20.87, p=0.8542\ Figure
38C), the amount of oxytocinergic neurons in the 25 ng/ml rrCNTF plus 50 pM
AG490 group was not significantly different from the 25 ng/ml rrCNTF treated
group. Although, subsequent statistical analysis directly comparing the two
groups in the PVN with a Student’s t-test demonstrated a significant decrease
(p=0.0230\ Figure 38B). However, incubation with 25 ng/ml rrCNTF plus
100 pM AG490 resulted in a statistically significant decrease in oxytocinergic
neurons in the SON (one-way ANOVA, F=42.72, p<0.0001\ Figure 38A), PVN
(one-way ANOVA, F=11.8, p=0.0054; Figure 38B), and ACC (one-way ANOVA,
F=20.87, p=0.0145; Figure 38C) to control levels. Similarly, inhibition of STAT3
activation via 10 pM cucurbitacin I in the presence of 25 ng/ml rrCNTF resulted in
a statistically significant decrease in oxytocinergic neurons in the SON (one-way
ANOVA, F=42.72, p<0.0001\ Figure 38A), PVN (one-way ANOVA, F=11.8,
p<0.0001\ Figure 38B), and ACC (one-way ANOVA, F=20.87, p<0.0001\
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Figure 38C) to control levels. When the hypothalamic organotypic explant
cultures were treated with inhibitors alone there was not a statistical difference in
the number of oxytocinergic neurons in the SON (one-way ANOVA, F=42.72,
p>0.05\ Figure 38A), PVN (one-way ANOVA, F=11.8, p>0.05\ Figure 38B), or
ACC (one-way ANOVA, F=20.87, p>0.05; Figure 38C) compared to the control
media-treated group, demonstrating that in the absence of rrCNTF, the
concentrations of the inhibitors used did not adversely affect oxytocinergic
neuron survival. Altogether, these data demonstrate that pharmacological
inhibition of the Jak-STAT pathway prevented CNTF-induced survival of
oxytocinergic neurons in the SON, PVN, and ACC.
Representative low magnification montages and higher magnification
micrographs of the SON further illustrate these results. Although the tissue
thickness and complexity of the processes prevented quantitative stereologic
analysis, we consistently observed an overall increase in process outgrowth
density in the SON following 14 days of 25 ng/ml rrCNTF administration
(Figures 39B and 40D) compared to control media treated cultures (Figures 39A
and 40A), suggesting that exogenous CNTF may have a role in mediating
process outgrowth of oxytocinergic magnocellular neurons. Moreover, no visual
difference was observed in magnocellular neuron process density following
inhibition of the Jak-STAT pathway with AG490 (Figures 39C and 40B) or
cucurbitacin I (Figures 39D and 40C) compared to control SON (Figures 39A and
40A). Similar results were observed when analyzing individual PVN following
pharmacological inhibition of the Jak-STAT pathway (see Figure 39).
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Specific Aim 3: Determine the Functional Role of the MAPK and PI3K-AKT
Pathways in CNTF Signal Transduction in Hypothalamic Organotypic Cultures
While the Jak-STAT pathway is considered the canonical CNTF signal
transduction pathway, CNTF has been demonstrated to activate multiple
intracellular signaling pathways, including the PI3K-AKT and MAPK pathways
(Bonni, etal., 1993; Cagnon & Braissant, 2009; Dolcet, etal., 2001; Gallagher, et
al., 2007; Kassen, et al., 2009; Loy, et al., 2011; Lutticken, et al., 1994; A. Muller,
et al., 2009; K. Park, et al., 2004; Peterson, et al., 2000; Rhee, et al., 2004;
Sango, et al., 2008; Symes, et al., 1994; Trimarchi, et al., 2009). This occurs
because there are multiple points of convergence between the signaling
components of the different pathways. Moreover, it appears that the activation of
a specific pathway is dependent on a combination of various factors, such as; the
stimulus, the cellular phenotype activated, and the research paradigm. Therefore,
I determined the temporal activation of other major signaling pathways following
exogenous rrCNTF injection on to the SON in vivo and I assessed the functional
role(s) of these pathways in mediating the CNTF-induced neuroprotective
mechanisms that are observed in the hypothalamic organotypic cultures as
described below.
Determine if Exogenous rrCNTF Injection Activates Components of the MAPK
and PI3K-AKT Pathways
In order to determine if exogenous rrCNTF injection activated signaling
components of pathways other than the Jak-STAT pathway, we performed
quantitative Western blot analysis of SON samples post-injection for
phosphorylated signaling proteins. Our analysis demonstrated that there was no
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significant difference in the protein levels of phosphorylated components of the
MAPK-ERKV2 pathway. Figure 41A demonstrated a band at 44 kDa for ERK1
and 42 kDa for ERK2. Quantitative Western blot analysis demonstrated no
change in the protein levels of pERK1 (one-way ANOVA, F=1.354, p=0.2853;
Figure 41A) or pERK2 (one-way ANOVA, F=0.1676, p=0.9170; Figure 41A) in
the SON at 1 or 3 hours post rrCNTF injection. Similarly, the protein levels of
pMEK>2, which was observed at 45 kDa, at 1 or 3 hours post rrCNTF injection
were not significantly different than control levels in the SON (one-way ANOVA,
F=3.236, p=0.0540\ Figure 41B). Moreover, when we analyzed signaling
components of the p38- and JNK-MAPK pathways we did not see a significant
difference in the levels of the phosphorylated proteins following rrCNTF injection.
Figure 42A demonstrated a band at approximately 38 kDa for p-p38 and t-p38.
Quantitative Western blot analysis demonstrated that there was no change in the
protein levels of p-p38 at 1 or 3 hours post rrCNTF injection (one-way ANOVA,
F=3.388, p=0.1345, p=0.1562; Figure 42A) compared to control levels. We
observed two bands for JNK, at 46 and 54 kDa, which correspond to the JNK1
and JNK2 isoforms, respectively. Quantitative Western blot analysis
demonstrated that there was no change in the protein levels of pJNK1 (p46; one
way ANOVA, F=1.489, p=0.2478; Figure 42B) or pJNK2 (p54; one-way ANOVA,
F=2.889, p=0.0609\ Figure 42B) in the SON at 1 or 3 hours post rrCNTF injection
compared to control levels. As purely a qualitative observation, we performed a
survey of the MAPK signaling components at other time points. Similar to what
was observed at 1 and 3 hours post rrCNTF injection in the SON, we did not see
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activation of pERK>2, pMEK>2, p-p38, or pJNK at 15, 30, 45 minutes, 6, 12, 24, or
48 hours post rrCNTF injection (Figure 43).
AKT, which has been demonstrated to be activated by CNTF in a Jakdependent manner (Dolcet, et al., 2001; Gold, et al., 1994; Oh, et al., 1998), has
two phosphorylation sites. The initial phosphorylation occurs at the Thr308 residue
and is phosphorylated by PDK1, (Alessi, et al., 1996; K. E. Anderson, et al.,
1998), with a secondary phosphorylation site located at the Ser473 residue, which
is believed to be phosphorylated by mTORC2 in order to achieve maximal
activation of AKT (Flresko & Mueckler, 2005; Sarbassov, et al., 2005). Figure 44A
demonstrates a band for AKT at the expected 60 kDa. Quantitative Western blot
analysis demonstrated that following pressure injection of rrCNTF into the SON
there was no change in the protein levels of pAKT (Thr308) (one-way ANOVA,
F=1.262, p=0.3143; Figure 44A) or pAKT (Ser473) (one-way ANOVA, F=0.4443,
p=0.7239; Figure 44B) compared to control levels.
Next, we analyzed our samples for activation of transcription factors that
CNTF has been demonstrated to activate, CREB and cJun. CREB was seen
around 43 kDa and Western blot analysis demonstrated that there was no
activation of CREB following rrCNTF injection into the SON (one-way ANOVA,
F=1.029, p=0.4008\ Figure 45A). Similarly, cJun was found at approximately
50 kDa and quantitative Western blot analysis demonstrated that there was no
significant difference in the amount of p-cJun in the SON following exogenous
rrCNTF injection compared to control (one-way ANOVA, F=3.879, p=0.1206;
Figure 45B). Next, as a qualitative observation, we performed a survey of AKT,
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CREB, and cJun at other time points. Similar to what was observed at 1 and
3 hours post rrCNTF injection in the SON, we did not see activation of pAKT
(Thr308), pAKT (Ser473), pCREB, or p-cJun at 15, 30, 45 minutes, 6, 12, 24, or
48 hours post rrCNTF injection (Figure 46).
Pharmacological Inhibition of the MAPK-ERK Pathway
We utilized three pharmacological inhibitors of the MAPK-ERK pathway,
U0126, PD98059, and PD184352. All of these inhibitors inhibit at the MAPKK
(MEK) level, which will prevent activation of the immediate downstream target,
ERK. Two of the inhibitors are structurally related, U0126 and PD98059, and
they have both been demonstrated to inhibit ERK14 and ERK5 (Ballif & Blenis,
2001; Su, Underwood, Rybalchenko, & Singh, 2011). However, the PD184352
has been recommended by others to be used to inhibit MEKV2 because it is
specific for ERK/4 (Bain et al., 2007). We also treated organotypic cultures with
U0124, which is a control molecule for the pharmacological inhibitor, U0126, and
does not inhibit MEK activity even at concentrations of 100 pM (manufacturer’s
technical sheet). Not surprisingly, when we treated organotypic cultures with
25 ng/ml rrCNTF plus 1 pM U0124, the control molecule, there was no significant
difference in the amount of surviving oxytocinergic neurons in the SON (one-way
ANOVA, F=46.83, p=0.4664; Figure 47A), PVN (one-way ANOVA, F=21.90,
p=0.8261; Figure 47B), and ACC (one-way ANOVA, F=32.72, p=0.7151; Figure
47C) compared to the 25 ng/ml rrCNTF group. Treatment with 25 ng/ml rrCNTF
plus 1 pM U0126, the pharmacological inhibitor, resulted in a statistically
significant decrease in the amount of surviving oxytocinergic neurons by 55% in
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the SON (one-way ANOVA, F=46.83, p<0.0001\ Figure 47A), by 40% in the PVN
(one-way ANOVA, F=21.90, p<0.0001\ Figure 47B), and by 42% in the ACC
(one-way ANOVA, F=32.72, p=0.0166; Figure 47C) compared to the 25 ng/ml
rrCNTF group. Although, only in the PVN did 1 pM U0126 plus 25 ng/ml rrCNTF
treatment reduce the amount of surviving oxytocinergic neurons to control levels.
Next, we treated organotypic cultures with the structurally related, later
generation inhibitor, PD98059 (75 pM) plus 25 ng/ml rrCNTF. Our analysis
demonstrated that 75 pM PD98059 in the presence of 25 ng/ml rrCNTF resulted
in a statistically significant decrease, to control levels, in the amount of surviving
oxytocinergic neurons by 80% in the SON (one-way ANOVA, F=46.83, p<0.0001\
Figure 47A), by 65% in the PVN (one-way ANOVA, F=21.90, p<0.0001\ Figure
47B), and by 82% in the ACC (one-way ANOVA, F=32.72, p<0.0001\ Figure
47C) compared to the 25 ng/ml rrCNTF group. In order to determine if ERK14 or
ERK5 is the signaling component necessary for CNTF-induced survival, we
utilized the ERK1/2-specific inhibitor, PD184352. Our analysis demonstrated that
5 pM PD184352 in the presence of 25 ng/ml rrCNTF resulted in a statistically
significant decrease, to control levels, in the amount of surviving oxytocinergic
neurons by 84% in the SON (one-way ANOVA, F=46.83, p<0.0001\ Figure 47A),
by 53% in the PVN (one-way ANOVA, F=21.90, p<0.0001\ Figure 47B), and by
99% in the ACC (one-way ANOVA, F=32.72, p<0.0001\ Figure 47C) compared to
the 25 ng/ml rrCNTF group. As controls for the inhibitors, we treated organotypic
cultures with the inhibitors alone and there was not a statistical difference in the
number of oxytocinergic neurons in the SON (one-way ANOVA, F=42.72,
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p>0.05\ Figure 47A), PVN (one-way ANOVA, F=11.8, p>0.05; Figure 47B), or
ACC (one-way ANOVA, F=20.87, p>0.05\ Figure 47C) compared to the control
media-treated group, demonstrating that in the absence of rrCNTF, the
concentrations of the inhibitors used did not adversely affect oxytocinergic
neuron survival. Altogether, these data demonstrate that pharmacological
inhibition of the MAPK-ERK!4 pathway prevented CNTF-induced survival of
oxytocinergic neurons in the SON, PVN, and ACC.
Representative low magnification montages of the magnocellular
neurosecretory system nuclei and higher magnification micrographs of the SON
further illustrate these results. The significant increase in the amount of
oxytocinergic neurons between control (Figure 48A) and the rrCNTF plus U0124
control molecule (Figure 48B), which is not different than rrCNTF alone (Figure
49D), is apparent. Moreover, no visual difference was observed in magnocellular
neuron process density following inhibition of the MAPK-ERK pathway with
U0126 (Figures 48C and 49A), PD98059 (Figures 48D and 49B), or PD184352
(Figures 48E and 49C) compared to control SON (Figure 48A). Similar
observations were observed when analyzing individual PVN following
pharmacological inhibition of the MAPK-ERK pathway (see Figure 48).
Pharmacological Inhibition of the p38- and JNK-MAPK Pathways
For the pharmacological inhibition of the p38-MAPK pathway, we used
SB203580, which inhibits the p38a and Q>isoforms, but not the y and 5 isoforms,
and does not inhibit any of the JNK- or ERK-MAPK isoforms (English & Cobb,
2002; Greenwood & Bushell, 2010; J. C. Lee, et al., 1994). Our analysis
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demonstrated that 75 pM SB203580 in the presence of 25 ng/ml rrCNTF did not
result in a statistically significant difference in the number of surviving
oxytocinergic neurons in the SON (one-way ANOVA, F=50.10, p=0.1358; Figure
50A) and PVN (one-way ANOVA, F=50.49, p=0.1915; Figure 50B) compared to
the 25 ng/ml rrCNTF group; but the number of surviving oxytocinergic neurons
was still significantly elevated from control. However, following p38 inhibition with
SB203580 in the presence of 25 ng/ml rrCNTF, we observed a statistically
significant increase in the number of surviving oxytocinergic neurons by 60% in
the ACC (one-way ANOVA, F=21.41, p<0.0001\ Figure 50C) compared to the
25 ng/ml rrCNTF group. Interestingly, when we treated organotypic cultures with
just SB203580 there was a statistically significant increase in the number of
oxytocinergic neurons by 184% in the SON (one-way ANOVA, F=50.10,
p<0.0001\ Figure 50A), by 72% in the PVN (one-way ANOVA, F=50.49,
p<0.0001; Figure 50B), and by 732% in the ACC (one-way ANOVA, F=21.41,
p<0.0001\ Figure 50C) compared to the control media-treated group. These data
suggest that the p38-MAPK pathway may be involved in the injury-induced cell
death process in hypothalamic organotypic cultures.
In order to inhibit the JNK-MAPK pathway, we utilized the SP600125 (JNK
Inhibitor II) inhibitor which has equal potency towards all three of the JNK
isoforms (JNK1-3) and has been shown to dose-dependently inhibit cJun
(Bennett et al., 2001), and was demonstrated to have a 300 fold greater
selectively for JNK compared to ERK or p38 (Ohnishi et al., 2010). Our analysis
demonstrated that 50 pM SP600125 in the presence of 25 ng/ml rrCNTF did not
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result in a statistically significant difference in the number of surviving
oxytocinergic neurons in the SON (one-way ANOVA, F=50.10, p=0.4440\
Figure 50A) and ACC (one-way ANOVA, F=21.41, p=0.0893; Figure 50B)
compared to the 25 ng/ml rrCNTF group; but the number of surviving
oxytocinergic neurons was still significantly elevated from control. Flowever,
following JNK inhibition with SP600125 in the presence of 25 ng/ml rrCNTF, we
observed a statistically significant increase in the number of surviving
oxytocinergic neurons by 66% in the PVN (one-way ANOVA, F=50.49, p<0.0001\
Figure 50B) compared to the 25 ng/ml rrCNTF group. Similar to inhibition with
SB203580, when we treated organotypic cultures with just SP600125 there was
a statistically significant increase in the number of oxytocinergic neurons by
194% in the SON (one-way ANOVA, F=50.10, p<0.0001\ Figure 50A), by 125%
in the PVN (one-way ANOVA, F=50.49, p<0.0001\ Figure 50B), and by 2152% in
the ACC (one-way ANOVA, F=21.41, p<0.0001\ Figure 50C) compared to the
control media-treated group. These data suggest that, in addition to the p38MAPK pathway, the JNK-MAPK pathway may also be involved in the injuryinduced cell death process in hypothalamic organotypic cultures.
Representative low magnification montages of the magnocellular
neurosecretory system nuclei and higher magnification micrographs of the SON
further illustrate these results. When visibly comparing the amount of
oxytocinergic neurons between SB203580 (Figures 51A and 52A) and the
rrCNTF plus SB203580 (Figures 51B and 52B) groups, a slight increase in the
number of surviving neurons in the rrCNTF plus SB203580 cultures can be
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appreciated. Consistent with the quantitative neuronal count data (Figure 50), it is
visibly apparent that there is a slight increase in the number of neurons in the
SON and PVN of the rrCNTF plus SP600125 (Figures 51D and 52D) group
compared to the SP600125 cultures (Figures 51C and 52C). Moreover, there
appears to be similar amount of processes present in both the inhibitor and
rrCNTF plus inhibitor groups (Figures 51 and 52). Similar observations were
observed when analyzing individual PVN following pharmacological inhibition of
the p38- and JNK-MAPK pathways (see Figure 51).
Pharmacological Inhibition of PI3K-AKT Pathway
We utilized two pharmacological inhibitors of the PI3K-AKT pathway that
act on two separate and distinct signaling components: LY294002, which acts on
the ATP binding site of PI3K (Zamin et al., 2006), and wortmannin (KY12420),
which blocks the catalytic activity of PI3K (Luo et al., 2007). Moreover, we also
utilized a control molecule for LY294002, LY303511, which contains a single
atom substitution in the morpholine ring compared to LY294002 and does not
inhibit PI3K even at 100 pM (manufacturer’s technical sheet). Our analysis
demonstrated that when exposing the cultures to the control molecule,
15 pM LY303511, in the presence of 25 ng/ml rrCNTF we did not observe a
statistically significant difference in the number of surviving oxytocinergic neurons
in the SON (one-way ANOVA, F=36.29, p=0.6014\ Figure 53A), PVN (one-way
ANOVA, F= 19.73, p=0.4931\ Figure 53B), and ACC nuclei (one-way ANOVA,
F=38.48, p=0.7503\ Figure 53C) compared to the 25 ng/ml rrCNTF group; but the
number of surviving oxytocinergic neurons were still significantly elevated from
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control. When inhibiting PI3K with 15 (jM LY294002 in the presence of
25 ng/ml rrCNTF, we did not observe a statistically significant difference in the
number of surviving oxytocinergic neurons in the SON (one-way ANOVA,
F=36.29, p=0.8791; Figure 53A) and ACC nuclei (one-way ANOVA, F=38.48,
p=0.0738; Figure 53C) compared to the 25 ng/ml rrCNTF group. Flowever, there
was a statistically significant increase in the number of surviving oxytocinergic
neurons by 35% in the PVN (one-way ANOVA, F=19.73, p=0.0373\ Figure 53B)
compared to the 25 ng/ml rrCNTF group. When we exposed the organotypic
cultures to 1 pM wortmannin plus 25 ng/ml rrCNTF, we did not observe a
significant difference in the number of surviving oxytocinergic neurons in the
SON (one-way ANOVA, F=36.29, p=0.3364; Figure 53A), PVN (one-way
ANOVA, F=19.73, p=0.7280; Figure 53B), or ACC (one-way ANOVA, F=38.48,
p=0.3753; Figure 53C) compared to the 25 ng/ml rrCNTF group. As controls for
the inhibitors, we treated organotypic cultures with the inhibitors alone and there
was not a statistical difference in the number of oxytocinergic neurons in the
SON (one-way ANOVA, F=38.48, p>0.05\ Figure 53A), PVN (one-way ANOVA,
F=19.73, p>0.05\ Figure 53B), or ACC (one-way ANOVA, F=38.48, p>0.05\
Figure 53C) compared to the control media-treated group, demonstrating that in
the absence of rrCNTF, the concentrations of the inhibitors used did not
adversely affect oxytocinergic neuron survival. Altogether, these data
demonstrate that pharmacological inhibition of the PI3K-AKT pathway does not
affect CNTF-induced oxytocinergic neuronal survival in hypothalamic organotypic
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explant cultures indicating that PI3K is not involved in the CNTF-induced
neuronal survival intracellular signaling cascade.
Representative low magnification montages of the magnocellular
neurosecretory system nuclei and higher magnification micrographs of the SON
further illustrate these results. When visibly comparing the number of
oxytocinergic neurons between rrCNTF (Figures 54B and 55B), the rrCNTF plus
LY294002 (Figures 54C and 55C), and the rrCNTF plus wortmannin (Figures
54D and 55D) groups, there are similar numbers of oxytocinergic neurons
present, and these groups all have more oxytocinergic neurons than the control
group (Figures 54A and 55A). However, what is visually apparent is that there
are fewer neuronal processes present in the groups receiving PI3K inhibition
compared to the rrCNTF group, even though they have the same number of
surviving oxytocinergic neurons (compare 54B to 54C and 55B to 55C). The
oxytocinergic neurons in the PI3K inhibited groups (Figures 55C and D) appear
to have short stubby processes, if any at all, emanating from their soma, while
the rrCNTF (Figure 55B) and control group (Figure 55A) have long, branching,
punctate processes radiating from their cell bodies. In addition, there are
numerous processes coursing between the nuclei in the rrCNTF group (Figures
54B and 55B), while there is a lack of these processes present in the PI3K
inhibited groups.
In order to quantify this observation, we utilized a quantitative optical
densitometric stereological analysis using the grain counting function in image
analysis software to determine the proportional area of neuronal processes.
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Figure 56 shows the various steps involved in generating these data in the SON
of hypothalamic organotypic cultures following PI3K inhibition. Figure 56A shows
the image of the SON captured such that the entire SON is centered in the
bottom of the image. A highlighted SON is shown following setting of the density
to highlight the neuronal processes and cell bodies (Figure 56B). Note that the
analysis is a conservative estimate of the proportional area of neuronal
processes because not all of the neuronal processes are highlighted (arrowhead,
Figure 56A, B). A highlighted SON is shown following the setting of the density to
highlight just the neuronal somata (Figure 56C). Note that similar to their
immunoreactive profiles, the nuclei are not highlighted by the density setting
(arrows, Figure 56A, C).
The value utilized in the statistical analysis was the ratio of process
proportional area to total number of neurons in the SON. Figure 57 demonstrated
that following administration of exogenous rrCNTF there was a significant
increase in the proportional area of neuronal processes compared to control
(one-way ANOVA, F=24.87, p<0.0001\ Figure 57). The LY303511 molecule
served as a control molecule for the LY294002 inhibitor and the proportional area
of neuronal processes in the LY303511 plus 25 ng/ml rrCNTF group did not differ
from the 25 ng/ml rrCNTF group (one-way ANOVA, F=24.87, p=0.6496\
Figure 57). However, when the PI3K inhibitors, LY294002 and wortmannin, were
administered to the organotypic cultures in the presence of 25 ng/ml rrCNTF,
there was a significant reduction in the proportional area of neuronal processes
in the SON compared to the 25 ng/ml rrCNTF group (one-way ANOVA, F=24.87,
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p<0.0001\ Figure 57). Moreover, the LY294002 plus 25 ng/ml rrCNTF group was
significantly reduced from control values (one-way ANOVA, F=24.87, p<0.0001\
Figure 57). These observations indicate that while PI3K signaling does not
appear to be involved in CNTF-mediated neuronal survival, it is involved in
CNTF-induced process outgrowth from oxytocinergic magnocellular neurons in
the SON.
Pharmacological Inhibition of mTOR
mTOR is a signaling molecule that is primarily involved in PI3K-AKT
signaling. We utilized two pharmacological inhibitors to inhibit mTOR; rapamycin
and torin-1. Rapamycin is a selective and potent inhibitor of mTORCI
(Marwarha, Dasari, Prabhakara, Schommer, & Ghribi, 2010), and in order to
understand the role of mTORC2 we also utilized torin-1, which is a selective and
potent inhibitor for both mTORCI and mTORC2 (Thoreen et al., 2012; Thoreen
et al., 2009; Thoreen & Sabatini, 2009). Moreover, torin-1 has been
demonstrated to provide more complete inhibition of mTORCI when compared
to rapamycin (Thoreen & Sabatini, 2009). Our analysis demonstrated that 10 pM
rapamycin in the presence of 25 ng/ml rrCNTF did not result in a statistically
significant difference in the number of surviving oxytocinergic neurons in the
SON (one-way ANOVA, F=44.16, p=0.1113; Figure 58A), PVN (one-way
ANOVA, F=24.50, p=0.6633\ Figure 58B), and ACC (one-way ANOVA, F=23.92,
p=0.0865\ Figure 58C) compared to the 25 ng/ml rrCNTF group; but the number
of surviving oxytocinergic neurons were still significantly elevated from control.
Similarly, when we treated organotypic cultures with 500 nM torin-1 plus 25 ng/ml
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rrCNTF, our results demonstrated that there was no significant difference in the
number of oxytocinergic neurons in the SON (one-way ANOVA, F=44.16,
p=0.1487] Figure 58A), PVN (one-way ANOVA, F=24.50, p=0.4250; Figure 58B),
and ACC (one-way ANOVA, F=23.92, p=0.1816; Figure 58C) compared to the
25 ng/ml rrCNTF group; but the number of surviving oxytocinergic neurons were
still significantly elevated from control. When we treated organotypic cultures with
rapamycin or torin-1, not in the presence of rrCNTF, there was a statistically
significant increase in the number of oxytocinergic neurons in the SON (one-way
ANOVA, F=44.16, p<0.0001; Figure 58A), PVN (one-way ANOVA, F=24.50,
p<0.0001\ Figure 58B), and ACC (one-way ANOVA, F=23.92, p<0.0001\
Figure 58C) compared to the control media-treated group. These data suggest
that mTOR signaling may be involved in the injury-induced cell death process in
hypothalamic organotypic cultures.
Representative low magnification montages of the magnocellular
neurosecretory system nuclei and higher magnification micrographs of the SON
further illustrate these results. When visibly comparing the amount of
oxytocinergic neurons between rapamycin (Figures 59A and 60A) and the
rrCNTF plus rapamycin (Figures 59B and 60B) groups, you can appreciate that
there was a slight increase in the number of surviving neurons in the SON of the
rrCNTF plus rapamycin cultures. Consistent with the quantitative neuronal count
data (Figure 58), it is visibly apparent that there is a slight increase in the number
of neurons in the SON of the rrCNTF plus torin-1 (Figures 59D and 60D) group
compared to the torin-1 cultures (Figures 59C and 60C). Moreover, while there
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appears to readily visible processes present in the inhibitor and rrCNTF plus
inhibitor groups, the neuronal processes in the rrCNTF plus inhibitor groups were
more commonly organized in bundles or tracts spanning in between the SON
and ipsilateral PVN (Figure 59B, D).
Pharmacological Inhibition of NF-kB
We utilized two pharmacological inhibitors to inhibit NF-k B; bay 11-7082
and sc-514, which both inhibit Ik Bo phosphorylation and prevent activation of
NF-k B (Phulwani, Esen, Syed, & Kielian, 2008). Our analysis demonstrated that
15 and 30 pM bay 11-7082 in the presence of 25 ng/ml rrCNTF did not result in a
statistically significant difference in the number of surviving oxytocinergic neurons
in the SON (one-way ANOVA, F=46.56, p=0.9228, p=0.0828\ Figure 61A), PVN
(one-way ANOVA, F=25.59, p=0.9003, p=0.0667\ Figure 61B), and ACC (one
way ANOVA, F=41.72, p=0.7507, p=0.2082\ Figure 61C) compared to the
25 ng/ml rrCNTF group; but the number of surviving oxytocinergic neurons were
still significantly elevated from control. Similarly, when we treated organotypic
cultures with 20 pM sc-514 plus 25 ng/ml rrCNTF, our results demonstrated that
there was no significant difference in the number of oxytocinergic neurons in the
SON (one-way ANOVA, F=46.56, p=0.7561; Figure 61 A), PVN (one-way
ANOVA, F=25.59, p=0.3522\ Figure 61B), and ACC (one-way ANOVA, F=41.72,
p=0.4565; Figure 61C) compared to the 25 ng/ml rrCNTF group; but the number
of surviving oxytocinergic neurons were still significantly elevated from control.
When we treated organotypic cultures with bay 11-7082, not in the presence of
rrCNTF, there was no significant difference in the number of oxytocinergic
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neurons in the SON (one-way ANOVA, F=46.56, p=0.1130, p=0.9030;
Figure 61 A), PVN (one-way ANOVA, F=25.59, p=0.1822, p=0.1013\ Figure 61B),
and ACC (one-way ANOVA, F=41.72, p=0.9098, p=0.1128; Figure 61C)
compared to the control media-treated group. However, when we treated the
organotypic cultures with sc-514 we observed a statistically significant increase
in the number of oxytocinergic neurons by 181% in the SON (one-way ANOVA,
F=46.56, p<0.0001\ Figure 61A), by 166% in the PVN (one-way ANOVA,
F=25.59, p<0.0001; Figure 61B), and by 2058% in the ACC (one-way ANOVA,
F=41.72, p<0.0001\ Figure 61C) compared to the control media-treated group.
Altogether, these data indicate that NF-k B is not involved in CNTF-mediated
oxytocinergic neuronal survival.
Representative low magnification montages of the magnocellular
neurosecretory system nuclei and higher magnification micrographs of the SON
further illustrate these results. The significant increase in the amount of
oxytocinergic neurons between control (Figures 62A and 63A) and the rrCNTF
(Figures 62B and 63B) is apparent. When comparing the cultures that received
NF-k B inhibition (Figures 62C, D and 63C, D), it is also visually apparent that the
number of oxytocinergic neurons is similar to rrCNTF (Figures 62B and 63B).
Moreover, no visual difference was observed in magnocellular neuron process
density following inhibition of NF-k B with bay 11-7082 (Figures 62C and 63C)
and sc-514 (Figures 62D and 63D) compared to rrCNTF (Figures 62B and 63B).
Similar observations were observed when analyzing individual PVN following
pharmacological inhibition of NF-k B (see Figure 61).
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Consistency of Organotypic Cultures
Within each study, separate control and rrCNTF groups were performed.
The previous experiments were performed over the course of three years, and
utilized many different vials of exogenous rrCNTF from two separate lots. Lot
#080M1730 of exogenous rrCNTF was utilized in the initial organotypic studies,
the Jak-STAT study (Figure 38), the MAPK-ERK study (Figure 47), and the PI3KAKT study (Figure 53), while lot #091M1403 was utilized for the p38- and JNKMAPK study (Figure 50), the mTOR study (Figure 58), and the NF-k B study
(Figure 61). Thus, we compared the control and rrCNTF groups from all of the
studies in order to determine if there were changes in the number of
oxytocinergic numbers within these groups across studies. Figure 64
demonstrated that throughout all of the experiments, there was no statistical
difference in the number of oxytocinergic neurons in control SON (one-way
ANOVA, F=1.437, p=0.1752; Figure 64A), PVN (one-way ANOVA, F=2.072,
p=0.0762; Figure 64B), and ACC (one-way ANOVA, F=1.153, p=0.3283\ Figure
64C). Similarly, when we compared the rrCNTF groups across the studies, our
analysis demonstrated that there was no significant difference in the number of
oxytocinergic neurons in the SON (one-way ANOVA, F=1.325, p=0.2256\ Figure
65A), PVN (one-way ANOVA, F=0.2128, p=0.9924; Figure 65B), and ACC (one
way ANOVA, F=1.458, p=0.1659; Figure 65C). These analyses demonstrated
that the organotypic cultures maintained consistency throughout the entirety of
the studies.
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CHAPTER IV
DISCUSSION
Specific Aim I
Previous studies have demonstrated that following unilateral lesion of the
hypothalamo-neurohypophysial tract there is a collateral sprouting response that
reinnervates the partially denervated NL (Watt, et al., 1999; Watt & Paden,
1991). The observed sprouting response does not occur as a result of a
functional deficit; conversely, the magnocellular neurons undergo an increase in
neurosecretory activity (Watt, et al., 1999). Therefore, the factor or factors
responsible for the sprouting remain to be determined. Following reports
demonstrating that CNTF promotes magnocellular neuron survival and possibly
potentiates process outgrowth (Rusnak, et al., 2002; Vutskits, et al., 1998), we
demonstrated an increase in the protein levels of CNTF and the CNTF receptor
complex in the sprouting and axotomized SON and NL. However, it remained be
determined if the observed changes in CNTF and the receptor complex were due
to the sprouting response or the increase in neurosecretory activity. The results
reported herein demonstrated that increased neurosecretory activity resulted in a
decrease in CNTF protein levels, indicating that the post-injury sprouting
response may be responsible for the observed increases in CNTF and the
receptor complex. In addition, we determined that astrocytes in the SON and
pituicytes and axons in the NL are the cellular phenotypes that express the entire
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CNTF receptor complex, suggesting that CNTF-mediated neuroprotective actions
in the SON occur in a paracrine mechanism.
While the collateral sprouting response occurs in 35 day old rats following
unilateral hypothalamic lesion (Watt & Paden, 1991), the same post-injury
sprouting response does not occur in 125 day old rats (J.A. Watt, unpublished
observation). We have hypothesized that this is due to a deficit in the CNTF
signaling process within the magnocellular neurosecretory system. To this point,
we demonstrated a reduction in CNTFRa protein levels in the 125 day old rat
SON. Moreover, following unilateral hypothalamic lesion in the 125 day old rat,
the protein levels of CNTF and the CNTF receptor complex were not significantly
heightened in the contralateral SON or axotomized NL. These data are
suggestive that CNTF is involved in the post-injury sprouting response in the
magnocellular neurosecretory system and a deficit in that response may underlie
the reduced sprouting observed in older animals.
Unilateral Lesion of Hypothalamo-Neurohypophysial
Tract in 35 Day Old Rat
The present observations confirm and extend our previous reports
demonstrating an increase in CNTF-immunoreactivity and CNTFRa mRNA
expression in the contralateral sprouting and axotomized SON (Watt, et al., 2006;
Watt, et al., 2009). It has been widely reported that injury results in increased
levels of CNTF in the proximity of the injury (M. Y. Lee, Deller, et al., 1997; X. G.
Xia, Flofmann, Deller, & Kirsch, 2002). Not surprisingly, within the axotomized
SON, protein levels of CNTF and the CNTF receptor complex are significantly
elevated. In the axotomized SON, however, these increases did not prevent the
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death of the injured magnocellular neurons. This may be due to the fact that
CNTF has not conclusively been demonstrated to be secreted in vivo and it has
been proposed that it is only released following loss of membrane integrity of the
astrocytes (Richardson, 1994). CNTF lacks the secretory signal sequence which
is necessary for protein secretion from the cell via the classic protein secretion
pathway through the ER and Golgi apparatus (Vergara & Ramirez, 2004). While
it has not been conclusively demonstrated if, or how, rat CNTF is secreted, chick
CNTF is secreted through a rion-classical secretory pathway (Reiness, et al.,
2001) and reports have demonstrated that CNTF may be secreted in the
absence of injury from cultured rat astrocytes (Kamiguchi, et al., 1995) and
cultured bovine corneal endothelium (Koh, 2002). However, a more likely
explanation for the extensive loss of the magnocellular neurons following the
unilateral hypothalamic lesion is the proximity of the injury. The lesion tract is
typically within 500 pm of the SON, and even if CNTF was being secreted, the
degree of injury might be too severe for the magnocellular neurons to overcome.
It was demonstrated that injury to the hypothalamo-neurohypophysial tract within
the median eminence via nerve compression, which is much more distal to the
magnocellular neurons than unilateral hypothalamic lesion, results in a significant
loss of 31% oxytocinergic and 64% vasopressinergic neurons in the SON
(Dolcet, et al., 2001; Shahar, et al., 2004). Magnocellular neuron loss following
unilateral hypothalamic lesion reaches 85-93%; further demonstrating that the
more proximal the injury is to the SON, the more severe the loss of
magnocellular neurons.
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Within the contralateral, sprouting SON, it was previously demonstrated
that there is an increase in the message levels of al- and I3>ll-tubulin (Paden et
al., 1995b), which are subunits that form the major structural units, microtubules,
that enable neurite extension. However, we did not observe this response in a- or
I3>ll-tubulin protein levels in the 35 day sprouting SON at 10 dpi. The observed
changes in the message levels of al- and Gll-tubulin were analyzed at 10 and
30 dpi; thus, the translational activity producing the al- and (ill-tubulin proteins
may not be initiated at 10 dpi since the post-lesion sprouting response occurs
over the 1 to 4 week post-lesion period (Watt, etal., 1999; Watt & Paden, 1991).
Therefore, studies assessing the a- or (ill-tubulin protein levels in the SON during
the entire 1 to 4 week post-lesion period would provide insight into the temporal
pattern of the collateral sprouting response.
In addition to the increases in CNTF and the CNTF receptor complex in
the axotomized SON, protein levels of CNTF and its receptor complex increased
in the contralateral SON during the period of robust collateral sprouting of intact
neurosecretory axons. The observed increases in CNTF and the CNTF receptor
complex occurred at 10 dpi, which is during the collateral sprouting response that
repopulates the axonal numbers to control levels between 1 and 4 weeks post
lesion (Watt, et al., 1999; Watt & Paden, 1991). CNTF is of particular interest with
regard to axonal sprouting due to its demonstrated effects on sprouting in the
central and peripheral nervous systems. Numerous reports have demonstrated
that CNTF promotes motorneuron sprouting (Gurney, et al., 1992; Guthrie, et al.,
1997; Kwon & Gurney, 1994; Oyesiku &Wigston, 1996; Siegel, et al., 2000;
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Simon, et al., 2010; Ulenkate, et al., 1994; Wright, et al., 2007; J. J. Xu, et al.,
2009) and process outgrowth of retinal ganglion cells (Leibinger, et al., 2009; A.
Muller, et al., 2007; A. Muller, et al., 2009). In addition, CNTF was previously
implicated in hypothalamic magnocellular neuron process outgrowth in vitro
(Vutskits, et al., 1998). Consistent with our results, others have demonstrated an
increase in astrocytic CNTF and CNTFRa expression during the period of
entorhinal cortex (M. Y. Lee, Deller, et al., 1997) and hippocampal sprouting
(Guthrie, et al., 1997), providing further evidence for a direct involvement of
CNTF in promoting post-injury axonal sprouting. The expression of CNTF and
the CNTF receptor complex by SON astrocytes indicates that astrocyte-derived
CNTF acts through an autocrine signaling mechanism to promote indirectly
magnocellular survival and axonal sprouting. This is further evidenced by our
data showing the absence of LIFRG-immunoreactivity on magnocellular neurons,
which would preclude receptor-mediated signaling in response to CNTF. These
data are consistent with the observations of Rusnak, et al., who indicated that
addition of CNTF to dissociated cultures of magnocellular neurons did not result
in increased neuronal survival (Rusnak, et al., 2003). However, when CNTF is
applied to stationary organotypic cultures of the SON and PVN, survival of
axotomized magnocellular neurons is increased significantly (House, et al., 2009
Rusnak, et al., 2002; Rusnak, et al., 2003; Vutskits, et al., 1998; Vutskits, et al.,
2003), indicating that CNTF is acting through astrocytes or other glial elements.
Thus, CNTF may influence axonal sprouting by stimulating production of other
factors known to influence process outgrowth including fibroblast growth factor-2
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(FGF-2) and nerve growth factor (NGF) (Albrecht, et al., 2002; F. Jiang, Levison,
& Wood, 1999; Semkova & Krieglstein, 1999; Wang et al., 2008). Consequently,
the precise mechanism(s) by which CNTF influences axonal sprouting remains
unclear.
Our results also demonstrated that following unilateral hypothalamic
lesion, the protein levels of CNTF and the CNTF receptor complex were elevated
in the NL, which is the terminal sprouting field. Consistent with our results, others
have shown that CNTF expression is elevated in the terminal sprouting field
following axotomy in the hippocampus (Guthrie, et al., 1997). There is evidence
indicating that CNTF-immunoreactive perivascular cells of the NL are
neuronophagic during the axonal degeneration that follows partial denervation of
the 35 day old rat NL (Lo et al., in preparation), providing a possible explanation
for the up-regulation of CNTF. Alternatively, another hypothesis for the observed
increases in CNTF and the CNTF receptor components in the NL following
axotomy is that CNTF in the INL may promote the collateral sprouting response;
although, magnocellular neuron sprouting still occurs following hypophysectomy
(Kiernan, 1971), which is an injury paradigm that completely removes the NL.
However, unilateral hypothalamic lesion is an injury paradigm that differs from
hypophysectomy in that it leaves a population of magnocellular neurons intact
following the injury, suggesting that the post-lesion responses following these
injuries may also be different. Therefore, while it is unlikely that the observed
collateral sprouting response is due directly to a CNTF signaling response in the
NL, there are reports indicating the CNTF/CNTFRa complex are retrogradely
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transported in sensory neuron axons following injury (Curtis et al., 1993), and
within the NL we demonstrated that oxytocinergic and vasopressinergic axons, in
addition to pituicytes, are the cellular source of the CNTF receptor components.
Therefore, these data indicate that a CNTF signaling response within the
axotomized NL may play a role in the collateral sprouting response, but a more
likely hypothesis may be that the collateral sprouting response is a combination
of coordinated signaling responses between the intact SON and axotomized NL.
An alternative hypothesis to the role of CNTF in the NL is that CNTF may
assist in neurosecretion of the neuropeptides from the neurosecretory axons.
This hypothesis is based on the localization of the CNTF receptor complex to the
neurosecretory axons and pituicytes within the NL. Early investigations of the NL
led to the hypothesis that pituicytes synthesized and released neuropeptides;
however, ultrastructural analyses later revealed that the neurosecretory granules
were inside the neurosecretory axons that were surrounded or engulfed by
pituicyte cytoplasm (Dreifuss, Sandri, Akert, & Moor, 1975). Although, numerous
reports have suggested that pituicytes influence the control of neuropeptide
release. For example, increased neurosecretory activity results in morphological
changes in the pituicytes that assist in neurosecretion (Hatton, 1988; Tweedle &
Hatton, 1980, 1982, 1987). In addition, CNTF has been demonstrated to induce
the morphological alterations of astrocytes in vivo (Lisovoski et al., 1997). Thus,
during states of increased neurosecretory activity, functioning through the CNTF
receptor complex located on the pituicytes, CNTF may promote the
morphological changes in the pituicytes to allow for the neuropeptide release
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from the neurosecretory axons. Future experiments involving the administration
of exogenous rrCNTF to ex vivo NL cultures and analyzing oxytocin and
vasopressin release would aid in the understanding of the possible role of CNTF
in the NL.
Increased Neurosecretory Activity in the Male Rat
In our previous studies we demonstrated that the cross sectional area of
oxytocinergic and vasopressinergic somata and nuclei are significantly increased
in the sprouting SON by 10 and 30 dpi, respectively (Watt, et al., 1999). This
hypertrophy is accompanied by increased neurosecretory activity as evidenced
by a persistent increase in urine osmolality accompanied by decreased urine
volume and water intake beginning 3 dpi and maintained throughout the
sprouting event (Watt & Paden, 1991). These data lead us to hypothesize that
collateral sprouting by intact magnocellular neurons occurs as a direct response
to increased activity rather than as a consequence of partial denervation in the
NL. This possibility is supported by studies demonstrating that the survival and
collateral axonal sprouting of oxytocinergic and vasopressinergic neurons after
axotomy is attenuated by decreased neuronal activity (Dohanics, et al., 1996;
Herman, Marciano, Wiegand, & Gash, 1987; Shahar, et al., 2004; Watt, et al.,
1999) and by evidence of increased magnocellular survival in response to
potassium chloride stimulation (Shahar, et al., 2004) and chronic intermittent salt
loading (Huang & Dellmann, 1996). Key to understanding the interaction between
increased activity and collateral sprouting is to determine the responses of
various growth factors to these events. The hypothesis that increased neuronal
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activity may be sufficient in itself to induce changes in expression levels of CNTF
and the CNTF receptor complex is supported by evidence for activity-induced
increases in brain-derived neurotrophic factor (BDNF) mRNA expression in
neurons in the PVN (Castren, Thoenen, & Lindholm, 1995) and SON (Aliaga,
Arancibia, Givalois, & Tapia-Arancibia, 2002) following osmotic stimulation.
Indeed, our data show that heightened metabolic activity in the absence of the
post-denervation sprouting response resulted in a significant decrease in CNTF
protein levels within the SON, but with no measureable change in CNTFRa,
LIFRI3>, or gp130 protein levels. However, it remains to be determined whether
the decrease in CNTF protein levels resulted from a down-regulation in CNTF
message levels or increased secretion as these two events would have
predictably different effects on neurosecretory behavior.
Heightened neuronal activity has been demonstrated to modulate
neurotrophin expression throughout the brain, such as increases in hippocampal
BDNF during seizure (Katoh-Semba, Takeuchi, Inaguma, Ito, & Kato, 1999) and
physical activity (Neeper, Gornez-Pinilla, Choi, & Cotman, 1996). Likewise,
increased expression of BDNF and its secretion from dendrites of magnocellular
neurons in the SON has been reported in salt-loaded rats (Aliaga, et al., 2002;
Arancibia, Lecomte, Silhol, Aliaga, & Tapia-Arancibia, 2007). While the precise
mechanisms of activity-dependent regulation of CNTF remain unclear, CNTF has
been demonstrated to increase the expression of GFAP (Kahn, Ellison, Chang,
Speight, & de Vellis, 1997) and morphological alterations in astrocytes in vivo
(Lisovoski, et al., 1997). SON astrocytes are highly plastic and modulate
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neurosecretory activity in part by altering their process morphology to facilitate
increased neuron to neuron contact (Bobak & Salm, 1996; Salm & Hawrylak,
2004). Thus, the activity-dependant decrease in CNTF levels observed herein
may influence magnocellular neuron behavior indirectly through decreased
astrocyte GFAP synthesis and process retraction.
Increased excitatory afferent input may also modulate CNTF expression in
the SON. The SON is the main target for the noradrenergic system arising from
the brainstem (Cunningham & Sawchenko, 1988; Sawchenko & Swanson,
1981a). During states of heightened neurosecretory activity, noradrenaline, via
the a-i-adrenoreceptor, plays a critical excitatory role in the release of oxytocin
and vasopressin from magnocellular neurons (W. E. Armstrong, Gallagher, &
Sladek, 1986; Leibowitz, Eidelman, Suh, Diaz, & Sladek, 1990; Willoughby,
Jervois, Menadue, & Blessing, 1987). Within the SON, the majority of adrenergic
varicosities are found ventral to the magnocellular cell bodies in the dendritic
zone (McNeill & Sladek, 1980; Swanson, et al., 1981). The dendritic zone is the
location of the magnocellular neuron dendrites and astrocyte processes
(W. E. Armstrong, etal., 1982; Dyball & Kemplay, 1982; Yulis, Peruzzo, &
Rodriguez, 1984) and adrenergic receptors are expressed on astrocytes of the
SON (Lafarga, Berciano, Del Olmo, Andres, & Pazos, 1992). In addition, reports
have demonstrated that noradrenaline decreases CNTF mRNA expression and
protein levels when applied to cultured astrocytes (Carroll, et al., 1993; Rudge, et
al., 1994). Collectively, these reports suggest that during states of heightened
neurosecretory activity in the SON, increased noradrenergic stimulation results in
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down-regulation of CNTF protein levels in the SON. Future experiments will test
this hypothesis by analyzing CNTF protein levels following chronic infusion of
adrenergic receptor agonists and antagonists into the SON of salt-loaded and
control rats in vivo.
During states of heightened neurosecretory activity, the NL also
undergoes reversible morphological changes that help facilitate neurosecretion.
During periods of low secretory activity, pituicytes completely surround and
engulf neurosecretory axons and their terminals in the NL (Tweedle & Hatton,
1980, 1982). However, in response to osmotic stimulation, pituicytes retract from
the parenchymal basement membrane resulting in an increase in neuronalbasement membrane contact area thereby facilitating neuropeptide release
(Tweedle & Hatton, 1980, 1982, 1987). During chronic neurosecretory activity,
we did not observe any changes in the protein levels of CNTF or the CNTF
receptor complex in the male rat NL. Thus, in the male rat, only the protein levels
of CNTF were decreased in the SON following increased neurosecretory activity.
Increased Neurosecretory Activity in the Female Rat
While the unilateral hypothalamic lesion paradigm has been exclusively
performed in male rats, the magnocellular neurosecretory system of female rats
can be activated to sustain chronic periods of increased neurosecretory activity
by lactation and chronic salt-loading. Thus, we sought to determine if the
observed response in male rats following increased neurosecretory activity
occurs within the female magnocellular neurosecretory system. Following
physiological activation in female rats via chronic salt-loading and sustained
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lactation there was an up-regulation in CNTFRa protein levels in the SON. Within
the SON, CNTFRa is localized to oxytocinergic and vasopressinergic
magnocellular neurons and astrocytes (Watt, et al , 2009). Previous results have
demonstrated that within the SON increased neuronal activity promotes neuron
survival of injured vasopressinergic magnocellular neurons (Huang & Dellmann,
1996; Shahar, et al., 2004), while decreased neuronal activity reduces the
survival of injured vasopressinergic magnocellular neurons in the SON
(Dohanics, et al., 1996). Thus, the increase in CNTFRa protein levels in the
female SON that occurred as a result of increased neuronal activity may make
the magnocellular neurons more responsive to trophic support (i.e. CNTF) and
contribute to the neuroprotective role of increased neuronal activity. However, the
same response was not observed in the male SON, and the previous
experiments demonstrating that increased neuronal activity was beneficial were
performed in male rats (Dohanics, et al., 1996; Huang & Dellmann, 1996;
Shahar, et al., 2004), suggesting that there might be a gender-specific response
to the physiological activation on CNTFRa protein levels in the SON.
Numerous reports have demonstrated differential gender-specific
regulation of neurotrophins within the brain, including; BDNF, NGF, and
neurotrophin-3 (NT-3) (Bakos et al., 2009; Matsuki, Shirayama, Hashimoto,
Tanaka, & Minabe, 2001). Recently, McGregor et al. (2010) reported that CNTF
promoted contrasting effects on bone growth and remodeling in male and female
mice, indicating a possible hormonal influence on the actions of CNTF. Also, a
suggested role for CNTF in the reproductive axis has been proposed in the
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female rat (Dozio et al., 2005; Stanley et al., 2000; Watanobe & Habu, 2001).
Furthermore, gonadal steroids have long been implicated in the regulation of the
magnocellular neurosecretory system (Amico, Seif, & Robinson, 1981; Skowsky,
Swan, & Smith, 1979). Therefore, given the recognized influence of gonadal
hormones on the SON (for review see Sladek & Somponpun, 2008), it would be
of interest to determine possible hormonal interactions with CNTFRa as well as
measuring CNTFRa protein levels within the rat SON throughout the female
reproductive cycle.
Similar to the male NL, chronic salt-loading in the female NL did not affect
the protein levels of CNTF or the CNTF receptor complex. Surprisingly, however,
sustained lactation induced a reduction in LIFRG protein levels in the NL. In the
current study we demonstrated that LIFRI3, is located on the axons and pituicytes
within the NL; however, little is known about the general role of LIFRfi in the NL,
or specifically, its role during lactation. In addition to being a receptor component
for CNTF, LIFRI3> is also involved in intracellular signaling for the following
neurotrophins; leukemia inhibitory factor (LIF), oncostatin M (OSM), cardiotrophin
1 (CT-1), and cardiotrophin-like cytokine (CLC) (Turnley & Bartlett, 2000). Thus,
the down-regulation in LIFRI3, protein levels in the female NL during lactation may
not be a CNTF-dependent response. Therefore, future studies further
characterizing the effects of lactation on cytokines that utilize LIFRft would help
in the understanding of the decrease of LIFRI3> in the NL during lactation.
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Maturing Rat Magnocellular Neurosecretory System
It has repeatedly been shown that the young brain can overcome injury by
axonal reorganization (Crutcher & Chandler, 1985; Saporta & Phelps, 1985; Watt
& Paden, 1991); however, it is well understood that the mature brain has a
reduced capacity for functional or structural reorganization following injury
(Crutcher, 1990; Scheff, Bernardo, & Cotman, 1978). While a robust sprouting
response occurs in the magnocellular neurosecretory system of 35 day old rats,
the same post-injury sprouting response does not occur in 125 day old rats
(J.A. Watt, unpublished observation). Since CNTF is capable of inducing
sprouting of injured motor neurons (Siegel, et al., 2000) and is implicated in the
sprouting of injured MCNs in vitro (Vutskits, et al., 1998), we hypothesized that
the reduced sprouting efficacy observed in mature rats was due to an agedependent reduction in CNTF protein levels in the SON. Alternatively, a reduction
in the proteins necessary for intracellular signaling in the mature SON, such as
the CNTF receptor complex components or the Jak-STAT signaling proteins,
might lead to a loss in sprouting efficacy. In this regard, it has been previously
demonstrated that between 3 and 8 months of age there is a reduction in tSTAT3
protein expression in the rat brain (De-Fraja, Conti, Govoni, Battaini, & Cattaneo,
2000); however, it was not reported if this decrease occurs specifically in the
magnocellular neurosecretory system. Interestingly, we demonstrated that from
35 to 125 days of age, there was a significant reduction in CNTFRa protein levels
in the SON, with no changes in CNTF, LIFRI2>, gp130, or tSTAT3 protein levels in
the maturing SON or NL. Since CNTFRa is the specific receptor for CNTF and
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CNTF signal transduction is unable to occur with only LIFRU and gp130 (Davis,
Aldrich, Stahl, et al., 1993), a reduction in CNTFRa could reduce the efficacy of
CNTF signaling in the SON of the 125 day old rat, which may prevent the
collateral sprouting response from occurring. Moreover, if the significant
reduction in CNTFRa in the SON does prevent the collateral sprouting response
from occurring, these data are suggestive that the collateral sprouting response
is initiated in the SON since the mature NL exhibits consistent CNTFRa protein
levels from 35 to 125 days of age.
In addition to the age-dependent decrease in CNTFRa protein levels in the
SON, the protein levels of CNTF and the CNTF receptor complex did not
increase in the contralateral SON or the axotomized NL following unilateral
hypothalamic lesion in the 125 day old rat, while in the 35 day old rat, from which
a sprouting response occurs following axotomy, all of these components are
increased in the aforementioned regions. These data suggest that the lack of
CNTFRa in the SON of the 125 day old rat precludes the heightened CNTF
response, which we believe is necessary for the collateral sprouting response to
occur. Interestingly, we did not see an increase in CNTF or the receptor
components in the axotomized NL, which is the site of the degeneration of the
axotomized axons. These data suggest that the increases in CNTF and the
receptor components in the axotomized 35 day, 10 dpi NL are due to the
sprouting event, and not the degeneration of the axotomized axons. However,
the precise role of CNTF in the NL is still not known. To this point, there is
evidence indicating that CNTF-immunoreactive perivascular cells of the NL are
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neuronophagic during the axonal degeneration that follows partial denervation of
the 35 day old rat NL (Lo et al., in preparation), indicating that CNTF may play an
injury-dependent role in the NL. However, the neuronophagic role of CNTF in the
125 day old rat NL has not been reported. Altogether, these data provide
evidence in support of the hypothesis that CNTF promotes the collateral
sprouting response observed in the magnocellular neurosecretory system
following partial denervation of the NL in the 35 day old rat. Studies in which
stereotaxic infusion of CNTFRa and CNTF in to the contralateral SON following
unilateral lesion in the 125 day rat are currently underway, and the results of
these studies will provide valuable insight into the mechanisms mediating the
collateral sprouting response.
Specific Aim I Conclusions
In conclusion, we provide the first evidence for activity-dependent
regulation of CNTF in the CNS in the absence of injury. In addition, our data
demonstrated that the increase in CNTF and CNTF-receptor complex observed
in the sprouting SON is related to the sprouting response per se and not to the
increased neurosecretory activity associated with the post-lesion response. We
also demonstrated that the absence of immunoreactivity for the LIFRI3>
component of the CNTF receptor complex on magnocellular neurons further
supports the hypothesis that CNTF is acting through an autocrine mechanism to
enhance, indirectly, neuronal survival and axonal sprouting of magnocellular
neurons. Moreover, we demonstrated that the absence of sprouting in the
125 day rat following unilateral hypothalamic lesion may be due to a deficit in
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CNTFRa in the SON, which appears to affect the responsiveness of CNTF and
the CNTF receptor complex in the contralateral SON and axotomized NL.
Together, these support our hypothesis that the observed increase in CNTF and
CNTF receptor complex is specifically related to the axonal sprouting response
and supports neuronal sprouting through an astrocyte-dependent paracrine
mechanism.
Specific Aim II
The Jak-STAT pathway is considered the canonical pathway for CNTF
signal transduction (Bonni, et al., 1993; Bonni, et al., 1997; Darnell, et al., 1994).
Moreover, our lab has demonstrated that exogenous rrCNTF injection into the
SON in vivo activates STAT3 in astrocytes (Askvig et al., 2012b). Thus, these
observations were extended to determine if pressure injection of exogenous
rrCNTF into the SON resulted in a rapid and transient activation of the Jak-STAT
pathway in vivo.
Others have demonstrated the neuroprotective effects that CNTF has on
hypothalamic magnocellular neurons in organotypic cultures (House, et al., 2009;
Rusnak, et al., 2002; Rusnak, et al., 2003; Shahar, et al., 2004; Vutskits, et al.,
1998; Vutskits, et al., 2003). However, the mechanisms of these neuroprotective
effects have not been reported. Therefore, utilizing hypothalamic organotypic
cultures we determined that the Jak-STAT pathway is necessary to mediate
CNTF-induced neuronal survival of oxytocinergic neurons. We utilized
organotypic cultures because they exhibit several advantages over other in vitro
culture systems primarily due to the preservation of the in vivo cytoarchitecture
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and the use of fully differentiated neurons (House, et al., 1998; Vutskits, et al.,
1998). Furthermore, the ability to directly manipulate the culture media with
growth factors and pharmacological agents and assess magnocellular neuron
survival in hypothalamic organotypic cultures facilitates analysis of pathwaymediated cellular events more rapidly than can be achieved using our in vivo
injury model system.
CNTF-Induced Activation of the Jak-STAT Pathway in the SON
Specific intracellular phosphorylation cascades mediate responses to
distinct extracellular stimuli, such as the response to growth factors or cytokines.
Ultimately, an injured cell’s ability to grow, survive, differentiate, or die is
controlled by the integrated action of numerous phosphorylation cascades. The
Jak-STAT intracellular signal transduction pathway is considered the canonical
intracellular signaling pathway utilized by CNTF and CNTF has been
demonstrated to preferentially phosphorylate STAT3 at Tyr705 (Bonni, et al.,
1997; Darnell, et al., 1994; Wegenka, et al., 1993). We previously identified
tSTAT3-immunoreactivity within the neurons and astrocyte cell bodies and
processes throughout the SON (Askvig et al., 2012b). Moreover, tSTAT3immunoreactivity was highly localized to the SON and not within the adjacent
optic chiasm or surrounding hypothalamic region (Askvig et al., 2012b). These
findings demonstrate specific localization of the Jak-STAT pathway to the SON.
CNS cells in general have comparable levels of tSTAT3, but they display
quantitatively different levels of pSTAT3 following activation of the STAT3
pathway (MacLennan et al., 2000). A single intravitreal injection of Axokine
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(Regeneron), a synthetic analog of CNTF, induced rapid and persistent activation
of STAT3 in retinal Muller cells, astrocytes, and retinal ganglion cells (Peterson,
et al., 2000). A rapid and transient activation of STAT3 was also observed in
facial motor neurons, spinal motor neurons, and cranial motor neurons following
a single injection of rrCNTF (MacLennan, et al., 2000). In accordance with these
findings, our data revealed that a single pressure injection of rrCNTF directly over
the SON resulted in a pronounced, but transient activation of STAT3 in the SON.
This activation was previously demonstrated to be astrocytic and we did not
observe pSTAT3 immunoreactivity in magnocellular neurons following rrCNTF
injection (Askvig et al., 2012b). This is in accordance with our previous
observation that magnocellular neurons in the SON are not immunoreactive for
LIFRft, which CNTF requires to mediate an intracellular signaling cascade
(Davis, Aldrich, Stahl, etal., 1993). Consistent with our results, neurons of the
hippocampus, neocortex, cerebellar cortex, and olfactory bulb express CNTFRa
and tSTAT3, yet CNTF administration does not lead to STAT3 activation within
these neurons (MacLennan, et al., 2000). Similarly, it was recently demonstrated
that intrahippocampal injection of exogenous CNTF activated STAT3 in
astrocytes and not neurons (Bechstein, et al., 2012). Altogether, these results
indicate a cell-type-dependent regulation of CNTF-mediated STAT3 activation in
the SON.
Hypothalamic Organotypic Cultures
Stationary hypothalamic organotypic cultures exhibit several advantages
over other in vitro culture systems primarily because of the preservation of the in
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vivo cytoarchitecture and the use of fully differentiated neurons (House, et al.,
1998; Vutskits, et al., 1998). Moreover, the ability to directly manipulate the
culture media with growth factors and pharmacological agents and assess
magnocellular neuron survival in hypothalamic organotypic cultures provides our
lab several advantages over in vivo injury model systems. Exogenous rrCNTF
has been shown to promote the survival of injured magnocellular neurons in
hypothalamic organotypic cultures (House, et al., 2009; Rusnak, et al., 2002;
Rusnak, et al., 2003; Vutskits, et al., 1998; Vutskits, et al., 2003). In the present
study we demonstrated that hypothalamic organotypic explant cultures exposed
to 25 ng/ml rrCNTF for 14 days had significantly more oxytocinergic
magnocellular neurons in the magnocellular neurosecretory system compared to
explant cultures not treated with rrCNTF. Furthermore, the effects that
exogenous rrCNTF has on injured magnocellular neurons was validated by the
use of a reverse sequence construct of rrCNTF, which demonstrated that it is the
specific protein sequence and tertiary structure of rrCNTF that resulted in the
survival of injured oxytocinergic magnocellular neurons in the magnocellular
neurosecretory system.
Others have reported that exogenous rrCNTF has a greater effect on
vasopressinergic magnocellular neuron survival in the SON (Rusnak, et al.,
2002) and the PVN (Vutskits, et al., 1998) compared to the observed effect on
oxytocinergic magnocellular neurons. However, in our hands vasopressinergic
magnocellular neurons did not survive in the presence of 25 ng/ml rrCNTF in the
magnocellular neurosecretory system. It should be noted that, unlike Vutskits et
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al. (1998), we did not differentiate between parvocellular and magnocellular
neurons within the PVN, therefore our analysis of the PVN contains a
heterogeneous population of neurons. Kusano et al. (1999) demonstrated that
vasopressinergic magnocellular neurons survived at 255 mOsm/l but not at
300 and 330 mOsm/l culture media, while the survival of oxytocinergic
magnocellular neurons did not change from 255 to 330 mOsm/l culture media.
The osmolality of the culture media used in the current study was maintained at
310 mOsm/l. Therefore, future studies utilizing 255 mOsm/l culture media will be
performed to promote vasopressinergic magnocellular neuron survival in the
magnocellular neurosecretory system.
Complex Administration
CNTFRa imparts its functionality either as a membrane bound receptor,
which lacks a transmembrane sequence and is attached via a GPI-linkage or as
a soluble receptor that results from the cleavage of the GPI-linked membranebound receptor in a phosphatidylinositol-specific phospholipase C (PI-PLC)dependent mechanism (Davis, Aldrich, Ip, et al., 1993; Davis, et al., 1991). The
enzymatic cleavage of membrane-bound CNTFRa releasing the soluble
CNTFRa into the extracellular space is thought to occur in response to cellular
injury, as demonstrated by its release from skeletal muscle following peripheral
nerve injury (Davis, Aldrich, Ip, et al., 1993). While most examples of soluble
receptors are thought to interfere with the binding of their ligands to membranebound receptors, soluble CNTFRa increases the biological activity of CNTF
30-fold (Ip, et al., 1993; Saggio, et al., 1995). Thus, soluble CNTFRa and CNTF
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can stimulate cells that are not normally responsive to CNTF through the
appropriate signal-transducing receptor components (gp130/LIFRI2>) (Davis,
Aldrich, Ip, et al., 1993), indicating that the GPI-linkage of CNTFRa may
participate in a coordinated injury-release mechanism allowing soluble CNTFRa
to potentially increase the functionality of CNTF.
Increasing evidence suggests that complex administration enhances the
neuroprotective outcomes of CNTF signal transduction in the CNS. In cultured
cortical neurons, complex protects against glutamate-mediated cytotoxicity as
well as promoting nerve regeneration (Ozog, et al., 2004; Ozog, et al., 2008).
However, our analyses demonstrated that complex administration did not
increase the survival of the magnocellular neurons compared to the cultures
receiving exogenous CNTF. Since astrocytes are the only cell type that contains
all of the CNTF receptors, and the magnocellular neurons do not express LIFRft,
the astrocytes are the only cell phenotype that would be able to respond to
CNTF, regardless of the presence of soluble CNTFRa. It has been previously
demonstrated that all three receptor components are needed to elicit a CNTF
signaling response (Davis, Aldrich, Stahl, et al., 1993); thus, it appears that
administration of soluble CNTFRa only increases the efficacy of CNTF signaling
if the target cell(s) lack the CNTFRa component and contained the gp130 and
LIFRO) components.
Temporal Response of Exogenous rrCNTF
It was previously demonstrated that hypothalamic organotypic cultures
that received CNTF for the initial 7-10 days in culture had an increase in
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magnocellular neuron survival; however, CNTF failed to rescue the injured
magnocellular neurons when added to the culture media only for the last 7 days
of the 14 day experimental period (Rusnak, et al., 2003). Moreover, it was
recently demonstrated that a single pretreatment injection of exogenous CNTF
promoted neuronal survival following kainate insult two days later (Bechstein, et
al., 2012). These reports suggest that an acute dose of CNTF can reprogram the
cell into producing the neuroprotective transcriptional products of CNTF that
would result in prolonged neuronal survival. Thus, we exposed organotypic
cultures to exogenous rrCNTF for either 24, 48, or 72 hours with the cultures
being exposed to control media for the remaining days of the 14 day
experimental period. Following these treatments, we did not see an increase in
the survival of oxytocinergic neurons. One possible explanation may be due to
the severity of the injury that occurs during the culture preparation. Similar to the
unilateral hypothalamic lesion paradigm in vivo, we demonstrated that there was
greater than a 90% loss of oxytocinergic neurons following 14 days in control
media following the organotypic culture preparation. And it has been
hypothesized that it takes 7-10 days for the axotomy-induced neuronal death to
subside (Rusnak, et al., 2003). Therefore, exposure of exogenous rrCNTF for the
first 1-3 days following axotomy may not be adequate to overcome the
substantial injury, especially since the production and release of inflammatory
cytokines and chemokines following the axotomy, termed the secondary
cascade of cell death (Beattie, 2004; Beattie, Farooqui, & Bresnahan, 2000), will
continue to result in neuronal death many days post-lesion. Therefore, the
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organotypic cultures would need exogenous rrCNTF throughout the period of the
secondary cascade of cell death, which supports the data of Rusnak et al.
(2003).
The Role of the Jak-STAT Pathway in
CNTF-Induced Neuroprotection
In the present study we utilized the pharmacological inhibitor, AG490,
which specifically inhibits the tyrosine phosphorylation of Jak2, and cucurbitacin
I, which specifically inhibits the tyrosine phosphorylation of STAT3. Our results
demonstrated that in the presence of AG490 and cucurbitacin I the pro-survival
responses of rrCNTF on oxytocinergic neurons were completely abolished.
These results are in agreement with others that have demonstrated that CNTF
promotes neuronal survival through the Jak-STAT pathway (Bonni, et al., 1993;
Dolcet, et al., 2001; Lutticken, et al., 1994; A. Muller, et al., 2009; K. Park, et al.,
2004; Peterson, et al., 2000; Rhee, et al., 2004; Sango, et al., 2008; Symes, et
al., 1994). In conjunction with our in vivo observations, these data indicate a
paracrine mechanism of CNTF-mediated magnocellular neuron survival through
associated astrocytes, which was initially hypothesized by Rusnak et al. (2003).
This conclusion is supported by the observations that while CNTF promotes
survival of magnocellular neurons in organotypic cultures (Flouse, et al., 2009;
Rusnak, et al., 2002; Rusnak, et al., 2003; Vutskits, et al., 1998; Vutskits, et al.,
2003), exogenous CNTF did not promote survival of cultured magnocellular
neurons that are dissociated from astrocytes (Rusnak, et al., 2003). However, the
astrocytic factor or factors that CNTF produces via the Jak-STAT pathway
remain to be determined.
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Various reports have demonstrated that neuronal survival can be
stimulated by an astrocytic response. For example, Muller and Seifert (1982)
demonstrated that a neurotrophic factor is produced and released by primary
astrocyte cultures that promotes the survival of cultured hippocampal neurons.
Furthermore, the combination of neurotrophic factors produced by astrocytes and
membrane-bound molecules that mediate cell-to-cell interactions resulted in the
long-term survival of neurons in culture (Schmalenbach & Muller, 1993).
Consistent with our findings, others have demonstrated that CNTF promotes the
survival of hippocampal (Bechstein, et al., 2012) and retinal neurons (Peterson,
et al., 2000) via activation of the Jak-STAT pathway in glia cells; however, the
CNTF-induced glia-derived factor(s) directly affecting neuronal survival are not
known. CNTF has been demonstrated to increase the production of multiple
neuroprotective proteins in glial cells including; vasoactive intestinal peptide (VIP)
(E. Jones & Symes, 2000; Pitts, Wang, Jones, & Symes, 2001; Symes, et al.,
1997; Symes, et al., 1994), connexin 43 (Ozog, et al., 2004; van Adel, et al.,
2005), FGF-2 (Albrecht, et al., 2002; Wang, et al., 2008), FGF receptor 1 (FGFR1) (F. Jiang, etal., 1999), insulin-like growth factor type 1 receptor (IGF-IR)
(F. Jiang, et al., 1999), NGF, p75 low-affinity receptor (Semkova & Krieglstein,
1999), and glial cell-line derived neurotrophic factor (GDNF) (Krady et al., 2008).
CNTF also increases the function of glial glutamate transporters (GT),
glutamate/aspartate transporter-1 (GLAST-1), and glutamine synthetase, which
protected striatal neurons (Beurrier et al., 2010) and retinal ganglion cells (van
Adel, et al., 2005) against insult. In addition, the cell adhesion molecule polysialic
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acid neural cell adhesion molecule (PSA-NCAM), which is localized to
magnocellular neuron dendrites and axons and astrocytes in the SON
(Theodosis, et al., 1991), was demonstrated to be necessary for CNTF-mediated
survival of oxytocinergic and vasopressinergic magnocellular neurons (Vutskits,
et al., 2003), possibly through the mediation of astrocyte-neuronal interactions.
Interestingly, while the CNTF-family member LIF also promotes the survival of
oxytocinergic and vasopressinergic magnocellular neurons, PSA-NCAM is only
involved in CNTF-mediated magnocellular neuron survival (Vutskits, et al., 2003).
Therefore, in order to better understand the mechanism of CNTF-induced
magnocellular neuron survival in the SON, studies are currently underway to
determine possible transcriptional products (i.e. growth factors, cellular adhesion
molecules, and/or transcription factors) of the CNTF-induced astrocytic JakSTAT pathway.
It was initially hypothesized that CNTF functions as a protective factor that
is activated after an injury (Sendtner, et al., 1990). Siegel et al. (2000)
hypothesized that since axonal sprouting also occurs as a result of neuronal
injury, a factor that becomes active upon injury, such as CNTF, might also be
involved in a sprouting response. Numerous reports have demonstrated that
CNTF promotes motorneuron sprouting (Gurney, et al., 1992; Guthrie, et al.,
1997; Kwon & Gurney, 1994; Oyesiku &Wigston, 1996; Siegel, et al., 2000;
Simon, et al., 2010; Ulenkate, et al., 1994; Wright, et al., 2007; J. J. Xu, et al.,
2009) and process outgrowth of retinal ganglion cells (Leibinger, et al., 2009;
A. Muller, et al., 2007; A. Muller, et al., 2009). Furthermore, CNTF has been
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implicated in hypothalamic magnocellular neuron sprouting in vitro (Vutskits, et
al., 1998). In the present study, our data suggests that CNTF induces process
outgrowth from oxytocinergic magnocellular neurons, but it remains to be
determined if the Jak-STAT pathway is involved in CNTF-induced process
outgrowth. However, in response to CNTF, others have demonstrated differential
effects of the Jak-STAT, PI3-AKT, and MAPK-ERK pathways in mediating cell
survival versus process outgrowth (Alonzi et al., 2001; Ozog, et al., 2008; Sango,
et al., 2008). Thus, CNTF may mediate differential neuroprotective responses via
different intracellular signal transduction pathways.
Specific Aim II Conclusions
In conclusion, we provide the first evidence for the CNTF-induced
activation of the Jak-STAT pathway in the SON in vivo. We demonstrated
previously that the Jak-STAT activation occurs within the astrocytes of the SON,
indicating that a paracrine role of neuroprotection for CNTF in the SON (Askvig et
al., 2012b). Moreover, we demonstrated that the exogenous rrCNTF promoted
the survival of oxytocinergic neurons in organotypic cultures, and that the JakSTAT pathway was necessary for CNTF to promote neuronal survival.
Specific Aim III
While the Jak-STAT pathway is considered the canonical CNTF signal
transduction pathway, CNTF has been demonstrated to activate multiple
intracellular signaling pathways (Bonni, et al., 1993; Cagnon & Braissant, 2009;
Dolcet, et al., 2001; Gallagher, et al., 2007; Kassen, et al., 2009; Loy, et al.,
2011; Lutticken, et al., 1994; A. Muller, et al., 2009; K. Park, et al., 2004;
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Peterson, et al., 2000; Rhee, et al., 2004; Sango, et al., 2008; Symes, et al.,
1994; Trimarchi, et al., 2009). This may occur because there are multiple points
of convergence between the signaling components of the different pathways.
Moreover, it appears that the activation of a specific pathway is dependent on a
combination of various factors, such as; the stimulus, the cellular phenotype
activated, and the research paradigm. However, we did not observe activation of
the MAPK or PI3K-AKT pathways in the SON following pressure injection of
exogenous rrCNTF. Although, our pharmacological inhibition studies
demonstrated that the MAPK-ERK1/2 pathway is necessary for CNTF-mediated
neuronal survival and the PI3K-AKT pathway is necessary to mediate CNTFinduced process outgrowth. Moreover, p38, JNK, and mTOR appear to be
involved in the injury-induced death of the oxytocinergic neurons.
The Role of the MAPK-ERKA Pathway in
CNTF-Induced Neuronal Survival
In addition to the Jak-STAT pathway, CNTF has been demonstrated to
activate the MAPK pathways via other SH2 domain-containing proteins, such as
the phosphatases SHP2 and She, which are bound to the activated receptors
(Giordano, et al., 1997; Stahl, et al., 1995). Numerous reports have
demonstrated that the MAPK-ERK1/2 pathway promotes neuronal survival
following injury (Chicoine & Bahr, 2007; Jover-Mengual, Zukin, & Etgen, 2007;
Nagata, 1999), primarily through the inhibition of the pro-apoptotic molecule BAD
and production of the anti-apoptotic molecules, Bcl-2 and Bcl-XL(Nagata, 1999).
We did not observe activation of the MAPK-ERK1/2 pathway following injection of
exogenous rrCNTF; however, our pharmacological inhibition studies
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demonstrated that the MAPK-ERK14 pathway is necessary to mediate CNTFinduced neuronal survival in the magnocellular neurosecretory system. To date,
however, it remains unclear whether the MAPK-ERK14 pathway is signaling in
the astrocytes with the Jak-STAT pathway, or within the neurons.
One possibility for the function of the MAPK-ERK1/2 pathway is that it may
lead to activation of the STAT3 molecule in the SON. Unlike Jak molecules,
which are tyrosine kinases, members of the MAPK pathway are serine/threonine
kinases. Thus, MAPK-dependent activation of STAT3 occurs at Ser727 as
opposed to the more commonly Jak-dependently phosphorylated Tyr705 (Decker
& Kovarik, 2000). However, following pressure injection of exogenous rrCNTF in
to the SON, we did not observe activation of STAT3 at the Ser727 residue, STAT3
activation was only observed at the Tyr705 residue. Thus, it appears that the
MAPK-ERKV2 pathway is not upstream of STAT3 activation in the astrocytes.
Reports have suggested that ligands that activate the Jak-STAT pathway also
activate the MAPK-ERKV2 pathway (Frank et al., 1995; Ihle & Kerr, 1995;
Winston & Hunter, 1996). This mechanism appears to be dependent on Jakmediated Ras or Raf activation, which are the initiating kinases for ERKV2
activation. While Jak-mediated activation of STAT molecules has been reported
to be Ras-independent, Jak-mediated activation of the MAPK-ERK1/2 pathway
has been demonstrated to be Ras-dependent (Winston & Hunter, 1995). Others
have demonstrated that Raf physically associates with Jak2, and Raf is tyrosine
phosphorylated when co-expressed with Jak2 (K. Xia et al., 1996). We did not
examine Ras or Raf activation in the SON or pharmacologically inhibit Ras or Raf
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in organotypic cultures to determine the role that these signaling components
have on neuronal survival. If these experiments demonstrated that Ras or Raf
were involved in CNTF-induced neuronal survival, experiments utilizing the
pharmacological inhibitor of Jak2, AG490, would have to be performed to
determine if their involvement was Jak-independent or -dependent. Regardless,
Jak may be activating STAT and MAPK-ERKV2 pathway in the astrocytes to allow
them to signal in parallel following exogenous CNTF administration to promote
neuronal survival, although, we have yet to observe activation of the MAPKERK1/2 pathway in the SON following exogenous rrCNTF injection or determine if
there is a signaling connection between Jak and the MAPK-ERK/4 pathway.
An alternate explanation, however, is that the MAPK-ERKV2 pathway may
be downstream of the Jak-STAT pathway and signaling in the neurons to
promote CNTF-mediated neuronal survival. In order for this to occur, there would
have to be communication between the astrocytes and neurons, such as growth
factors, cellular adhesion molecules, and/or transcription factors of the CNTFinduced astrocytic Jak-STAT pathway, which would induce the activation of the
MAPK-ERKV2 in the neurons to directly promote neuronal survival. Recent
observations from our lab indicate that in response to exogenous rrCNTF,
cultured cortical astrocytes produce and release a molecule that promoted
neuronal survival in the magnocellular neurosecretory system (K.E. Behm,
unpublished observation). However, we have yet to observe activation of a
signaling component in the neurons following pressure injection of exogenous
rrCNTF in to the SON in vivo. Moreover, the temporal and spatial involvement of
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the MAPK-ERK1/2 pathway in mediating CNTF-induced neuronal survival remains
unknown. Therefore, future experiments utilizing small hairpin RNA (shRNA)
lentiviral particles to silence the MAPK-ERKM- pathway in organotypic cultures
and dissociated magnocellular neurons co-cultured with astrocytes will test these
hypotheses in order to determine the cellular phenotype and temporal activation
of the MAPK-ERKV2 pathway following exogenous rrCNTF administration in the
magnocellular neurosecretory system.
The Role of the p38-, JNK-MAPK, and mTOR Pathways
in Injury-Induced Neuronal Death
The p38- and JNK-MAPK pathways are structurally similar, but
functionally distinct, from the classic MAPKs (ERKs). These pathways are
preferentially activated by environmental stresses such as UV radiation, heat and
osmotic shock, and by pro-inflammatory cytokines, such as tumor necrosis factor
(TNF) and interleukin-1 (IL-1) (Tibbies & Woodgett, 1999). Others have
demonstrated that CNTF, which is classified as a pro-inflammatory cytokine, is
capable of activating the p38- (Loy, et al., 2011) and the JNK-MAPK pathways
(Cagnon & Braissant, 2009). Flowever, we did not observe activation of the p38or JNK-MAPK pathways in the SON following pressure injection of exogenous
rrCNTF. Moreover, pharmacological inhibition of the p38- and JNK-MAPK
pathways did not affect CNTF-mediated neuronal survival in hypothalamic
organotypic cultures. The SB203580 inhibitor only inhibits the p38a and
I3>isoforms and not the y and 5 isoforms, and does not inhibit any of the JNK- or
ERK-MAPK isoforms (English & Cobb, 2002). The SP600125 inhibitor has equal
potency towards all three of the JNK isoforms (JNK1-3) and has been shown to
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inhibit cJun in a dose dependent manner (Bennett, et al., 2001). Unexpectedly,
when the organotypic cultures were cultured only in the presence of the
inhibitors, there was an increase in the survival of oxytocinergic neurons.
Similarly, when the cultures were cultured only in the presence of the mTOR
inhibitors, rapamycin and torin-1, we observed a similar increase in the survival
of oxytocinergic neurons. These data suggest that the p38-, JNK-MAPK, and
mTOR pathways are involved in the post-axotomy responses that lead to
neuronal death in the organotypic cultures.
Our analysis demonstrated that the axotomy during the preparation of the
organotypic cultures resulted in a greater than 90% loss of oxytocinergic and
vasopressinergic neurons. It has been demonstrated previously that the
vasopressinergic, but not oxytocinergic, magnocellular neurons in the PVN of
organotypic cultures undergo neuronal death via apoptosis (Vutskits, et al.,
1998). However, the anti-apoptotic agent, Bcl-xL, protected both oxytocinergic
and vasopressinergic magnocellular neurons in the SON of organotypic cultures
from degeneration, and an inhibitor of caspases, Z-VAD-fmk, rescued
oxytocinergic magnocellular neurons in the SON (House, et al., 2006). These
data suggest that the axotomy during the organotypic culture preparation results
in an apoptotic response; however, due to the severe nature of the axotomy, a
necrotic response cannot be discounted. The most quoted function of the p38and JNK-MAPK pathways is its role in apoptosis (Cuenda & Rousseau, 2007;
Dhanasekaran & Reddy, 2008). Moreover, because of the overlap of the
MAPKKKs, specifically MKK4, involved in the p38- and JNK-MAPK pathways,
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these pathways could be activated by the same stimulus. Thus, a possible
explaination of the protection of the oxytocinergic neurons in the presence of the
p38 and JNK inhibitors following axotomy is that both the p38- and JNK-MAPK
pathways are activated by the injury to induce the apoptotic cascade in the
neurons.
As mentioned above, the diverse signaling molecule, mTOR, was also
protective of injured oxytocinergic neurons in the absence of exogenous rrCNTF.
While mTOR has been primarily linked to the PI3K-AKT pathway, numerous
reports have demonstrated mTOR signaling in the MAPK pathways (L. Chen,
Liu, Luo, & Huang, 2008; S. Chen et al., 2011; Karassek et al., 2010; Kato et al.,
2012; A. L. Miller, Garza, Johnson, & Thompson, 2007; B. Xu et al., 2011). While
the main functions of mTOR signaling are involved in promoting process
outgrowth, cell survival, cell proliferation, and cell growth, those functions
primarily appear to be linked directly to the PI3K-AKT pathway (H. Zhou &
Huang, 2010). However, when signaling within the MAPK pathways, mTOR
activity may promote cell survival or cell death, depending on the stimulus
(L. Chen, et al., 2008; S. Chen, et al., 2011; Karassek, et al., 2010; Kato, et al.,
2012; A. L. Miller, et al., 2007; B. Xu, et al., 2011). Recently, a report
demonstrated that mTORCI signaling resulted in apoptosis through inhibition of
AKT and selective activation of the JNK-MAPK pathway (Kato, et al., 2012).
These reports suggest that JNK is capable of mediating an apoptotic response
via mTOR, leading to our hypothesis that the following the axotomy during the
organotypic culture preparation the p38- and JNK-MAPK pathways were co140

activated to induce an apoptotic cascade in the oxytocinergic neurons through
the downstream signaling of mTOR.
Within the magnocellular neurosecretory system, understanding the
specific mechanisms that regulate injury-induced neuronal apoptosis has not
been well characterized. These novel data provide valuable insight into the
mechanisms of axotomy-induced cell death that may lead to therapies that
promote neuronal survival. However, exogenous rrCNTF administration resulted
in more oxytocinergic magnocellular neurons surviving in the SON compared to
inhibition of the p38-, JNK-MAPK, or mTOR pathways. Thus, it appears that
targeting an extracellular neurotrophin receptor that would reprogram the cell’s
transcriptional machinery into a neuroprotective mode may be more beneficial
than inhibiting pro-apoptotic machinery. Until future in vivo analyses can be
performed, this hypothesis remains unclear. Consequently, the therapeutic
potential of the p38, JNK, and mTOR inhibitors will be tested in the SON in vivo
utilizing the infundibular nerve crush paradigm, which results in the apoptotic
death of 30-65% of the magnocellular neurons in the SON (Dohanics, et al.,
1996; Shahar, et al., 2004). Following infundibular nerve crush, chronic infusion
of the inhibitors, or exogenous rrCNTF, into the SON will determine if p38, JNK,
and mTOR are involved in the post-injury apoptotic response and which
therapeutic method has the greatest potential to promote neuronal survival in
vivo.
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The Role of the PI3K-AKT Pathway in CNTFInduced Process Outgrowth
In addition to activating the Jak-STAT and MAPK pathways, reports have
also demonstrated that CNTF can activate the PI3K-AKT pathway (Dolcet, et al.,
2001; Gold, etal., 1994; Oh, et al., 1998). Moreover, it appears that CNTFdependent activation of the PI3K-AKT pathway is a Jak-dependent mechanism
(Dolcet, et al., 2001). In our analysis we did not observe activation of AKT
following pressure injection of exogenous rrCNTF into the SON, however, we did
not screen for activation of the PI3K signaling molecule. Pharmacological
inhibition of PI3K did not affect CNTF-induced neuronal survival, indicating that
CNTF does not utilize the PI3K-AKT pathway to promote oxytocinergic neuronal
survival in the magnocellular neurosecretory system. Interestingly, there was a
remarkable decrease in process outgrowth in the SON following pharmacological
inhibition of PI3K compared to the CNTF-treated cultures. Although the tissue
thickness and complexity of the processes prevented stereologic analysis of
aspects of neurite outgrowth such as elongation, branching, and neurite caliber,
we utilized quantitative optical densitometric stereological analysis using the
grain counting function in image analysis software to determine the proportional
area of neuronal processes which was corrected for the total number of neurons
in the SON. This analysis resulted in a quantitative, yet conservative, analysis of
process outgrowth, which confirmed our visual observation that there were fewer
neuronal processes present in the SON following PI3K inhibition. Thus, these
data suggest that the PI3K-AKT pathway is involved in regulating CNTFmediated process outgrowth, but not involved in mediating neuronal survival.
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It is not surprising that diverse intracellular signaling pathways mediate
distinct neuroprotective processes in response to CNTF. Numerous reports have
demonstrated divergent pathway mediation of CNTF-induced neuronal survival
and process outgrowth (Dolcet, et al., 2001; Ozog, et al., 2008; K. Park, et al.,
2004; Sango, et al., 2008). Similarities between those reports and our own
observations indicate that the PI3K-AKT pathway plays a predominant role in
mediating CNTF-induced process outgrowth in a variety of neuronal phenotypes.
The PI3K-AKT pathway has been well-documented to promote neuronal survival,
however, more recently the PI3K-AKT pathway has been revealed to be a key
regulator in several aspects of process outgrowth, including elongation,
branching, and neurite caliber (Read & Gorman, 2009). While the majority of the
studies have focused on the role of AKT in mediating process outgrowth, our
analysis directly implicates PI3K in CNTF-mediated process outgrowth. Since
AKT is the primary downstream effector of PI3K, it is likely that AKT is also
involved in mediating CNTF-induced process outgrowth. However, the direct role
of AKT in mediating CNTF-induced process outgrowth has not been explored.
There are many transcription factors that are downstream of PI3K that have been
demonstrated to influence process outgrowth, including; CREB (Du & Montminy,
1998), NF-k B (Kane, et al., 1999; Romashkova & Makarov, 1999), and mTORCI
(Asnaghi, et al., 2004; Nave, et al., 1999). Not surprisingly, the transcriptional
products of the PI3K-AKT pathway that directly mediate process outgrowth are
cytoskeletal elements, such as microtubules (Kobayashi et al., 1997).
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mTOR functions as two distinct signaling complexes, mTORCI and
mTORC2. These two complexes consist of unique mTOR-interacting proteins
which determine their substrate specificity (H. Zhou & Huang, 2010). In a
rapamycin-sensitive complex, mTORCI consists of mTOR, raptor (regulatory
associated protein of mTOR), DEPTOR, and GftL (Asnaghi, et al., 2004; Nave, et
al., 1999), while mTORC2 consists of mTOR, Sin1, and rictor (rapamycininsensitive companion of mTOR) (Jacinto et al., 2004). Interestingly, the roles of
the mTOR complexes in the PI3K-AKT pathway are quite distinct. It is believed
that mTORC2 functions upstream of AKT to assist in regulating maximal activity
of AKT (Hresko & Mueckler, 2005; Sarbassov, et al., 2005), while mTORCI is a
downstream regulator of AKT activity (H. Zhou & Huang, 2010). It was
demonstrated that PI3K-AKT-mTOR signaling has been shown to promote
growth and branching of hippocampal neurons (Jaworski, Spangler, Seeburg,
Hoogenraad, & Sheng, 2005). Our analysis demonstrated that pharmacological
inhibition of mTORCI and mTORC2 did not affect the survival or process
outgrowth of oxytocinergic neurons, suggesting that mTOR is not involved in
CNTF-mediated PI3K-AKT dependent process outgrowth of oxytocinergic
neurons.
In addition to mTOR, NF-k B has been demonstrated to function as a
transcription factor mediating process outgrowth in the PI3K-AKT pathway.
NF-k B has been shown by several groups to regulate process outgrowth
(S. J. Armstrong, Wiberg, Terenghi, & Kingham, 2008; Gutierrez, Hale, Dolcet, &
Davies, 2005; O'Neill & Kaltschmidt, 1997; Sole et al., 2004). Our analysis
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demonstrated that the NF-k B transcription factor was not necessary to mediate
CNTF-induced neuronal survival or process outgrowth. Thus, the downstream
effectors of the PI3K-AKT pathway that mediate CNTF-induced process
outgrowth remain unknown. There are numerous downstream effectors of the
PI3K-AKT pathway that have not been analyzed, including, but not limited to:
CREB and 5-catenin, both of which have been demonstrated to play a role in
process outgrowth (Read & Gorman, 2009). Furthermore, these data do not
provide evidence for, or preclude, AKT as a signaling component involved in
CNTF-mediated process outgrowth. To date, our evidence only indicates that
PI3K is involved in CNTF-mediated process outgrowth. Therefore, future
experiments will be performed that will determine the transcription factors and
transcriptional products utilized in the PI3K pathway that mediate CNTF-induced
process outgrowth. These experiments will provide clarity to the mechanisms that
underlie CNTF-induced process outgrowth.
Similar to the MAPK-ERKV2 pathway, it remains unclear whether the PI3KAKT pathway is signaling in the astrocytes or within the neurons. Since the
magnocellular neurons do not contain all of the CNTF receptor components, the
immediate signaling response within the SON has to occur within astrocytes.
While immediate activation of the Jak-STAT pathway in the astrocytes may
induce an indirect response on the magnocellular neurons to elicit activation of
the PI3K-AKT pathway that mediates process outgrowth, it is still unclear if the
Jak-STAT pathway is involved in CNTF-mediated process outgrowth. Another
hypothesis is that the PI3K-AKT pathway is activated in the astrocytes, and the
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transcriptional products of this activation modulate the neurons to promote
process outgrowth. Muller et al. (2009) demonstrated that astrocytes indirectly
promoted process outgrowth via CNTF, however, it was mediated via the MAPKERK1/2 pathway as opposed to the PI3K-AKT pathway. Regardless, the ability of
astrocytes to elicit an intracellular signaling response that leads to process
outgrowth has been demonstrated. Future experiments utilizing dissociated
magnocellular neurons co-cultured with astrocytes may help determine the
temporal and spatial activity of the PI3K-AKT pathway in mediating CNTFinduced process outgrowth. Furthermore, in vivo experiments involving the
infusion of the PI3K inhibitors into the sprouting SON following unilateral
hypothalamic lesion in the 35 day old rat will directly test the hypothesis that the
PI3K-AKT pathway is involved in the collateral sprouting response.
Specific Aim III Conclusions
In addition to the Jak-STAT pathway, we demonstrated that the MAPKERKY2 pathway was also necessary to promote CNTF-induced neuronal survival
of oxytocinergic neurons in the magnocellular neurosecretory system. To date,
however, it remains unclear whether the MAPK-ERKV2 pathway is signaling in
the astrocytes with the Jak-STAT pathway, or within the neurons. Interestingly,
we discovered that the p38-, JNK-MAPK, and mTOR pathways were involved in
the apoptotic cascade of the oxytocinergic neurons following axotomy. These
observations provide another therapeutic target to promote neuronal survival in
post-injury conditions. However, the full potential of the pharmacological
inhibition of these pathways in vivo needs to be explored. It has been previously
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demonstrated that CNTF has been implicated in hypothalamic magnocellular
neuron sprouting in vitro (Vutskits, et al., 1998), however, we demonstrated the
first quantitative evidence indicating that CNTF promotes process outgrowth from
oxytocinergic magnocellular neurons in the SON. Moreover, we demonstrated
that the PI3K signaling component was necessary to facilitate CNTF-induced
process outgrowth. Altogether, these data indicate that diverse intracellular
signaling pathways mediate distinct neuroprotective processes in response to
CNTF. The results of these studies will provide the basis for future studies that
will continue to elucidate the mechanisms underlying CNTF-mediated
neuroprotection in the CNS. The long-term goal is that these mechanisms will
lead to the development of future therapeutic strategies that will target nervous
system injuries or disorders that result in neurodegenerative processes.
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APPENDIX

CNTF

Figure 1.

Intracellular Signaling Pathways Activated by CNTF. Schematic
representation of the activation and interconnectivity of intracellular
signaling pathways, including the Jak-STAT, MAPK, and PI3K-AKT
pathways, which can be activated by CNTF.
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Table 1. Antibodies used in this study.
Host Species

Source

IHC

WB

A kt

ra b b it

C e ll S ig n a lin g

NA

1 :2 0 0 0

p A k t (S e r4M)

ra b b it

C e ll S ig n a lin g

NA

1 :2 0 0 0

p A k t (T h rjUo)

ra b b it

C e ll S ig n a lin g

NA

1 :5 0 0 0

m ouse

S e ro te c

NA

1 :5 0 ,0 0 0

c -J u n

ra b b it

C e ll S ig n a lin g

NA

1 :6 0 0 0

p -c -J u n (S e r“ )

ra b b it

C e ll S ig n a lin g

NA

1 :3 0 0 0
1 :5 0 0 0
NA

Antibody

13-actin

CNTF

ra b b it

S e ro te c

NA

CNTF

goat

R & D S y s te m s

1 :1 0 0

CNTFRa

goat

R & D S y s te m s

1 :2 0

NA

NA

1 :2 0 ,0 0 0

m ouse

B D P h a rm ig e n

CREB

ra b b it

C e ll S ig n a lin g

NA

1 :6 0 0 0

p C R E B (S e rlja )

ra b b it

C e ll S ig n a lin g

NA

1 :3 0 0 0

E R K 1/2

ra b b it

C e ll S ig n a lin g

NA

1 :3 0 0 0

CNTFRa

ra b b it

C e ll S ig n a lin g

NA

1 :2 0 0 0

G FAP

m ouse

S ig m a

1 :1 0 0 0

NA

G FAP

goat

S ig m a

1 :1 0 0 0

NA

gp130

ra b b it

S a n ta C ru z

1 :2 0 0

1 :5 0 0 0

p J a k 1 ( T y r ,u~ n u jJ)

ra b b it

R & D S y s te m s

NA

1 :1 0 0 0

Jak2

ra b b it

C e ll S ig n a lin g

NA

1 :2 0 0 0

p J a k 2 (T y rluu/,luuo)

ra b b it

Abeam

NA

1 :2 0 0 0

NA

1 :2 0 0 0
1 :2 0 0 0

p E R K ’/2 ( T h r ^ H y O

JN K

ra b b it

R & D S y s te m s

p J N K ( T y r l“ '',B:>)

ra b b it

R & D S y s te m s

NA

L IF R Ii (F I-2 20)

ra b b it

S a n ta C ru z

1 :2 5

NA

L IF R 6 (C -1 9 )

ra b b it

S a n ta C ru z

NA

1 :5 0 0 0

M E K 1/2

ra b b it

C e ll S ig n a lin g

NA

1 :3 0 0 0

p M E K ’/ ^ S e r ^ 1)

ra b b it

C e ll S ig n a lin g

NA

1 :3 0 0 0

g u in e a pig

P e n in s u la L a b s

1 :1 0 0 0

NA

m ouse

H a l G a in e r la b

1 :5 0 0

NA

ra b b it

C e ll S ig n a lin g

NA

1 :1 0 0 0
1 :2 0 0 0

o x y to c in
o x y to c in -n e u ro p h y s in
p38M A P K

ra b b it

C e ll S ig n a lin g

NA

m ouse

M illip o re

1 :1 0 0 0

NA

STAT1

ra b b it

C e ll S ig n a lin g

NA

1 :3 0 0 0

p S T A H ( S e r /4')

ra b b it

C e ll S ig n a lin g

NA

1 :2 0 0 0

p S T A T 1 (T y r/u1)

ra b b it

C e ll S ig n a lin g

NA

1 :1 0 0 0

STAT3

ra b b it

C e ll S ig n a lin g

NA

1 :3 0 0 0
1 :5 0 0 0

p -p 3 8 M A P K (T h r1HU/T y r1B^)
s100S

p S T A T 3 (S e r™ )

ra b b it

C e ll S ig n a lin g

NA

p S T A T 3 (T y r,U5)

ra b b it

C e ll S ig n a lin g

1 :3 0 0

1 :1 0 0 0

Tyk2

ra b b it

C e ll S ig n a lin g

NA

1 :2 0 0 0

p T y k 2 (T y r1UMnu“ )
v a s o p re s s in
v a s o p re s s in -n e u ro p h y s in

ra b b it

C e ll S ig n a lin g

NA

1 :1 0 0 0

g u in e a pig

P e n in s u la L a b s

1 :1 0 0 0

NA

m ouse

H a l G a in e r la b

1 :5 0 0

NA

IHC = immunohistochemistry; NA = not app icable; p = phosphorylated; WB = Western
blot
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Table 2. Pharmacological inhibitors used in this study.
Inhibitor
(Concentration
Used)

Pathway

Site of Action

AG490
(50, 100 pM)

Jak-STAT

Jak2

Bay 11-7082
(15 mM)

NF-kB
transcription
factor

Cucurbitacin I
(aka. JSI-124)
(10 pM)

LY294002
(15 (JM)

LY303511
(15 (jM)

PD184352
(5 pM)

PD98059
(5 pM)

Rapamycin
(10 pM)

SB203580
(75 pM)

Jak-STAT

Inhibits phosphorylation of
kBa

Suppresses tyrosine
phosphorylation of STAT3

Cross Reactivity?

Source
Company

Can inhibit Jak3, but
Jak3 is only
hematopoetically
expressed

Calbiochem
#658401-5MG

Calbiochem
No mention on tech,
sheet.

Does not affect Ras,
AKT, JNK, or ERK’/ 2

# 19687010MG
Calbiochem
#238590-1 MG

PI3K-AKT

Control
molecule for
LY294002

MAPK-ERK

MAPK-ERK

mTOR

p38 MAPK

Acts on ATP binding site of
PI3K

Contains single atom
substitution in morpholine
ring compared to
LY294002

Inhibitor of MEK. Specific
for ERK’/2 and not ERK5.

Acts by inhibiting activation
of MEK and subsequent
phosphorylation of MAPK
substrates. Is the same
inhibitor as U 0126 except
they are from different
generation of production.

Inhibitor of mTORCI.
Selectively inhibits
phosphorylation and
activation of p70 S6 kinase

A highly specific, potent,
cell permeable, selective,
reversible, and ATPcompetitive inhibitor of p38
MAPK
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Does not effect, EGF
receptor kinase,
MAPK, PKC, PI-4
kinase, S6 kinase, or
c-Src.
Does not inhibit PI3K
even at concentrations
of 100 pM.

Does not inhibit ERK5
(PD98059 and U0126
can, see reference),
more specific for
ERK’/ 2
Has no effect on
phosphorylation of Trk
or Src, or PI3K.
Can inhibit ERK5 as
well as ERKVl

Calbiochem
#440202

Calbiochem
# 440203

Santa Cruz
#sc-202759

Calbiochem
#513000

Calbiochem
No mention on
technical sheet.

Does not significantly
inhibit JNK or p42
MAPK at 100 pM.

#553210

Calbiochem
# 559389

Table 2 cont. Pharmacological inhibitors used in this study.
Inhibitor
(Concentration
Used)
SC-514
(aka. Ikk-2
inhibitor)
(20 pM)

Pathway

Site of Action

Cross Reactivity?

Source
Company

NF-kB
transcription
factor

Acts as a potent,
reversible, ATPcompetitive, and highly
selective inhibitor of Ikk-

Does not affect MAPK
signaling pathways.

Calbiochem
#401479

2 ( 3)
SP600125
(aka. JNK
Inhibitor II)
(50 pM)

Torin-1
(500 nM)

U 0124
(1 pM)

U 0126
(1 pM)

Wortmannin
(aka. KY12420)
d pM)

JNK MAPK

mTOR

Control
molecule for
U0126.

MAPK-ERK

PI3K-AKT

A potent, cell-permeable,
selective, reversible and
ATP-competitive inhibitor of
c-Jun N-terminal kinase
(JNK).

Exhibits over 300 fold
greater selectivity for
JNK as compared to
ERK 1/2 and p38
MAPK.

Calbiochem

A potent and selective
mTOR inhibitor, for
mTORCI and mTORC2.

Displays 200 fold
selectivity for mTOR
over DNA-PK, ATM,
and hVps34.

Tocris (R&D
Systems)

Does not inhibit MEK
activity even at 100
pM.

Calbiochem

Useful negative control for
U 0126.

A potent and specific
inhibitor of MEK1 and
MEK2.

A potent, selective, and
irreversible inhibitor of
PI3K. Blocks the catalytic
activity of PI3K without
affecting upstream
signaling effects.
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Has very little effect on
Abl, Cdk2, Cdk4, ERK,
JNK, MEKK, MKK4/SEK, MKK-6, PKC,
and Raf.
Can inhibit ERK5 as
well as ERK1/*.
Can block
phospholipase D,
myosin light chain
kinase, and PI4K at
high concentrations.

#420119

#4247

# 662006

Calbiochem
# 662005

Calbiochem
#681675
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Figure 2.

Pharmacological Inhibition of the Jak-STAT Pathway. Schematic
illustration demonstrating the pharmacological inhibitors of the JakSTAT pathway, AG490 and curcibitacin I, and their site of action.
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Gene
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Pharmacological Inhibition of the MAPK Pathway. Schematic
illustration demonstrating the pharmacological inhibitors of the
MAPK pathways, U0126, PD98059, PD184352, SB203580, and
SP600125, and their sites of action.
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Figure 4.

Pharmacological Inhibition of the PI3K-AKT Pathway. Schematic
illustration demonstrating the pharmacological inhibitors of the
PI3K-AKT pathway, LY294002 and wortmannin, and mTOR,
rapamycin and torin-1, and their sites of action.
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Figure 5.

Pharmacological Inhibition of NF-k B. Schematic illustration
demonstrating the pharmacological inhibitors of NF-k B, bay 117082 and sc-514, and their site of action.
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Figure 6.

Visual Confirmation of Successful Unilateral Hypothalamic Lesion.
(A) Cresyl violet counterstained image confirming unilateral
hypothalamic lesion. The lesion tract (arrows) is visible just lateral
to the III ventricle and medial to the ipsilateral SON and cuts
through the optic chiasm. Also apparent is the non-injured,
contralateral SON which contains more neurons than the lesioned
SON. (B) Immunofluorescently stained image for anti-oxytocin in
the median eminence. The lack of oxytocin-immunoreactivity from
the right hemisphere is indicative of a successful unilateral
hypothalamic lesion while the intact magnocellular neurons on the
contralateral hemisphere send oxytocinergic axons that course
through the internal zone of the median eminence (arrows). OC,
optic chiasm. SON, supraoptic nucleus. Scale bar A=300 pm;
B=100 pm.

157

Figure 7.

Magnocellular Neuron Survival Following Unilateral Flypothalamic
Lesion in the 35 Day Rat SON. Immunohistochemical labeling of
oxytocinergic and vasopressinergic magnocellular neurons were
used to identify individual magnocellular neurons. Cell counts
demonstrated no significant difference in the number of
oxytocinergic or vasopressinergic neurons in the SON contralateral
to the unilateral hypothalamic lesion. However, at 10 dpi the
numbers of oxytocinergic and vasopressinergic neurons were
reduced by 85% and 90% respectively in the axotomized SON.
Column bars and error bars represent the mean and SD of each
group. Each group is comprised of a minimum of six sections
sampled from each of 5 animals. ***p<0.0001.
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Figure 8.

Pre-Adsorption Controls for CNTF and CNTFRa Western Blots. (A)
Normal staining pattern for anti-CNTF. In addition to the expected
band at 23 kDa, there are two additional bands between 36 and
55 kDa which are consistent with literature reports. (B) Following
the pre-adsorption of the anti-CNTF antibody with a 10 molar
excess of exogenous rrCNTF, there was a dramatic reduction in
band intensity. (C) Normal staining pattern for anti-CNTFRa. In
addition to the band at the expected molecular weight of 40 kDa,
there was an additional band at 60 kDa which correlates to
glycosylated CNTFRa. (D) Following the pre-adsorption of the antiCNTFRa antibody with a 10 molar excess of exogenous rrCNTFRa,
there was the complete absence of any bands. These controls
indicate that the anti-CNTF and -CNTFRa antibodies are specific
for their appropriate antigens.
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Figure 9.

CNTF and CNTF Receptor Complex are Increased at 10dpl in the
35 Day Rat SON. Western blot analysis demonstrated a significant
increase in CNTF (A), CNTFRa (B), LIFRB (C), and gp130 (D)
protein levels in the axotomized SON compared to age-matched
control. Within the sprouting SON contralateral to the lesion, CNTF
(A), CNTFRa (B), LIFRI3> (C), and gp130 (D) protein levels were
significantly increased compared to age-matched control. Column
bars and error bars represent the mean and SD of 5 groups. Each
group represents isolated SON pooled from six rats. **p<0.01,
***p<0.0001.
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Figure 10.

CNTF and CNTF Receptor Complex are Increased at 10dpl in the
35 Day Rat NL. Western blot analysis demonstrated a significant
increase in CNTF (A), CNTFRa (B), LIFRft (C), and gp130 (D)
protein levels in the axotomized NL compared to age-matched
control. Column bars and error bars represent the mean and SD of
5 groups. Each group represents isolated SON pooled from six
rats. *p<0.05, **p<0.01, ***p<0.0001.
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Figure 11.

a- and (3.II-Tubulin Protein Levels in the 35 Day Old Rat SON and
NL at 10dpl. Western blot analysis demonstrated no significant
difference in a- (A) or I3>ll-tubulin (B) protein levels in the SON at
10dpl. Similarly, no significant difference was observed in a- (C) or
I3>ll-tubulin (D) protein levels in the NL at 10dpl. Column bars and
error bars represent the mean and SD of 5 groups. Each group
represents isolated SON pooled from six rats.
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Figure 12.

Chronic Salt-Loading Decreased CNTF Protein Levels in the Male
Rat SON. (A) Western blot analysis revealed a significant decrease
in CNTF protein levels in the male salt-loaded SON compared to
the age-matched control SON. Moreover, Western blot analysis
revealed no change in CNTFRa (B), LIFRI2> (C), and gp130 (D)
protein levels in the male salt-loaded SON compared to the agematched control SON. Column bars and error bars represent the
mean and SD of 5 groups. Each group represents isolated SON
pooled from six rats. ***p<0.0001.
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Figure 13.

Chronic Salt-Loading Did Not Affect Protein Levels of CNTF or the
CNTF Receptor Complex in the Male Rat NL. (A) Western blot
analysis revealed no change in CNTF (A), CNTFRa (B), LIFRI3> (C),
or gp130 (D) protein levels in the male salt-loaded NL compared to
the age-matched control NL. Column bars and error bars represent
the mean and SD of each group. Each group represents isolated
SON pooled from six rats.

169

Figure 14.

Chronic Physiological Activation Increased CNTFRa Protein Levels
in the Female Rat SON. (A) Western blot analysis revealed no
significant difference in CNTF protein levels in the female lactating
or female salt-loaded SON compared to the age-matched control
SON. (B) However, both lactation and chronic salt-loading
significantly increased CNTFRa protein levels in the female rat
SON compared to age-matched control SON. Moreover, Western
blot analysis revealed no change in LIFRG. (C) or gp130 (D) protein
levels in the female lactating or female salt-loaded SON compared
to the age-matched control SON. Column bars and error bars
represent the mean and SD of 5 groups. Each group represents
isolated SON pooled from six rats. **p<0.01, ***p<0.0001.
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Figure 15.

Lactation Decreased Protein Levels of LIFRft in the Female Rat NL.
Western blot analysis revealed no change in CNTF (A) or CNTFRa
(B) protein levels in the lactating or female salt-loaded NL
compared to the age-matched control NL. However, LIFRI3> (C)
protein levels in the lactating NL were significantly decreased from
age-matched control and female salt-loaded LIFRf3> protein levels.
gp130 (D) protein levels in the lactating or female salt-loaded NL
were not significantly different from age-matched control NL.
Column bars and error bars represent the mean and SD of
5 groups. Each group represents isolated SON pooled from six
rats. ***p<0.0001.
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Figure 16.

CNTF Protein Levels Did Not Change in the Maturing SON or NL.
Western blot analysis revealed no change in CNTF protein levels in
the control SON (A) or control NL (B) from 35 to 125 days of age.
Column bars and error bars represent the mean and SD of
5 groups. Each group represents isolated SON pooled from six
rats.

175

Figure 17.

CNTFRa Protein Levels Decreased in the Maturing SON. (A)
Western blot analysis revealed a significant decrease in CNTFRa
protein levels in the control SON from 35 to 125 days of age. (B)
(B) However, no significant difference was observed in the control
NL from 35 to 125 days of age. Column bars and error bars
represent the mean and SD of 5 groups. Each group represents
isolated SON pooled from six rats. *p<0.05 **p<0.01.
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Figure 18.

LIFRI2, Protein Levels Did Not Change in the Maturing SON or NL.
Western blot analysis revealed no change in LIFRI3. protein levels in
the control SON (A) or control NL (B) from 35 to 125 days of age.
Column bars and error bars represent the mean and SD of
5 groups. Each group represents isolated SON pooled from six
rats.
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Figure 19.

gp130 Protein Levels Did Not Change in the Maturing SON or NL.
Western blot analysis revealed no change in gp130 protein levels in
the control SON (A) or control NL (B) from 35 to 125 days of age.
Column bars and error bars represent the mean and SD of
5 groups. Each group represents isolated SON pooled from six
rats.
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Figure 20.

Total-STAT3 Protein Levels Did Not Change in the Maturing SON
or NL. Western blot analysis revealed no change in total-STAT3
(tSTAT3) protein levels in the control SON (A) or control NL (B)
from 35 to 125 days of age. Column bars and error bars represent
the mean and SD of 5 groups. Each group represents isolated SON
pooled from six rats.
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Figure 21.

CNTF and CNTF Receptor Complex are Increased at 10dpl in the
125 Day Rat Axotomized SON. Western blot analysis demonstrated
a significant increase in CNTF (A), CNTFRa (B), LIFRft (C), and
gp130 (D) protein levels were not significantly different compared to
age-matched control. Column bars and error bars represent the
mean and SD of 5 groups. Each group represents isolated SON
pooled from six rats. *p<0.05, **p<0.01, ***p<0.0001.
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Figure 22.

CNTF and CNTF Receptor Complex Did Not Increase at 10dpl in
the 125 Day Rat NL. Western blot analysis demonstrated no
significant difference in CNTF (A), CNTFRa (B), LIFRI3. (C), and
gp130 (D) protein levels in the 125 day axotomized NL compared to
age-matched control. Column bars and error bars represent the
mean and SD of 5 groups. Each group represents isolated SON
pooled from six rats.
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Figure 23.

Magnocellular Neuron Survival Following Unilateral Hypothalamic
Lesion in the 125 Day Rat SON. Immunohistochemical labeling of
oxytocinergic and vasopressinergic magnocellular neurons were
used to identify individual magnocellular neurons. Cell counts
demonstrated no significant difference in the number of
oxytocinergic or vasopressinergic neurons in the SON contralateral
to the unilateral hypothalamic lesion. However, at 10 dpi the
numbers of oxytocinergic and vasopressinergic neurons were
reduced by 88% and 93% respectively in the axotomized SON.
Column bars and error bars represent the mean and SD of each
group. Each group is comprised of a minimum of six sections
sampled from each of [n] animals. ***p<0.0001.
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Figure 24.

a and G.II-Tubulin Protein Levels in the 125 Day Old Rat SON and
NL at 10dpl. Western blot analysis demonstrated no significant
difference in a- (A) or (3.Il-tubulin (B) protein levels in the SON at
10dpl. Similarly, no significant difference was observed in a- (C) or
Rll-tubulin (D) protein levels in the NL at 10dpl. Column bars and
error bars represent the mean and SD of 5 groups. Each group
represents isolated SON pooled from six rats.
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Figure 25.

Differential Expression of CNTF Receptor Complex on Astrocytes
and Magnocellular Neurons. Dual fluorescent colocalization of antigp130 (A), with anti-VP (B), revealed co-localization in
vasopressinergic neurons (C, arrows). Note the gp130immunoreactive profiles in presumptive astrocytes in the ventral
glial limitans (VGL) of the SON (A, C, arrowheads). Similar
observations were observed with anti-OT (not shown).
Immunocytochemical analysis also demonstrated colocalization of
anti-gp130 (D), with GFAP-immunoreactive astrocytes (E), of the
SON (F, arrows). Also present are presumptive magnocellular
neurons that are immunopositive for gp130 (D, F, asterisks). Unlike
gp130, there was no observable colocalization of anti-LIFRft in the
magnocellular neurons of the SON (G-l). Note the LIFRISimmunoreactive profiles surrounding blood vessels (v) in the SON
(G, I, arrowheads) which do not colocalize with anti-VP (H) or antiOT (not shown). However, strong LIFRG-immunoreactivity in the
ventral glial limitans (VGL) of the SON (J), revealed extensive
colocalization of anti-LIFRI3> (J), with anti-GFAP (K), throughout the
entire SON (L, arrows). As a control for the dual label fluorescence
immunohistochemistry, incubations with the primary antibodies
were followed by incubation with the species specific fluorescentconjugated secondary antibodies for the opposite primary antibody.
These controls demonstrated an absence of immunoreactivity in
the rat SON (M-N). OC, optic chiasm; OT, oxytocin; v, blood vessel
VGL, ventral glial limitans; VP, vasopressin. Scale bars A-L=
50 pm, M-N= 100 pm.
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Figure 26.

The CNTF Receptor Complex is Localized to Axons and Pituicytes
in the NL. Dual-label immunohistochemistry demonstrated that
CNTFRa- (A-C), LIFRI3>- (l-K), and gp130- (Q-S) immunoreactive
profiles are localized to oxytocinergic and vasopressinergic (not
shown) axons. However, it is apparent that there are
immunoreactive profiles that do not co-localize with the axonal
profiles. We further determined that CNTFRa- (E-G), LIFRI2>- (M-O),
and gp130- (U-W) immunoreactive profiles also are localized to
s100l3>-immunoreactive pituicytes, which are the astrocyte
population of the NL. The controls demonstrated a decrease or
complete lack of immunoreactivity present. The pre-adsorption
controls for anti-CNTFRa with Texas red (D) and FITC (H)
demonstrated a strong decrease in immunoreactivity, indicating that
the anti-CNTFRa antibody is specific for CNTFRa. Moreover,
negative controls for LIFRI3, (L and P), and gp130 (T and X)
demonstrated a lack of immunoreactivity, indicating that the
secondary antibody was specific for species of the primary
antibody. OT, oxytocin. Scale bars =10 pm.
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Exogenous rrCNTF Resulted in the Rapid and Transient Activation
of STAT3 in the Rat SON That is Inhibited by AG490. (A) Western
blot analysis of dissected SON samples demonstrated that acute
pressure injection of 100 ng/pl rrCNTF induced a statistically
significant increase in pSTAT3 (Tyr705) levels in the SON at 1 hr
post-CNTF-injection. At 3 hrs post-CNTF-injection pSTAT3 levels
still remained significantly elevated compared to contralateral
control and vehicle-infused control SON; however, the pSTAT3
(Tyr705) levels at 3 hrs post-CNTF-injection were significantly
decreased from the pSTAT3 (Tyr705) levels at 1 hr post-CNTFinjection. Administration of AG490 (10 mg/kg IP) 1 hour prior to
rrCNTF injection significantly decreased the pSTAT3 (Tyr705) levels
to levels that are not significantly different from vehicle-infused
control SON but still significantly elevated from contralateral control
SON. (B) Western blot analysis demonstrated no activation of
pSTAT3 (Ser727) in the SON following pressure injection of
exogenous rrCNTF. Column bars and error bars represent the
mean and SD of 6 groups. Each group represents isolated SON
pooled from three rats. In order to determine the amount of total
protein that is phosphorylated, the ROD of the phosphorylated
protein was normalized to the ROD of the total protein, as opposed
to the ROD of G-actin, to obtain a ratio used for statistical analysis.
pSTAT3, phosphorylated STAT3; ROD, relative optical density;
tSTAT3, total STAT3.*p<0.05, ***p<0.0001.
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Figure 28.

Exogenous rrCNTF Did Not Activate STAT1, Tyk2, or Jak2.
Western biot analysis of dissected SON samples demonstrated that
acute pressure injection of 100 ng/pl rrCNTF did not result in
activation of STAT1 (Tyr701) (A), STAT1 (Ser727) (B), Jak2 (C), or
Tyk2 (D) in the SON. However, AG490 administration significantly
decreased the level of pJak2 compared to all other groups (C).
Column bars and error bars represent the mean and SD of
6 groups. Each group represents isolated SON pooled from three
rats. In order to determine the amount of total protein that is
phosphorylated, the ROD of the phosphorylated protein was
normalized to the ROD of the total protein, as opposed to the ROD
of 8>-actin, to obtain a ratio used for statistical analysis. pJak2,
phosphorylated Jak2; pSTATI, phosphorylated STAT1; pTyk2,
phosphorylated Tyk2; ROD, relative optical density; tJak2, total
Jak2; tSTATI, total STAT1; tTyk2, total Tyk2.***p<0.0007.
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Figure 29.

Qualitative Survey of Jak-STAT Pathway. A qualitative Western blot
assessment of the Jak-STAT pathway was performed at various
time points. Similar to what was observed at 1 and 3 hours post
rrCNTF injection, we did not see activation of pSTAT3 (Ser727) at
15, 30, 45 minutes, 6, 12, 24, or 48 hours post rrCNTF injection.
The bands present in the pSTAT3 (Tyr705) survey extend the
quantitative observations observed at 1 and 3 hours post rrCNTF
injection. pSTAT3 (Tyr705) activation is apparent by 30 and 45
minutes post rrCNTF injection and visible bands of pSTAT3 (Tyr705)
are still apparent at 6 and 12 hours post rrCNTF injection; however,
by 24 and 48 hours post rrCNTF injection we no longer see
pSTAT3 (Tyr705) bands in the SON. Consistent with the levels of
pSTATI (Ser727) and (Tyr701), pJak2, and pTyk2 at 1 and 3 hours
post rrCNTF injection, we did not see an apparent increase in
activation of these band sizes at any of the time points surveyed.
pJak2, phosphorylated Jak2; pSTATI, phosphorylated STAT1;
pSTAT3, phosphorylated STAT3; pTyk2, phosphorylated Tyk2;
tJak2, total Jak2; tSTATI, total STAT1; tSTAT3, total STAT3;
tTyk2, total Tyk2.
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Figure 30.

Preservation of the Cytoarchitecture in Hypothalamic Organotypic
Cultures. (A) A representative micrograph demonstrating that
oxytocinergic magnocellular neurons maintains its in vivo
cytoarchitecture in culture and contains two dendrites (thick arrows)
with an axon (thin arrows) branching from one of the dendrites. (B)
A representative micrograph montage demonstrating the
preservation of the specific magnocellular nuclei after being in
culture for 14 days. The organization of the oxytocinergic
magnocellular neurons into their respective magnocellular
neurosecretory system nuclei (PVN and SON) is typical of what is
observed in adult rat magnocellular neurosecretory system nuclei.
(C) Analysis of control organotypic culture media demonstrated that
the osmolality and pH did not change during the entire experimental
period, with levels maintained around 310 mmol/kg and 8.1,
respectively. PVN, paraventricular nucleus; SON, supraoptic
nucleus. Scale bar A=50 pm, B=300 pm.
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Table 3. Survival of rat hypothalamic oxytocinergic (OT) and vasopressinergic
(VP) neurons in the SON, PVN, and ACC in vitro.
N u c le i/
P h e n o ty p e

In ta c t
P6

C o n tro l

10 n g /m l rrC N T F

2 5 n g /m l rrC N T F

5 0 n g /m l
rrC N T F

S O N /O T

8 7 8 .6 + 3 0 5 .3
(1 5 )

2 0 .7 4 1 2 9 .9 5
(1 7 )

6 2 .7 1 4 1 .0 2

1 6 2 .4 1 6 5 .3 6

(1 5 )

(1 5 ) ***

1 5 1 .3 1 7 4 .1 4
(1 7 ) ***

5 2 9 .1 ± 2 7 1 .2
(1 4 )

3 .8 8 1 4 .4 5
(1 6 )

8 .3 9 1 9 .0
(1 8 )

P V N /O T

1 0 9 2 1 3 4 5 .5
(1 5 )

7 0 .7 1 ± 4 4 .8 5
(1 7 )

P V N /V P

2 6 7 .8 1 1 2 3 .4
(1 4 )

3 6 .1 3 1 2 6 .3 2

A C C /O T

A C C /V P

S O N /V P

(1 5 )

1 3 . 9 2 H 1.6 2
(1 9 )*

5 3 .3 3 1 2 2 .0
(1 5 )

1 2 2 .3 1 5 4 .6 8
(1 5 ) ***

1 6 2 .8 l3 8 .5 3
(1 7 ) ***

3 1 .4 4 1 2 7 .1 3
(1 8 )

1 9 .7 8 1 1 8 .2 2
(1 5 )*

1 0 .7 1 l9 .2 7

(1 6 )

9 1 7 .7 ± 2 4 3 .8
(1 5 )

3 .8 5 1 4 .9
(1 7 )

1 8 .9 1 2 7 .8
(1 5 )

7 4 .5 7 1 5 5 .1
(1 5 )***

7 4 .9 1 1 5 6 .5 7
(1 7 )***

2 4 8 .8 ± 1 1 8 .9
(1 4 )

0 .7 5 1 1 .2 8

0 .4 4 1 0 .7 8
(1 8 )

1 .0 7 1 1 .6 2
(1 5 )

1 .4 7 1 1 .7 2
(1 9 )

(1 6 )

. 1 0 .9 7 1 1 3 .6 8

(1 9 ) **

Mean = cells/filter ±SD (n).
n = number of filters which is equivalent to number of neonatal hypothalami.
Asterisks represent significant differences compared to control in same row
(*p<0.05, **p<0.01, ***p<0.0001).
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Figure 31.

Exogenous rrCNTF Promotes Survival of Oxytocinergic Neurons in
Vitro. Administration of 25 ng/ml rrCNTF for 14 days significantly
increased the number of surviving oxytocinergic magnocellular
neurons in the SON (A), PVN (C), and ACC (E). However, only a
slight increase in the number of sun/iving vasopressinergic
magnocellular neurons was observed in the SON following
treatment with 50 ng/ml rrCNTF for 14 days (B), while there was no
significant increase in the number of surviving vasopressinergic
neurons in the PVN (D), or ACC (F). Column bars and error bars
represent the mean and SD of [n] groups. ACC, accessory nuclei;
PVN, paraventricular nucleus; SON, supraoptic nucleus. *p<0.05,
**p<0.01, ***p<0.0001.
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Figure 32.

Soluble CNTFRa Does Not Enhance CNTF-Mediated
Neuroprotection in Vitro. Administration of 25 ng/ml rrCNTF +
250 ng/ml rrCNTFRa (complex) for 14 days did not significantly
increase the number of surviving oxytocinergic magnocellular
neurons in the SON (A), PVN, (C), or ACC (E). We did not observe
a significant increase in the number of vasopressinergic neurons in
the SON (B), or ACC (F), following complex treatment; although,
we did observe a significant increase in the number of surviving
vasopressinergic neurons in the PVN following complex
administration compared to exogenous rrCNTF administration (D).
However, there was a significant decrease in the number of
surviving vasopressinergic neurons in the PVN following
exogenous rrCNTF administration (D), and complex administration
recovers the amount of vasopressinergic neurons in the PVN to
control levels (D). Column bars and error bars represent the mean
and SD of [n] groups. ACC, accessory nuclei; PVN, paraventricular
nucleus; SON, supraoptic nucleus. *p<0.05, **p<0.01, ***p<0.0001.

201

202

\

\

\

\

\

\

\

'

V-

n

* % s *0/

\

\\

HI

HI

HI

* Vasopressinergic Neurons in ACC

\ v |s

8 § 8 § § I

# Oxytocinergic Neurons in ACC

P5

\

\

\

\

V

V

\
a/

*

o

8

8

8

HI

3

* Vasopressinergic Neurons in PVN

HI

8I i8 i8 •8 «2

# Oxytocinergic Neurons In PVN

O

# Oxytocinergic Neurons in SON

^

O8 8 8 8 8 § 8 §

Figure 33.

Micrograph Montages of Magnocellular Neurosecretory System
Nuclei in Hypothalamic Organotypic Cultures
Immunohistochemically Stained for Oxytocinergic Neurons. (A)
Micrograph montage of magnocellular neurosecretory system
nuclei of a representative explant slice fixed and
immunohistochemically stained for oxytocinergic neurons at the
time of sacrifice (post-natal day 6). Note the hypothalamoneurohypophysial tract (A, arrows), which contains the
magnocellular neuron axons that project to the NL. (B) Micrograph
of oxytocinergic neurons of a representative explant slice that
received control media for 14 days. Note the preservation of
magnocellular neurosecretory system nuclei organization. (C)
Montage of oxytocinergic neurons from a representative explant
slice that received 25 ng/ml rrCNTF treatment for 14 days. Note the
substantial increase in oxytocinergic neurons in the SON and PVN
as well as the maintenance of process density following rrCNTF
treatment (arrows) compared to control (B). (D) Montage of
oxytocinergic neurons from a representative explant slice that
receive complex (25 ng/ml rrCNTF + 250 ng/ml rrCNTFRa) for
14 days. Similar to the culture receiving only exogenous rrCNTF,
the culture receiving complex for 14 days also displayed a
prominent increase in oxytocinergic neuron number and process
density throughout the magnocellular neurosecretory system nuclei,
particularly processes extending between the nuclei (arrows). Note
that the representative images were obtained from approximately
the same level of the magnocellular neurosecretory system, which
is apparent when comparing the III ventricle between the images.
ACC, accessory nuclei; PVN, paraventricular nucleus; SON,
supraoptic nucleus. Scale bar=300 pm.
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Figure 34.

Micrograph Montages of Magnocellular Neurosecretory System
Nuclei in Hypothalamic Organotypic Cultures
Immunohistochemically Stained for Vasopressinergic Neurons. (A)
Micrograph montage of magnocellular neurosecretory system
nuclei of a representative explant slice that received control media
for 14 days. While there are an observable number of
vasopressinergic neurons in the PVN, the majority of the neurons
that are present appear to be parvocellular neurons, as opposed to
the larger, more prominent, magnocellular neurons. (B) Montage of
vasopressinergic neurons from a representative explant slice that
received 25 ng/ml rrCNTF treatment for 14 days. It is apparent that
there was not a significant increase in the amount of
vasopressinergic neurons following exogenous rrCNTF treatment.
Note that the representative images were not obtained from the
same level of the magnocellular neurosecretory system. The
micrograph in (B) is slightly more rostral than the micrograph in (A),
which is apparent by the presence of the suprachiasmatic nucleus.
PVN, paraventricular nucleus; SCN, suprachiasmatic nucleus;
SON, supraoptic nucleus. Scale bar=300 pm.
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Figure 35.

Exogenous rrCNTF for Seven Days Enhanced Survival of
Oxytocinergic Neurons in the PVN and ACC. Administration of
25 ng/ml rrCNTF for 7 days did not significantly increase the
number of surviving oxytocinergic magnocellular neurons in the
SON (A). However, 7 days of exogenous rrCNTF administration
enhanced the survival of oxytocinergic neurons in the PVN (C) and
ACC (E). Vasopressinergic magnocellular neuron survival in the
SON (B), PVN (D), and ACC (F) were significantly increased with
7 days of exogenous rrCNTF administration compared to both the
7 day control and 14 day rrCNTF groups. Column bars and error
bars represent the mean and SD of [n] groups. ACC, accessory
nuclei; PVN, paraventricular nucleus; SON, supraoptic nucleus.
*p<0.05, **p<0.01, ***p<0.0001.
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Figure 36.

Acute Exposure to Exogenous rrCNTF Does Not Promote Survival
of Oxytocinergic Neurons. Our results demonstrated that 24, 48, or
72 hours of acute exposure to exogenous rrCNTF did not result in a
significant increase in the number of oxytocinergic neurons in the
SON (A), PVN (B), or ACC (C) compared to control. Column bars
and error bars represent the mean and SD of [n] groups. ACC,
accessory nuclei; PVN, paraventricular nucleus; SON, supraoptic
nucleus. *p<0.05, **p<0.01, ***p<0.0001.
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pSTAT3 Activation In Vitro Occurs in Astrocytes in the SON. In the
control treated cultures, pSTAT3 activation in the SON occurs
exclusively in GFAP-immunoreactive astrocytes (arrows, A-C) and
not oxytocinergic magnocellular neurons of the SON (asterisks, DF). Similarly, after a 1 hour exogenous rrCNTF treatment, pSTAT3
activation only occurred in GFAP-immunoreactive astrocytes
(arrows, G-l) and not in oxytocinergic magnocellular neurons of the
SON (asterisks, J-L). GFAP, glial fibrillary acidic protein; OT,
oxytocinergic neuron; pSTAT3, phosphorylated STAT3. Scale
bar=20 pm.
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Figure 38.

The Jak-STAT Pathway is Necessary to Mediate CNTF-Induced
Survival of Oxytocinergic Neurons. Immunohistochemical neuronal
cell counts demonstrated that exogenous rrCNTF promoted the
survival of oxytocinergic neurons while inhibition of the Jak-STAT
pathway with AG490 or cucurbitacin I significantly reduced the
number of surviving oxytocinergic neurons in the SON (A), PVN
(B), and ACC (C). Column bars and error bars represent the mean
and SD of [n] groups. ACC, accessory nuclei; Cucu I, cucurbitacin I;
PVN, paraventricular nucleus; SON, supraoptic nucleus. * p<0.05,
***p<0.0001.
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Figure 39.

Micrograph Montages of Hypothalamic Organotypic Cultures
Following Jak-STAT Inhibition. (A) Micrograph montage of
magnocellular neurosecretory system nuclei of a representative
explant slice that received 25 ng/ml reverse sequence CNTF. Note
the preservation of the hypothalamic nuclei and the few neurons
present in the SON. (B) Micrograph of oxytocinergic magnocellular
neurons of a representative explarit slice that received 25 ng/ml
rrCNTF treatment for 14 days. Note the substantial increase in
oxytocinergic neurons in the SON, PVN, and ACC as well as the
maintenance of process density following rrCNTF treatment
compared to control (A). After pharmacological inhibition of the JakSTAT pathway with AG490 (C) and curcibitacin I (D), it is apparent
that the number of surviving oxytocinergic neurons is consistent
with what is observed in the control group (A). Note that the
representative images were obtained from approximately the same
level of the magnocellular neurosecretory system, which is
apparent when comparing the III ventricle between the images.
ACC, accessory nuclei; PVN, paraventricular nucleus; SON,
supraoptic nucleus. Scale bar =300 pm.
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Micrographs of Individual SON Following Inhibition of the Jak-STAT
Pathway. Note the substantial increase in neuron numbers in the
SON following rrCNTF administration (D) compared to the control
media group (A), and the groups receiving the pharmacological
inhibition of the Jak-STAT pathway (B, C) Moreover, the
maintenance of process density in the rrCNTF group (D) is
apparent compared to the control group (A) and the Jak-STAT
inhibited SON (B, C). Scale bar =100 pm.
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Figure 41.

Exogenous rrCNTF Did Not Activate ERK!4 or MEK14. Western blot
analysis of dissected SON samples demonstrated that acute
pressure injection of 100 ng/pl rrCNTF did not result in activation of
ERKV2 (A) or MEKVz (B) in the SON. Column bars and error bars
represent the mean and SD of 6 groups. Each group represents
isolated SON pooled from three rats. In order to determine the
amount of total protein that is phosphorylated, the ROD of the
phosphorylated protein was normalized to the ROD of the total
protein, as opposed to the ROD of R-actin, to obtain a ratio used for
statistical analysis. pERK1, phosphorylated ERK1; pERK2,
phosphorylated ERK2; pMEK1/2, phosphorylated MEKV2; ROD,
relative optical density; tERK1, total ER.K1; tERK2, total ERK2;
tMEK 1/2, total MEK1
/ 2.
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Figure 42.

Exogenous rrCNTF Did Not Activate p38 or JNK. Western blot
analysis of dissected SON samples demonstrated that acute
pressure injection of 100 ng/pl rrCNTF did not result in activation of
p38 (A) or JNK (B) in the SON. Column bars and error bars
represent the mean and SD of 6 groups. Each group represents
isolated SON pooled from three rats. In order to determine the
amount of total protein that is phosphorylated, the ROD of the
phosphorylated protein was normalized to the ROD of the total
protein, as opposed to the ROD of li-actin, to obtain a ratio used for
statistical analysis. p46 pJNK, phosphorylated JNK1; p54 pJNK,
phosphorylated JNK2; p46 tJNK, total JNK1; p54 tJNK, total JNK2;
p-p38, phosphorylated p38; ROD, relative optical density; t-p38,
total p38.

217

pERK 1/2 p

tERK1/2 j j
P

P

M

W

P

I., m

m

l

m

m

l

pMEK1/2 |

tMEK1/2 |
.

p-p38

t-p38 ^

___

.

pJNK I

tJNK |.^

mm* mm m m

*
Hr W

^

(3-actin L

J

m

...1 — T
M

i

/

/

l

l

^

1
/

/

/

post acute rrCNTF pressure injection
Figure 43.

Qualitative Survey of MAPK Pathways. A qualitative Western blot
assessment of the MAPK pathways was performed at various time
points. Similar to what was observed at 1 and 3 hours post rrCNTF
injection, we did not see activation of pERK1/4, MEK/4, p38, or JNK
at 15, 30, 45 minutes, 6, 12, 24, or 48 hours post rrCNTF injection.
p46 pJNK, phosphorylated JNK1; p54 pJNK, phosphorylated JNK2;
p46 tJNK, total JNK1; p54 tJNK, total JNK2; pERK1,
phosphorylated ERK1; pERK2, phosphorylated ERK2; pMEK1/2,
phosphorylated MEK1/2; p-p38, phosphorylated p38; tERK1, total
ERK1; tERK2, total ERK2; tMEK1/2, total MEK1/2; t-p38, total p38.
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n o * * *

Exogenous rrCNTF Did Not Activate AKT in the SON. Western blot
analysis of dissected SON samples demonstrated that acute
pressure injection of 100 ng/pl rrCNTF did not result in activation of
AKT (Thr3™) (A) or AKT (Ser473) (B) in the SON. Column bars and
error bars represent the mean and SD of 6 groups. Each group
represents isolated SON pooled from three rats. In order to
determine the amount of total protein that is phosphorylated, the
ROD of the phosphorylated protein was normalized to the ROD of
the total protein, as opposed to the ROD of l2>-actin, to obtain a ratio
used for statistical analysis. pAKT, phosphorylated AKT; ROD,
relative optical density; tAKT, total AKT.
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Figure 45.

Exogenous rrCNTF did not Activate CREB or cJun in the SON.
Western blot analysis of dissected SON samples demonstrated that
acute pressure injection of 100 ng/pl rirCNTF did not result in
activation of CREB (A) or cJun (B) in the SON. Column bars and
error bars represent the mean and SD of 6 groups. Each group
represents isolated SON pooled from three rats. In order to
determine the amount of total protein that is phosphorylated, the
ROD of the phosphorylated protein was normalized to the ROD of
the total protein, as opposed to the ROD of R-actin, to obtain a ratio
used for statistical analysis. p-cJun, phosphorylated cJun; pCREB,
phosphorylated CREB; ROD, relative optical density; t-cJun, total
cJun; tCREB, total CREB.
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Figure 46.

Qualitative Survey of AKT, CREB, and cJun. A qualitative Western
blot assessment of the AKT, CREB, and cJun was performed at
various time points. Similar to what was observed at 1 and 3 hours
post rrCNTF injection, we did not see activation of AKT, CREB, or
cJun at 15, 30, 45 minutes, 6, 12, 24, or 48 hours post rrCNTF
injection. pAKT, phosphorylated AKT; p-cJun, phosphorylated cJun;
pCREB, phosphorylated CREB; tAKT, total AKT; t-cJun, total cJun;
tCREB, total CREB.

221

Figure 47.

The MAPK-ERKVz Pathway is Necessary to Mediate the CNTFInduced Survival of Oxytocinergic Neurons. Immunohistochemical
neuronal cell counts demonstrated that exogenous rrCNTF
promoted the survival of oxytocinergic neurons while inhibition of
the MAPK-ERKY2 pathway with U0126, PD98059, and PD184352
significantly reduced the number of surviving oxytocinergic neurons
in the SON (A), PVN (B), and ACC (C). Column bars and error bars
represent the mean and SD of [n] groups. ACC, accessory nuclei;
PVN, paraventricular nucleus; SOM, supraoptic nucleus.
***p<0.0001.
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Figure 48.

Micrograph Montages of Hypothalamic Organotypic Cultures
Following MAPK-ERKKi Inhibition. (A) Micrograph montage of
magnocellular neurosecretory system nuclei of a representative
explant slice that received control media for 14 days. Note the
preservation of the hypothalamic nuclei and the small number of
neurons present in the SON. (B) Micrograph of oxytocinergic
magnocellular neurons of a representative explant slice that
received 25 ng/ml rrCNTF for 14 days. Note the substantial
increase in oxytocinergic neurons in the SON, PVN, and ACC as
well as the maintenance of process density following rrCNTF
treatment compared to control (A). After pharmacological inhibition
of the MAPK-ERK1/2 pathway with U0126 (C), PD98059 (D), and
PD184352 (E), it is apparent that the number of surviving
oxytocinergic neurons is consistent with what is observed in the
control group (A). Note that the representative images were
obtained from approximately the same level of the magnocellular
neurosecretory system, which is apparent when comparing the III
ventricle between the images. ACC, accessory nuclei; PVN,
paraventricular nucleus; SON, supraoptic nucleus. Scale bar =
300 pm.
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Micrographs of Individual SON Following Inhibition of the MAPKERKV2 Pathway. Note the substantial increase in neuron numbers
in the SON following rrCNTF administration (D) compared to the
groups receiving the pharmacological inhibition of the MAPK-ERK1/2
pathway (A,B, C). Scale bar =100 pm.
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Figure 50.

The p38- and JNK-MAPK Pathways Are Not Necessary to Mediate
the CNTF-Induced Survival of Oxytocinergic Neurons.
Immunohistochemical neuronal cell counts demonstrated that
exogenous rrCNTF promoted the survival of oxytocinergic neurons
while inhibition of the p38- and JNK-MAPK pathways with
SB203580 and SP600125, respectively, did not affect the number
of surviving oxytocinergic neurons in the SON (A), PVN (B), and
ACC (C). Flowever, when cultures were treated with the inhibitors
alone, there was a significant increase in the number of surviving
oxytocinergic neurons in the SON (A), PVN (B), and ACC (C),
compared to control. Column bars and error bars represent the
mean and SD of [n] groups. ACC, accessory nuclei; PVN,
paraventricular nucleus; SON, supraoptic nucleus. *p<0.05,
***p<0.0001.
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Figure 51.

Micrograph Montages of Hypothalamic Organotypic Cultures
Following p38- and JNK-MAPK Inhibition. (A) Micrograph montage
of magnocellular neurosecretory system nuclei of a representative
explant slice that received SB203580 for 14 days. Note the
prominent processes and preservation of oxytocinergic neurons.
(B) Micrograph of oxytocinergic magnocellular neurons of a
representative explant slice that received pharmacological inhibition
of the p38-MAPK pathway with SEI203580 in the presence of
25 ng/ml rrCNTF for 14 days. Note the slight increase in the
number of oxytocinergic neurons and processes in the SON, PVN,
and ACC following inhibition of the p38-MAPK pathway in the
presence of rrCNTF compared to SB203580 (A). (C) Micrograph
montage of magnocellular neurosecretory system nuclei of a
representative explant slice that received SP600125 for 14 days.
Note the prominent processes and preservation of oxytocinergic
neurons. (D) Micrograph of oxytocinergic magnocellular neurons of
a representative explant slice that received pharmacological
inhibition of the JNK-MAPK pathway with SP600125 in the
presence of 25 ng/ml rrCNTF for 14 days. Note the slight increase
in the number of oxytocinergic neurons and processes in the SON,
PVN, and ACC following inhibition of the JNK-MAPK pathway in the
presence of rrCNTF compared to SP600125 (C). The
representative images were obtained from approximately the same
level of the magnocellular neurosecretory system, which is
apparent when comparing the III ventricle between the images.
ACC, accessory nuclei; PVN, paraventricular nucleus; SON,
supraoptic nucleus. Scale bar =300 pm.
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Micrographs of Individual SON Following Inhibition of the p38- and
JNK-MAPK Pathways. Note the slight increase in neuron numbers
and process density in the SON following inhibition of the p38 (B)
and JNK (D) pathways in the presence of rrCNTF compared to the
groups receiving the inhibitors alone (A and C). Scale bar =100 pm
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Figure 53.

The PI3K-AKT Pathway is Not Necessary to Mediate the CNTFInduced Survival of Oxytocinergic Neurons. Immunohistochemical
neuronal cell counts demonstrated that exogenous rrCNTF
promoted the survival of oxytocinergic neurons while inhibition of
the PI3K-AKT pathway with LY294002 and wortmannin did not
affect the number of surviving oxytocinergic neurons in the SON
(A), PVN (B), and ACC (C). Column bars and error bars represent
the mean and SD of [n] groups. ACC, accessory nuclei; PVN,
paraventricular nucleus; SON, supraoptic nucleus. *p<0.05,
**p<0.01, ***p<0.0001.
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Figure 54.

Micrograph Montages of Hypothalamic Organotypic Cultures
Following PI3K Inhibition. When visibly comparing the number of
oxytocinergic neurons between rrCNTF (B), the rrCNTF plus
LY294002 (C), and the rrCNTF plus wortmannin (D), groups, it is
apparent that there are similar numbers of oxytocinergic neurons
present, and these groups all have more oxytocinergic neurons
than the control group (A). Furthermore, what is visually apparent is
that there are fewer neuronal processes present in the groups
receiving PI3K inhibition compared to the rrCNTF group, even
though they have the same number of surviving oxytocinergic
neurons. Note that the representative images were obtained from
approximately the same level of the magnocellular neurosecretory
system, which is apparent when comparing the III ventricle between
the images. ACC, accessory nuclei; PVN, paraventricular nucleus;
SON, supraoptic nucleus. Scale bar =300 pm.
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Micrographs of Individual SON Following Inhibition of the PI3K-AKT
Pathway. Note the increase in neuron numbers and process
density in the SON from control (A) to the rrCNTF group (B). The
number of oxytocinergic neurons following inhibition of PI3K (C, D)
is not different than the rrCNTF group (B); however, visibly there
are fewer processes in the PI3K-inhibited groups (C, D) compared
to the rrCNTF group (B). Scale bar =100 pm.
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Figure 56.

Micrographs Illustrating the Steps Involved in Quantifying the Area
Occupied by Neuronal Processes in the SON. (A) The image of the
SON, captured such that the entire SON is centered in the bottom
of the image. (B) A highlighted SOM is shown following setting of
the density. The density has been set to highlight the neuronal
processes and cell bodies, however, note that the analysis is a
conservative estimate of the proportional area of neuronal
processes because not all of the neuronal processes are
highlighted (arrowheads, A, B). (C) A highlighted SON is shown
following the setting of the density to highlight just the neuronal
somata. Note that similar to their immunoreactive profiles, the
nuclei are not highlighted by the density setting (arrows, A, C).
Scale bar =100 pm.
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Figure 57.

The PI3K-AKT Pathway is Necessary to Mediate the CNTFInduced Process Outgrowth of Oxytocinergic Neurons in the SON.
The ratio of process proportional area to total number of neurons in
the SON demonstrated that following administration of exogenous
rrCNTF there was a significant increase in the proportional area of
neuronal processes compared to control. The LY303511 molecule
served as a control molecule for the LY294002 inhibitor and the
proportional area of neuronal processes in the LY303511 in
conjunction with 25 ng/ml rrCNTF group did not differ from the
25 ng/ml rrCNTF group. However, when the PI3K inhibitors,
LY294002 and wortmannin, were administered to the organotypic
cultures in the presence of 25 ng/ml rrCNTF, there was a significant
reduction in the proportional area of neuronal processes in the SON
compared to the 25 ng/ml rrCNTF group. Moreover, the LY294002
plus 25 ng/ml rrCNTF group was significantly reduced from control
values. Column bars and error bars represent the mean and SD of
[n] groups. **p<0.01, ***p<0.0001.
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Figure 58.

mTOR is Not Necessary to Mediate the CNTF-Induced Survival of
Oxytocinergic Neurons. Immunohistochemical neuronal cell counts
demonstrated that exogenous rrCNTF promoted the survival of
oxytocinergic neurons while inhibition of mTOR with rapamycin and
torin-1 did not affect the number of surviving oxytocinergic neurons
in the SON (A), PVN (B), and ACC (C). Flowever, when cultures
were treated with the inhibitors alone, there was a significant
increase in the number of surviving oxytocinergic neurons in the
SON (A), PVN (B), and ACC (C), compared to control. Column bars
and error bars represent the mean and SD of [n] groups. ACC,
accessory nuclei; PVN, paraventricular nucleus; SON, supraoptic
nucleus. ***p<0.0001.
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Figure 59.

Micrograph Montages of Hypothalamic Organotypic Cultures
Following mTOR Inhibition. (A) Micrograph montage of
magnocellular neurosecretory system nuclei of a representative
explant slice that received rapamycin for 14 days. Note the
preservation of oxytocinergic neurons. (B) Micrograph of
oxytocinergic magnocellular neurons of a representative explant
slice that received pharmacological inhibition of mTOR with
rapamycin in the presence of 25 ng/ml rrCNTF for 14 days. Note
the slight increase in the number of oxytocinergic neurons and
processes in the SON, PVN, and ACC following inhibition of mTOR
in the presence of rrCNTF compared to rapamycin (A). (C)
Micrograph montage of magnocellular neurosecretory system
nuclei of a representative explant slice that received torin-1 for
14 days. Note the prominent processes and preservation of
oxytocinergic neurons. (D) Micrograph of oxytocinergic
magnocellular neurons of a representative explant slice that
received pharmacological inhibition of mTOR with torin-1 in the
presence of 25 ng/ml rrCNTF for 14 days. Note the slight increase
in the number of oxytocinergic neurons and processes in the SON,
PVN, and ACC following inhibition of mTOR in the presence of
rrCNTF compared to torin-1 (C). The representative images were
obtained from approximately the same level of the magnocellular
neurosecretory system, which is apparent when comparing the
III ventricle between the images. ACC, accessory nuclei; PVN,
paraventricular nucleus; SON, supraoptic nucleus. Scale bar =
300 pm.
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Figure 60.

Micrographs of Individual SON Following Inhibition of mTOR. Note
the slight increase in neuron numbers and process density in the
SON following inhibition of mTOR with rapamycin (B) and torin-1
(D) in the presence of rrCNTF compared to the groups receiving
the inhibitors alone (A and C). Scale bar =100 pm.
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Figure 61.

NF-kB is Not Necessary to Mediate the CNTF-Induced Survival of
Oxytocinergic Neurons. Immunohistochemical neuronal cell counts
demonstrated that exogenous rrCNTF promoted the survival of
oxytocinergic neurons while inhibition of NF-k B with bay 11-7082
and sc-514 did not affect the number of surviving oxytocinergic
neurons in the SON (A), PVN (B), and ACC (C). Flowever, when
cultures were treated with sc-514 alone, there was a significant
increase in the number of surviving oxytocinergic neurons in the
SON (A), PVN (B), and ACC (C), compared to control. Column bars
and error bars represent the mean and SD of [n] groups. ACC,
accessory nuclei; PVN, paraventricular nucleus; SON, supraoptic
nucleus. **p<0.01, ***p<0.0001.
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Figure 62.

Micrograph Montages of Hypothalamic Organotypic Cultures
Following NF-k B Inhibition. (A) Micrograph montage of
magnocellular neurosecretory system nuclei of a representative
explant slice that received control media for 14 days. Note the
preservation of oxytocinergic neurons in their respective nuclei. (B)
Micrograph montage of a representative explant slice that received
25 ng/ml rrCNTF for 14 days. The significant increase in the
number of oxytocinergic neurons compared to control (A) is
obvious, as well as the visual increase in the process density.
Micrograph of oxytocinergic magnocellular neurons of a
representative explant slice that received pharmacological inhibition
of NF-k B with bay 11-7082 (C) and sc-514 (D) in the presence of
25 ng/ml rrCNTF for 14 days. Note the similar appearance of
processes and neurons compared to the rrCNTF group (B). The
representative images were obtained from approximately the same
level of the magnocellular neurosecretory system, which is
apparent when comparing the III ventricle between the images.
ACC, accessory nuclei; PVN, paraventricular nucleus; SON,
supraoptic nucleus. Scale bar =300 pm.
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Figure 63.

■

Micrographs of Individual SON Following Inhibition of NF-k B. Note
the increase in neuron numbers and process density in the SON
from control (A) to the rrCNTF group (B). The number and process
density of oxytocinergic neurons following inhibition of NF-k B (C, D)
appears not to be different than the rrCNTF group (B). Scale bar
=100 pm.
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Figure 64.

Consistency of Control Groups Throughout the Study. Throughout
all of the experiments, there was no statistical difference in the
number of oxytocinergic neurons in control SON (A), PVN (B), or
ACC (C). Column bars and error bars represent the mean and SD
of [n] groups.

250

B

A

^

PVN

^

<e*rf»$* ^ 4* 4* ^ 4s*^ 4*

/VVVVVVVVV

/x^vvvvvvv

AKKK^AK k ^

/ / / / / / / / / /
?'£■ '£ v ❖ <f> & <& <t> <tf>

ACC

&

/ / / / / / / / / /
<t> #

<& <f> >t> >t> «f> <tf> -f>

200'

I T J , T J(22]

£ ISO-

I20I

115)

I» l

m

!2»l

III

?100'

c

I

O
» 50

^ ^

^

^ ^ ^ #

/ / / / / / / / / ^
Figure 65.

Consistency of rrCNTF Groups Throughout the Study. Throughout
all of the experiments, there was no statistical difference in the
number of oxytocinergic neurons in the rrCNTF-treated SON (A),
PVN (B), or ACC (C). Column bars and error bars represent the
mean and SD of [n] groups.
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